20644716|t|Themis2/ICB1 is a signaling scaffold that selectively regulates macrophage Toll-like receptor signaling and cytokine production.
20644716|a|BACKGROUND: Thymocyte expressed molecule involved in selection 1 (Themis1, SwissProt accession number Q8BGW0) is the recently characterised founder member of a novel family of proteins. A second member of this family, Themis2 (Q91YX0), also known as ICB1 (Induced on contact with basement membrane 1), remains unreported at the protein level despite microarray and EST databases reporting Themis2 mRNA expression in B cells and macrophages. METHODOLOGY/PRINCIPAL FINDINGS: Here we characterise Themis2 protein for the first time and show that it acts as a macrophage signalling scaffold, exerting a receptor-, mediator- and signalling pathway-specific effect on TLR responses in RAW 264.7 macrophages. Themis2 over-expression enhanced the LPS-induced production of TNF but not IL-6 or Cox-2, nor TNF production induced by ligands for TLR2 (PAM3) or TLR3 (poly IratioC). Moreover, LPS-induced activation of the MAP kinases ERK and p38 was enhanced in cells over-expressing Themis2 whereas the activation of JNK, IRF3 or NF-kappaB p65, was unaffected. Depletion of Themis2 protein by RNA inteference inhibited LPS-induced TNF production in primary human macrophages demonstrating a requirement for Themis2 in this event. Themis2 was inducibly tyrosine phosphorylated upon LPS challenge and interacted with Lyn kinase (P25911), the Rho guanine nucleotide exchange factor, Vav (P27870), and the adaptor protein Grb2 (Q60631). Mutation of either tyrosine 660 or a proline-rich sequence (PPPRPPK) simultaneously interrupted this complex and reduced by approximately 50% the capacity of Themis2 to promote LPS-induced TNF production. Finally, Themis2 protein expression was induced during macrophage development from murine bone marrow precursors and was regulated by inflammatory stimuli both in vitro and in vivo. CONCLUSIONS/SIGNIFICANCE: We hypothesise that Themis2 may constitute a novel, physiological control point in macrophage inflammatory responses.
20644716	0	7	Themis2	Gene	230787(Species:10090)
20644716	8	12	ICB1	Gene	230787(Species:10090)
20644716	75	93	Toll-like receptor	Gene	142980(Species:10090),24088(Species:10090)
20644716	108	116	cytokine	Gene	16193(Species:10090),21926(Species:10090),7124(Species:9606)
20644716	141	193	Thymocyte expressed molecule involved in selection 1	Gene	210757(Species:10090)
20644716	195	202	Themis1	Gene	210757(Species:10090)
20644716	347	354	Themis2	Gene	230787(Species:10090)
20644716	379	383	ICB1	Gene	230787(Species:10090)
20644716	385	428	Induced on contact with basement membrane 1	Gene	230787(Species:10090)
20644716	518	525	Themis2	Gene	230787(Species:10090)
20644716	623	630	Themis2	Gene	230787(Species:10090)
20644716	791	794	TLR	Gene	142980(Species:10090),24088(Species:10090)
20644716	831	838	Themis2	Gene	230787(Species:10090)
20644716	894	897	TNF	Gene	21926(Species:10090)
20644716	906	910	IL-6	Gene	16193(Species:10090)
20644716	914	919	Cox-2	Gene	19225(Species:10090)
20644716	925	928	TNF	Gene	21926(Species:10090)
20644716	963	967	TLR2	Gene	24088(Species:10090)
20644716	978	982	TLR3	Gene	142980(Species:10090)
20644716	1039	1050	MAP kinases	Gene	26413(Species:10090),26416(Species:10090),26419(Species:10090)
20644716	1051	1054	ERK	Gene	26413(Species:10090)
20644716	1059	1062	p38	Gene	26416(Species:10090)
20644716	1101	1108	Themis2	Gene	230787(Species:10090)
20644716	1135	1138	JNK	Gene	26419(Species:10090)
20644716	1140	1144	IRF3	Gene	54131(Species:10090)
20644716	1148	1161	NF-kappaB p65	Gene	19697(Species:10090)
20644716	1192	1199	Themis2	Gene	9473(Species:9606)
20644716	1249	1252	TNF	Gene	7124(Species:9606)
20644716	1275	1280	human	Species	Species:9606
20644716	1325	1332	Themis2	Gene	9473(Species:9606)
20644716	1348	1355	Themis2	Gene	230787(Species:10090)
20644716	1433	1443	Lyn kinase	Gene	17096(Species:10090)
20644716	1458	1496	Rho guanine nucleotide exchange factor	Gene	22324(Species:10090)
20644716	1498	1501	Vav	Gene	22324(Species:10090)
20644716	1536	1540	Grb2	Gene	14784(Species:10090)
20644716	1709	1716	Themis2	Gene	230787(Species:10090)
20644716	1740	1743	TNF	Gene	21926(Species:10090)
20644716	1765	1772	Themis2	Gene	230787(Species:10090)
20644716	1839	1845	murine	Species	Species:10090
20644716	1984	1991	Themis2	Gene	230787(Species:10090)

19778378|t|U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint.
19778378|a|Chk1 is a conserved protein kinase originally identified in fission yeast, required to delay entry of cells with damaged or unreplicated DNA into mitosis. The requirement of Chk1 for both S and G2/M checkpoints has been elucidated while only few studies have connected Chk1 to the mitotic spindle checkpoint. We used a small interference RNA strategy to investigate the role of Chk1 in unstressed conditions. Chk1 depletion in U2OS human osteosarcoma cells inhibited cell proliferation and raised the percentage of cells with a 4N DNA content, which correlated with accumulation of giant polynucleated cells morphologically distinct from apoptotic cells, while no increased number of cells in G2 or mitosis could be detected. Down-regulation of Chk1 also caused accumulation of cells in the last step of cytokinesis, and of tetraploid cells in G1 phase, which coincided with activation of p53 and increased levels of p21. In addition, Chk1-depleted U2OS cells failed to arrest in mitosis after spindle disruption by nocodazole and showed decreased protein levels of Mad2 and BubR1. These studies show that U2OS cells lacking Chk1 undergo abnormal mitosis and fail to activate the spindle checkpoint, suggesting a role of Chk1 in this checkpoint.
19778378	0	4	U2OS	Species	Species:9606
19778378	19	23	Chk1	Gene	1111(Species:9606)
19778378	94	98	Chk1	Gene	1111(Species:9606)
19778378	114	128	protein kinase	Gene	1111(Species:9606)
19778378	154	167	fission yeast	Species	Species:4896
19778378	268	272	Chk1	Gene	1111(Species:9606)
19778378	363	367	Chk1	Gene	1111(Species:9606)
19778378	472	476	Chk1	Gene	1111(Species:9606)
19778378	503	507	Chk1	Gene	1111(Species:9606)
19778378	521	525	U2OS	Species	Species:9606
19778378	526	531	human	Species	Species:9606
19778378	839	843	Chk1	Gene	1111(Species:9606)
19778378	983	986	p53	Gene	7157(Species:9606)
19778378	1011	1014	p21	Gene	1026(Species:9606)
19778378	1029	1033	Chk1	Gene	1111(Species:9606)
19778378	1043	1047	U2OS	Species	Species:9606
19778378	1160	1164	Mad2	Gene	4085(Species:9606)
19778378	1169	1174	BubR1	Gene	701(Species:9606)
19778378	1200	1204	U2OS	Species	Species:9606
19778378	1219	1223	Chk1	Gene	1111(Species:9606)
19778378	1315	1319	Chk1	Gene	1111(Species:9606)

26017929|t|Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation.
26017929|a|Accumulating evidence suggests that obesity and enhanced inflammatory reactions are predisposing conditions for developing colon cancer. Obesity is associated with high levels of circulating leptin. Leptin is an adipocytokine that is secreted by adipose tissue and modulates immune response and inflammation. Lipid droplets (LD) are organelles involved in lipid metabolism and production of inflammatory mediators, and increased numbers of LD were observed in human colon cancer. Leptin induces the formation of LD in macrophages in a PI3K/mTOR pathway-dependent manner. Moreover, the mTOR is a serine/threonine kinase that plays a key role in cellular growth and is frequently altered in tumors. We therefore investigated the role of leptin in the modulation of mTOR pathway and regulation of lipid metabolism and inflammatory phenotype in intestinal epithelial cells (IEC-6 cells). We show that leptin promotes a dose- and time-dependent enhancement of LD formation. The biogenesis of LD was accompanied by enhanced CXCL1/CINC-1, CCL2/MCP-1 and TGF-b production and increased COX-2 expression in these cells. We demonstrated that leptin-induced increased phosphorylation of STAT3 and AKT and a dose and time-dependent mTORC activation with enhanced phosphorilation of the downstream protein P70S6K protein. Pre-treatment with rapamycin significantly inhibited leptin effects in LD formation, COX-2 and TGF-b production in IEC-6 cells. Moreover, leptin was able to stimulate the proliferation of epithelial cells on a mTOR-dependent manner. We conclude that leptin regulates lipid metabolism, cytokine production and proliferation of intestinal cells through a mechanism largely dependent on activation of the mTOR pathway, thus suggesting that leptin-induced mTOR activation may contribute to the obesity-related enhanced susceptibility to colon carcinoma.
26017929	0	6	Leptin	Gene	25608(Species:10116)
26017929	21	25	mTOR	Gene	56718(Species:10116)
26017929	98	106	cytokine	Gene	81503(Species:10116),24770(Species:10116),59086(Species:10116)
26017929	343	349	leptin	Gene	3952(Species:9606)
26017929	351	357	Leptin	Gene	25608(Species:10116)
26017929	364	377	adipocytokine	Gene	25608(Species:10116)
26017929	612	617	human	Species	Species:9606
26017929	632	638	Leptin	Gene	25608(Species:10116)
26017929	687	691	PI3K	Gene	298947(Species:10116)
26017929	692	696	mTOR	Gene	56718(Species:10116)
26017929	737	741	mTOR	Gene	56718(Species:10116)
26017929	747	770	serine/threonine kinase	Gene	56718(Species:10116)
26017929	887	893	leptin	Gene	25608(Species:10116)
26017929	915	919	mTOR	Gene	56718(Species:10116)
26017929	1022	1027	IEC-6	Species	Species:10116
26017929	1049	1055	leptin	Gene	25608(Species:10116)
26017929	1170	1175	CXCL1	Gene	81503(Species:10116)
26017929	1176	1182	CINC-1	Gene	81503(Species:10116)
26017929	1184	1188	CCL2	Gene	24770(Species:10116)
26017929	1189	1194	MCP-1	Gene	24770(Species:10116)
26017929	1199	1204	TGF-b	Gene	59086(Species:10116)
26017929	1230	1235	COX-2	Gene	29527(Species:10116)
26017929	1284	1290	leptin	Gene	25608(Species:10116)
26017929	1328	1333	STAT3	Gene	25125(Species:10116)
26017929	1338	1341	AKT	Gene	24185(Species:10116)
26017929	1372	1377	mTORC	Gene	56718(Species:10116)
26017929	1445	1451	P70S6K	Gene	83840(Species:10116)
26017929	1514	1520	leptin	Gene	25608(Species:10116)
26017929	1546	1551	COX-2	Gene	29527(Species:10116)
26017929	1556	1561	TGF-b	Gene	59086(Species:10116)
26017929	1576	1581	IEC-6	Species	Species:10116
26017929	1599	1605	leptin	Gene	25608(Species:10116)
26017929	1671	1675	mTOR	Gene	56718(Species:10116)
26017929	1711	1717	leptin	Gene	25608(Species:10116)
26017929	1746	1754	cytokine	Gene	81503(Species:10116),24770(Species:10116),59086(Species:10116)
26017929	1863	1867	mTOR	Gene	56718(Species:10116)
26017929	1898	1904	leptin	Gene	25608(Species:10116)
26017929	1913	1917	mTOR	Gene	56718(Species:10116)

25277705|t|Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection.
25277705|a|BACKGROUND: Respiratory syncytial virus (RSV) infects the lung epithelium where it stimulates the production of numerous host cytokines that are associated with disease burden and acute lung injury. Characterizing the host cytokine response to RSV infection, the regulation of host cytokines and the impact of neutralizing an RSV-inducible cytokine during infection were undertaken in this study. METHODS: A549, primary human small airway epithelial (SAE) cells and wild-type, TIR-domain-containing adapter-inducing interferon-b (Trif) and mitochondrial antiviral-signaling protein (Mavs) knockout (KO) mice were infected with RSV and cytokine responses were investigated by ELISA, multiplex analysis and qPCR. Neutralizing anti-leukemia inhibitory factor (LIF) IgG or control IgG was administered to a group of wild-type animals prior to RSV infection. RESULTS AND DISCUSSION: RSV-infected A549 and SAE cells release a network of cytokines, including newly identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, CXCL12 and stem cell growth factor beta (SCGF-b). These RSV-inducible cytokines were also observed in the airways of mice during an infection. To identify the regulation of RSV inducible cytokines, Mavs and Trif deficient animals were infected with RSV. In vivo induction of airway IL-1b, IL-4, IL-5, IL-6, IL-12(p40), IFN-g, CCL2, CCL5, CCL3, CXCL1, IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on Mavs expression in mice. Loss of Trif expression in mice altered the RSV induction of IL-1b, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-g. Silencing of retinoic acid-inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression. To evaluate the role of LIF in the airways during RSV infection, animals were treated with neutralizing anti-LIF IgG, which enhanced RSV pathology observed with increased airspace protein content, apoptosis and airway hyperresponsiveness compared to control IgG treatment. CONCLUSIONS: RSV infection in the epithelium induces a network of immune factors to counter infection, primarily in a RIG-I dependent manner. Expression of LIF protects the lung from lung injury and enhanced pathology during RSV infection.
25277705	0	26	Leukemia inhibitory factor	Gene	16878(Species:10090),3976(Species:9606)
25277705	52	63	respiratory	Species	Species:12814
25277705	103	130	Respiratory syncytial virus	Species	Species:12814
25277705	132	135	RSV	Species	Species:12814
25277705	335	338	RSV	Species	Species:12814
25277705	417	420	RSV	Species	Species:12814
25277705	511	516	human	Species	Species:9606
25277705	542	545	SAE	Species	Species:7797
25277705	568	619	TIR-domain-containing adapter-inducing interferon-b	Gene	106759(Species:10090)
25277705	621	625	Trif	Gene	106759(Species:10090)
25277705	631	672	mitochondrial antiviral-signaling protein	Gene	228607(Species:10090)
25277705	674	678	Mavs	Gene	228607(Species:10090)
25277705	694	698	mice	Species	Species:10090
25277705	718	721	RSV	Species	Species:12814
25277705	820	846	leukemia inhibitory factor	Gene	3976(Species:9606)
25277705	848	851	LIF	Gene	3976(Species:9606)
25277705	930	933	RSV	Species	Species:12814
25277705	969	972	RSV	Species	Species:12814
25277705	991	994	SAE	Species	Species:7797
25277705	1060	1063	RSV	Species	Species:12814
25277705	1084	1087	LIF	Gene	3976(Species:9606)
25277705	1089	1116	migration inhibitory factor	Gene	4282(Species:9606)
25277705	1118	1121	MIF	Gene	4282(Species:9606)
25277705	1124	1140	stem cell factor	Gene	4254(Species:9606)
25277705	1142	1145	SCF	Gene	4254(Species:9606)
25277705	1148	1153	CCL27	Gene	10850(Species:9606)
25277705	1148	1154	CCL27,	Gene	10850(Species:9606)
25277705	1155	1161	CXCL12	Gene	6387(Species:9606)
25277705	1166	1194	stem cell growth factor beta	Gene	6320(Species:9606)
25277705	1196	1202	SCGF-b	Gene	6320(Species:9606)
25277705	1211	1214	RSV	Species	Species:12814
25277705	1272	1276	mice	Species	Species:10090
25277705	1328	1331	RSV	Species	Species:12814
25277705	1353	1357	Mavs	Gene	228607(Species:10090)
25277705	1362	1366	Trif	Gene	106759(Species:10090)
25277705	1404	1407	RSV	Species	Species:12814
25277705	1437	1442	IL-1b	Gene	16176(Species:10090)
25277705	1444	1448	IL-4	Gene	16189(Species:10090)
25277705	1450	1454	IL-5	Gene	16191(Species:10090)
25277705	1456	1460	IL-6	Gene	16193(Species:10090)
25277705	1462	1467	IL-12	Gene	16160(Species:10090)
25277705	1468	1471	p40	Gene	16160(Species:10090)
25277705	1474	1479	IFN-g	Gene	15978(Species:10090)
25277705	1481	1485	CCL2	Gene	20296(Species:10090)
25277705	1487	1491	CCL5	Gene	20304(Species:10090)
25277705	1493	1497	CCL3	Gene	20302(Species:10090)
25277705	1499	1504	CXCL1	Gene	14825(Species:10090)
25277705	1506	1511	IP-10	Gene	15945(Species:10090)
25277705	1512	1518	CXCL10	Gene	15945(Species:10090)
25277705	1520	1525	IL-22	Gene	50929(Species:10090)
25277705	1527	1530	MIG	Gene	17329(Species:10090)
25277705	1531	1536	CXCL9	Gene	17329(Species:10090)
25277705	1541	1544	MIF	Gene	17319(Species:10090)
25277705	1563	1567	Mavs	Gene	228607(Species:10090)
25277705	1582	1586	mice	Species	Species:10090
25277705	1596	1600	Trif	Gene	106759(Species:10090)
25277705	1615	1619	mice	Species	Species:10090
25277705	1632	1635	RSV	Species	Species:12814
25277705	1649	1654	IL-1b	Gene	16176(Species:10090)
25277705	1656	1660	IL-5	Gene	16191(Species:10090)
25277705	1662	1668	CXCL12	Gene	20315(Species:10090)
25277705	1670	1673	MIF	Gene	17319(Species:10090)
25277705	1675	1678	LIF	Gene	16878(Species:10090)
25277705	1680	1686	CXCL12	Gene	20315(Species:10090)
25277705	1691	1696	IFN-g	Gene	15978(Species:10090)
25277705	1711	1741	retinoic acid-inducible gene-1	Gene	23586(Species:9606)
25277705	1743	1748	RIG-I	Gene	23586(Species:9606)
25277705	1799	1802	RSV	Species	Species:12814
25277705	1828	1873	melanoma differentiation-associated protein 5	Gene	64135(Species:9606)
25277705	1875	1879	MDA5	Gene	64135(Species:9606)
25277705	1885	1924	laboratory of genetics and physiology 2	Gene	79132(Species:9606)
25277705	1926	1930	LGP2	Gene	79132(Species:9606)
25277705	1937	1941	Trif	Gene	148022(Species:9606)
25277705	1978	1981	LIF	Gene	16878(Species:10090)
25277705	2004	2007	RSV	Species	Species:12814
25277705	2063	2066	LIF	Gene	16878(Species:10090)
25277705	2087	2090	RSV	Species	Species:12814
25277705	2240	2243	RSV	Species	Species:12814
25277705	2345	2350	RIG-I	Gene	23586(Species:9606)
25277705	2383	2386	LIF	Gene	16878(Species:10090),3976(Species:9606)
25277705	2452	2455	RSV	Species	Species:12814

21172391|t|The kinesin superfamily protein KIF17 is regulated by the same transcription factor (NRF-1) as its cargo NR2B in neurons.
21172391|a|The kinesin superfamily of motor proteins is known to be ATP-dependent transporters of various types of cargoes. In neurons, KIF17 is found to transport vesicles containing the N-methyl-D-aspartate receptor NR2B subunit from the cell body specifically to the dendrites. These subunits are intimately associated with glutamatergic neurotransmission as well as with learning and memory. Glutamatergic synapses are highly energy-dependent, and recently we found that the same transcription factor, nuclear respiratory factor 1 (NRF-1), co-regulates energy metabolism (via its regulation of cytochrome c oxidase and other mitochondrial enzymes) and neurochemicals of glutamatergic transmission (NR1, NR2B, GluR2, and nNOS). The present study tested our hypothesis that NRF-1 also transcriptionally regulates KIF17. By means of in silico analysis, electrophoretic mobility shift and supershift assays, in vivo chromatin immunoprecipitation assays, promoter mutations, and real-time quantitative PCR, we found that NRF-1 (but not NRF-2) functionally regulates Kif17, but not Kif1a, gene. NRF-1 binding sites on Kif17 gene are highly conserved among mice, rats, and humans. Silencing of NRF-1 with small interference RNA blocked the up-regulation of Kif17 mRNA and proteins (and of Grin1 and Grin2b) induced by KCl-mediated depolarization, whereas over-expressing NRF-1 rescued these transcripts and proteins from being suppressed by TTX. Thus, NRF-1 co-regulates oxidative enzymes that generate energy and neurochemicals that consume energy related to glutamatergic neurotransmission, such as KIF17, NR1, and NR2B, thereby ensuring that energy production matches energy utilization at the molecular and cellular levels.
21172391	4	11	kinesin	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	4	31	kinesin superfamily protein	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	32	37	KIF17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	63	83	transcription factor	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	85	90	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	105	109	NR2B	Gene	14812(Species:10090),24410(Species:10116),2904(Species:9606)
21172391	126	133	kinesin	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	179	205	ATP-dependent transporters	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	247	252	KIF17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	299	327	N-methyl-D-aspartate recepto	Gene	14812(Species:10090),24410(Species:10116),2904(Species:9606)
21172391	299	328	N-methyl-D-aspartate receptor	Gene	14812(Species:10090),24410(Species:10116),2904(Species:9606)
21172391	329	333	NR2B	Gene	14812(Species:10090),24410(Species:10116),2904(Species:9606)
21172391	617	645	nuclear respiratory factor 1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	647	652	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	709	729	cytochrome c oxidase	Gene	17708(Species:10090),26195(Species:10116),4512(Species:9606)
21172391	813	816	NR1	Gene	14810(Species:10090),24408(Species:10116),2902(Species:9606)
21172391	818	822	NR2B	Gene	14812(Species:10090),2904(Species:9606)
21172391	824	829	GluR2	Gene	14800(Species:10090),2891(Species:9606),29627(Species:10116)
21172391	835	839	nNOS	Gene	18125(Species:10090),24598(Species:10116),4842(Species:9606)
21172391	887	892	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	926	931	KIF17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	1131	1136	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	1146	1151	NRF-2	Gene	18024(Species:10090),4780(Species:9606),83619(Species:10116)
21172391	1176	1181	Kif17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	1191	1196	Kif1a	Gene	16560(Species:10090),363288(Species:10116),547(Species:9606)
21172391	1204	1209	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	1227	1232	Kif17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	1265	1269	mice	Species	Species:10090
21172391	1271	1275	rats	Species	Species:10116
21172391	1281	1287	humans	Species	Species:9606
21172391	1302	1307	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	1365	1370	Kif17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	1397	1402	Grin1	Gene	14810(Species:10090),24408(Species:10116),2902(Species:9606)
21172391	1407	1413	Grin2b	Gene	14812(Species:10090),2904(Species:9606)
21172391	1479	1484	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	1560	1565	NRF-1	Gene	18181(Species:10090),312195(Species:10116),4899(Species:9606)
21172391	1579	1596	oxidative enzymes	Gene	14810(Species:10090),14812(Species:10090),16559(Species:10090),24408(Species:10116),24410(Species:10116),2902(Species:9606),2904(Species:9606),500571(Species:10116),57576(Species:9606)
21172391	1709	1714	KIF17	Gene	16559(Species:10090),500571(Species:10116),57576(Species:9606)
21172391	1716	1719	NR1	Gene	14810(Species:10090),24408(Species:10116),2902(Species:9606)
21172391	1725	1729	NR2B	Gene	14812(Species:10090),24410(Species:10116),2904(Species:9606)

24204098|t|STAT3 regulates proliferation and survival of CD8+ T cells: enhances effector responses to HSV-1 infection, and inhibits IL-10+ regulatory CD8+ T cells in autoimmune uveitis.
24204098|a|STAT3 regulates CD4+ T cell survival and differentiation. However, its effects on CD8+ T cells are not well understood. Here, we show that in comparison to WT CD8+ T cells, STAT3-deficient CD8+ T cells exhibit a preactivated memory-like phenotype, produce more IL-2, proliferate faster, and are more sensitive to activation-induced cell death (AICD). The enhanced proliferation and sensitivity to AICD correlated with downregulation of class-O forkhead transcription factors (FoxO1, FoxO3A), p21(waf1), p27(KIP1), Bcl-2, OX-40, and upregulation of FasL, Bax, and Bad. We examined whether STAT3-deficient CD8+ T cells can mount effective response during herpes simplex virus (HSV-1) infection and experimental autoimmune uveitis (EAU). Compared to WT mice, HSV-1-infected STAT3-deficient mice (STAT3KO) produced less IFN-gamma and virus-specific KLRG-1+ CD8+ T cells. STAT3KO mice are also resistant to EAU and produced less IL-17-producing Tc17 cells. Resistance of STAT3KO to EAU correlated with marked expansion of IL-10-producing regulatory CD8+ T cells (CD8-Treg) implicated in recovery from autoimmune encephalomyelitis. Thus, increases of IL-6-induced STAT3 activation observed during inflammation may inhibit expansion of CD8-Tregs, thereby impeding recovery from uveitis. These results suggest that STAT3 is a potential therapeutic target for upregulating CD8+ T cell-mediated responses to viruses and suggest the successful therapeutic targeting of STAT3 as treatment for uveitis, derived, in part, from promoting CD8-Treg expansion.
24204098	0	5	STAT3	Gene	20848(Species:10090)
24204098	46	49	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	91	96	HSV-1	Species	Species:10298
24204098	121	126	IL-10	Gene	16153(Species:10090)
24204098	139	142	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	175	180	STAT3	Gene	20848(Species:10090)
24204098	191	194	CD4	Gene	12504(Species:10090)
24204098	257	260	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	334	337	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	348	353	STAT3	Gene	20848(Species:10090)
24204098	364	367	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	436	440	IL-2	Gene	16183(Species:10090)
24204098	611	649	class-O forkhead transcription factors	Gene	56458(Species:10090),56484(Species:10090)
24204098	651	656	FoxO1	Gene	56458(Species:10090)
24204098	658	664	FoxO3A	Gene	56484(Species:10090)
24204098	667	670	p21	Gene	12575(Species:10090)
24204098	671	675	waf1	Gene	12575(Species:10090)
24204098	678	687	p27(KIP1)	Gene	12576(Species:10090)
24204098	689	694	Bcl-2	Gene	12043(Species:10090)
24204098	696	701	OX-40	Gene	22163(Species:10090)
24204098	723	727	FasL	Gene	14103(Species:10090)
24204098	729	732	Bax	Gene	12028(Species:10090)
24204098	738	741	Bad	Gene	12015(Species:10090)
24204098	763	768	STAT3	Gene	20848(Species:10090)
24204098	779	782	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	828	856	herpes simplex virus (HSV-1)	Species	Species:10298
24204098	925	929	mice	Species	Species:10090
24204098	931	936	HSV-1	Species	Species:10298
24204098	946	951	STAT3	Gene	20848(Species:10090)
24204098	962	966	mice	Species	Species:10090
24204098	968	975	STAT3KO	Gene	20848(Species:10090)
24204098	991	1000	IFN-gamma	Gene	15978(Species:10090)
24204098	1020	1026	KLRG-1	Gene	50928(Species:10090)
24204098	1028	1031	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	1042	1049	STAT3KO	Gene	20848(Species:10090)
24204098	1050	1054	mice	Species	Species:10090
24204098	1099	1104	IL-17	Gene	16171(Species:10090)
24204098	1141	1148	STAT3KO	Gene	20848(Species:10090)
24204098	1192	1197	IL-10	Gene	16153(Species:10090)
24204098	1219	1222	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	1233	1236	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	1320	1324	IL-6	Gene	16193(Species:10090)
24204098	1333	1338	STAT3	Gene	20848(Species:10090)
24204098	1404	1407	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	1482	1487	STAT3	Gene	20848(Species:10090)
24204098	1539	1542	CD8	Gene	12525(Species:10090),12526(Species:10090)
24204098	1633	1638	STAT3	Gene	20848(Species:10090)
24204098	1698	1701	CD8	Gene	12525(Species:10090),12526(Species:10090)

22905138|t|Gene profile of chemokines on hepatic stellate cells of schistosome-infected mice and antifibrotic roles of CXCL9/10 on liver non-parenchymal cells.
22905138|a|Hepatic stellate cells (HSCs) play a key role in the development of liver fibrosis caused by schistosomiasis. Chemokines were widely expressed and involved in cellular activation, proliferation and migration in inflammatory and infectious diseases. However, little is known about the expressions of chemokines on HSCs in the schistosoma infection. In addition, the roles of chemokines in pathogenesis of liver fibrosis are not totally clear. In our study, we used microarray to analyze the temporal gene expressions of primary HSCs isolated from mice with both acute and chronic schistosomiasis. Our microarray data showed that most of the chemokines expressed on HSCs were upregulated at 3 weeks post-infection (p.i) when the egg granulomatous response was not obviously evoked in the liver. However, some of them like CXCL9, CXCL10 and CXCL11 were subsequently decreased at 6 weeks p.i when the granulomatous response reached the peak. In the chronic stage, most of the differentially expressed chemokines maintained persistent high-abundances. Furthermore, several chemokines including CCR2, CCR5, CCR7, CXCR3, CXCR4, CCL2, CCL5, CCL21, CXCL9 and CXCL10 were expressed by HCSs and the abundances of them were changed following the praziquantel treatment in the chronic stage, indicating that chemokines were possibly necessary for the persistence of the chronic stage. In vitro experiments, hepatic non-parenchymal cells, primary HSCs and human HSCs line LX-2 were stimulated by chemokines. The results showed that CXCL9 and CXCL10, but not CXCL11 or CXCL4, significantly inhibited the gene expressions of Col1a1, Col3a1 and a-SMA, indicating the potential anti-fibrosis effect of CXCL9 and CXCL10 in schistosomiasis. More interestingly, soluble egg antigen (SEA) of Schistosoma japonicum was able to inhibit transcriptional expressions of some chemokines by LX-2 cells, suggesting that SEA was capable of regulating the expression pattern of chemokine family and modulating the hepatic immune microenvironment in schistosomiasis.
22905138	16	26	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	77	81	mice	Species	Species:10090
22905138	108	116	CXCL9/10	Gene	17329(Species:10090),15945(Species:10090)
22905138	259	269	Chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	448	458	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	474	485	schistosoma	Species	Species:6182
22905138	523	533	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	695	699	mice	Species	Species:10090
22905138	789	799	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	969	974	CXCL9	Gene	17329(Species:10090)
22905138	976	982	CXCL10	Gene	15945(Species:10090)
22905138	987	993	CXCL11	Gene	56066(Species:10090)
22905138	1146	1156	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	1217	1227	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	1238	1242	CCR2	Gene	12772(Species:10090)
22905138	1244	1248	CCR5	Gene	12774(Species:10090)
22905138	1250	1254	CCR7	Gene	12775(Species:10090)
22905138	1256	1261	CXCR3	Gene	12766(Species:10090)
22905138	1263	1268	CXCR4	Gene	12767(Species:10090)
22905138	1270	1274	CCL2	Gene	20296(Species:10090)
22905138	1276	1280	CCL5	Gene	20304(Species:10090)
22905138	1282	1287	CCL21	Gene	18829(Species:10090)
22905138	1289	1294	CXCL9	Gene	17329(Species:10090)
22905138	1299	1305	CXCL10	Gene	15945(Species:10090)
22905138	1444	1454	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	1591	1596	human	Species	Species:9606
22905138	1631	1641	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	1667	1672	CXCL9	Gene	17329(Species:10090)
22905138	1677	1683	CXCL10	Gene	15945(Species:10090)
22905138	1693	1699	CXCL11	Gene	6373(Species:9606)
22905138	1703	1708	CXCL4	Gene	12767(Species:10090)
22905138	1758	1764	Col1a1	Gene	1277(Species:9606),12842(Species:10090)
22905138	1766	1772	Col3a1	Gene	1281(Species:9606),12825(Species:10090)
22905138	1777	1782	a-SMA	Gene	11475(Species:10090),59(Species:9606)
22905138	1833	1838	CXCL9	Gene	17329(Species:10090),4283(Species:9606)
22905138	1843	1849	CXCL10	Gene	15945(Species:10090),3627(Species:9606)
22905138	1919	1940	Schistosoma japonicum	Species	Species:6182
22905138	1997	2007	chemokines	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)
22905138	2011	2015	LX-2	Species	Species:9606
22905138	2095	2104	chemokine	Gene	12766(Species:10090),12767(Species:10090),12772(Species:10090),12774(Species:10090),12775(Species:10090),15945(Species:10090),17329(Species:10090),18829(Species:10090),20296(Species:10090),20304(Species:10090),56066(Species:10090)

27230238|t|RhBMP-2 Activates Hippo Signaling through RASSF1 in Esophageal Cancer Cells.
27230238|a|Despite that recombinant human bone morphogenetic protein-2 (rhBMP-2) has been reported as a stimulatory effecter of cancer cell growth because of its characteristic like morphogen, the biological functions of rhBMP-2 in human esophageal cancer cells are unknown. The purpose of this study was to investigate whether rhBMP-2 has an inhibitory effect on the growth of human esophageal squamous carcinoma cells (ESCC). RhBMP-2 significantly inhibited proliferation of ESCC cells in a dose-dependent manner in the MTT assay. Cell cycle arrest at the G1 phase was induced 24 h after rhBMP2 treatment. RhBMP-2 also reduced cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK 6 activities, and stimulated p-Smad1/5/8, p53, and p21 levels at 12 h. In contrast, rhBMP-2 diminished poly (ADP-ribose) polymerase (PARP) protein expression levels and activated cleaved PARP, cleaved caspase-7, and cleaved-caspase 9 levels in ESCC cells. In addition, rhBMP-2 increased MST1, MOB1, and p-YAP protein levels and the RASSF1 binds Mst1 more upon treatment with rhBMP2. The induced p-YAP expression in TE-8 and TE-12 cells by rhBMP-2 was reversed by the RASSF1 knockdown. In vivo study, rhBMP-2 decreased tumor volume following subcutaneous implantation and showed higher radiologic score (less bony destruction) after femoral implantation compared to those in a control group. These results suggest that rhBMP-2 inhibits rather than activates proliferation of human esophageal cancer cells which is mediated through activating the hippo signaling pathway.
27230238	0	7	RhBMP-2	Gene	650(Species:9606)
27230238	42	48	RASSF1	Gene	11186(Species:9606)
27230238	102	107	human	Species	Species:9606
27230238	108	136	bone morphogenetic protein-2	Gene	650(Species:9606)
27230238	138	145	rhBMP-2	Gene	650(Species:9606)
27230238	287	294	rhBMP-2	Gene	650(Species:9606)
27230238	298	303	human	Species	Species:9606
27230238	394	401	rhBMP-2	Gene	650(Species:9606)
27230238	444	449	human	Species	Species:9606
27230238	496	501	BMP-2	Gene	650(Species:9606)
27230238	656	662	rhBMP2	Gene	650(Species:9606)
27230238	674	681	RhBMP-2	Gene	650(Species:9606)
27230238	695	704	cyclin D1	Gene	595(Species:9606)
27230238	706	737	cyclin-dependent kinase (CDK) 4	Gene	1019(Species:9606)
27230238	742	747	CDK 6	Gene	1021(Species:9606)
27230238	777	786	Smad1/5/8	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
27230238	788	791	p53	Gene	7157(Species:9606)
27230238	797	800	p21	Gene	1026(Species:9606)
27230238	832	837	BMP-2	Gene	650(Species:9606)
27230238	849	877	poly (ADP-ribose) polymerase	Gene	142(Species:9606)
27230238	879	883	PARP	Gene	142(Species:9606)
27230238	933	937	PARP	Gene	142(Species:9606)
27230238	947	956	caspase-7	Gene	840(Species:9606)
27230238	970	979	caspase 9	Gene	842(Species:9606)
27230238	1015	1022	rhBMP-2	Gene	650(Species:9606)
27230238	1033	1037	MST1	Gene	4485(Species:9606)
27230238	1039	1043	MOB1	Gene	55233(Species:9606)
27230238	1051	1054	YAP	Gene	10413(Species:9606)
27230238	1078	1084	RASSF1	Gene	11186(Species:9606)
27230238	1091	1095	Mst1	Gene	4485(Species:9606)
27230238	1123	1127	BMP2	Gene	650(Species:9606)
27230238	1143	1146	YAP	Gene	10413(Species:9606)
27230238	1161	1165	TE-8	Species	Species:10090
27230238	1170	1175	TE-12	Species	Species:9606
27230238	1185	1192	rhBMP-2	Gene	650(Species:9606)
27230238	1213	1219	RASSF1	Gene	11186(Species:9606)
27230238	1246	1253	rhBMP-2	Gene	650(Species:9606)
27230238	1464	1471	rhBMP-2	Gene	650(Species:9606)
27230238	1520	1525	human	Species	Species:9606

28393188|t|A heptameric peptide purified from Spirulina sp. gastrointestinal hydrolysate inhibits angiotensin I-converting enzyme- and angiotensin II-induced vascular dysfunction in human endothelial cells.
28393188|a|In this study, a marine microalga Spirulina sp.-derived protein was hydrolyzed using gastrointestinal enzymes to produce an angiotensin I (Ang I)-converting enzyme (ACE) inhibitory peptide. Following consecutive purification, the potent ACE inhibitory peptide was composed of 7 amino acids, Thr-Met-Glu-Pro-Gly-Lys-Pro (molecular weight, 759 Da). Analysis using the Lineweaver-Burk plot and molecular modeling suggested that the purified peptide acted as a mixed non-competitive inhibitor of ACE. The inhibitory effects of the peptide against the cellular production of vascular dysfunction-related factors induced by Ang II were also investigated. In human endothelial cells, the Ang II-induced production of nitric oxide and reactive oxygen species was inhibited, and the expression of inducible nitric oxide synthase (iNOS) and endothelin-1 (ET-1) was downregulated when the cells were cultured with the purified peptide. Moreover, the peptide blocked the activation of p38 mitogen-activated protein kinase. These results indicated that this Spirulina sp.-derived peptide warrants further investigation as a potential pharmacological inhibitor of ACE and vascular dysfunction.
28393188	35	47	Spirulina sp	Species	Species:1157
28393188	87	118	angiotensin I-converting enzyme	Gene	1636(Species:9606)
28393188	124	138	angiotensin II	Gene	183(Species:9606)
28393188	171	176	human	Species	Species:9606
28393188	230	242	Spirulina sp	Species	Species:1157
28393188	320	359	angiotensin I (Ang I)-converting enzyme	Gene	1636(Species:9606)
28393188	361	364	ACE	Gene	1636(Species:9606)
28393188	433	436	ACE	Gene	1636(Species:9606)
28393188	688	691	ACE	Gene	1636(Species:9606)
28393188	814	820	Ang II	Gene	183(Species:9606)
28393188	848	853	human	Species	Species:9606
28393188	877	883	Ang II	Gene	183(Species:9606)
28393188	984	1015	inducible nitric oxide synthase	Gene	4843(Species:9606)
28393188	1017	1021	iNOS	Gene	4843(Species:9606)
28393188	1027	1039	endothelin-1	Gene	1906(Species:9606)
28393188	1041	1045	ET-1	Gene	1906(Species:9606)
28393188	1169	1205	p38 mitogen-activated protein kinase	Gene	1432(Species:9606)
28393188	1241	1253	Spirulina sp	Species	Species:1157
28393188	1346	1349	ACE	Gene	1636(Species:9606)

19536134|t|TAK1 is an essential regulator of BMP signalling in cartilage.
19536134|a|TGFbeta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis. To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter. Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion. This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-deficient mice. BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases. TAK1 mediates Smad1 phosphorylation at C-terminal serine residues. These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways. Our experiments reveal an essential role for TAK1 in the morphogenesis, growth, and maintenance of cartilage.
19536134	0	4	TAK1	Gene	26409(Species:10090)
19536134	34	37	BMP	Gene	12159(Species:10090)
19536134	63	89	TGFbeta activated kinase 1	Gene	26409(Species:10090)
19536134	91	95	TAK1	Gene	26409(Species:10090)
19536134	114	120	MAPKKK	Gene	26409(Species:10090)
19536134	288	292	TAK1	Gene	26409(Species:10090)
19536134	320	324	mice	Species	Species:10090
19536134	356	360	Tak1	Gene	26409(Species:10090)
19536134	396	400	Tak1	Gene	26409(Species:10090)
19536134	407	411	mice	Species	Species:10090
19536134	621	664	bone morphogenetic protein receptor (BMPR)1	Gene	12166(Species:10090)
19536134	669	673	Gdf5	Gene	14563(Species:10090)
19536134	684	688	mice	Species	Species:10090
19536134	690	694	BMPR	Gene	12166(Species:10090)
19536134	731	735	TAK1	Gene	26409(Species:10090)
19536134	803	806	BMP	Gene	12159(Species:10090)
19536134	858	867	Smad1/5/8	Gene	17125(Species:10090),17129(Species:10090),55994(Species:10090)
19536134	872	875	p38	Gene	26416(Species:10090)
19536134	876	879	Jnk	Gene	26419(Species:10090)
19536134	880	883	Erk	Gene	26413(Species:10090)
19536134	884	895	MAP kinases	Gene	26413(Species:10090),26416(Species:10090),26419(Species:10090)
19536134	897	901	TAK1	Gene	26409(Species:10090)
19536134	911	916	Smad1	Gene	17125(Species:10090)
19536134	1019	1028	mammalian	Species	Species:9606
19536134	1041	1045	TAK1	Gene	26409(Species:10090)
19536134	1062	1065	BMP	Gene	12159(Species:10090)
19536134	1128	1137	Smad1/5/8	Gene	17125(Species:10090),17129(Species:10090),55994(Species:10090)
19536134	1182	1192	MAP kinase	Gene	26413(Species:10090),26416(Species:10090),26419(Species:10090)
19536134	1248	1252	TAK1	Gene	26409(Species:10090)

28777492|t|Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
28777492|a|Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the in vitro function of gankyrin is well known, its role in vivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
28777492	0	8	Gankyrin	Gene	53380(Species:10090)
28777492	17	22	STAT3	Gene	20848(Species:10090)
28777492	225	236	oncoprotein	Gene	53380(Species:10090)
28777492	237	245	gankyrin	Gene	53380(Species:10090)
28777492	345	353	gankyrin	Gene	5716(Species:9606)
28777492	442	450	gankyrin	Gene	53380(Species:10090)
28777492	484	488	mice	Species	Species:10090
28777492	526	534	gankyrin	Gene	53380(Species:10090)
28777492	545	548	Alb	Gene	11657(Species:10090)
28777492	553	561	gankyrin	Gene	53380(Species:10090)
28777492	573	581	gankyrin	Gene	53380(Species:10090)
28777492	652	660	gankyrin	Gene	53380(Species:10090)
28777492	669	677	Gankyrin	Gene	5716(Species:9606)
28777492	690	724	vascular endothelial growth factor	Gene	22339(Species:10090)
28777492	752	760	Gankyrin	Gene	53380(Species:10090)
28777492	770	833	Src homology 2 domain-containing protein tyrosine phosphatase-1	Gene	15170(Species:10090)
28777492	835	840	SHP-1	Gene	15170(Species:10090)
28777492	939	989	signal transducer and activator of transcription 3	Gene	20848(Species:10090)
28777492	991	996	STAT3	Gene	20848(Species:10090)
28777492	999	1007	Gankyrin	Gene	53380(Species:10090)
28777492	1083	1088	STAT3	Gene	20848(Species:10090)
28777492	1099	1117	interleukin (IL)-6	Gene	16193(Species:10090)
28777492	1159	1163	Bmi1	Gene	12151(Species:10090)
28777492	1168	1201	epithelial cell adhesion molecule	Gene	17075(Species:10090)
28777492	1203	1208	EpCAM	Gene	17075(Species:10090)
28777492	1298	1306	gankyrin	Gene	5716(Species:9606)
28777492	1325	1330	human	Species	Species:9606
28777492	1338	1346	Gankyrin	Gene	5716(Species:9606)
28777492	1447	1455	patients	Species	Species:9606
28777492	1502	1510	gankyrin	Gene	53380(Species:10090)

30202097|t|Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis.
30202097|a|Solute carrier family 7 member 2 (SLC7A2, also known as CAT2) is an inducible transporter of the semi-essential amino acid L-arginine (L-Arg), which has been implicated in wound repair. We have reported that both SLC7A2 expression and L-Arg availability are decreased in colonic tissues from inflammatory bowel disease patients and that mice lacking Slc7a2 exhibit a more severe disease course when exposed to dextran sulfate sodium (DSS) compared to wild-type (WT) mice. Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). SLC7A2 was localized predominantly to colonic epithelial cells in WT mice. Utilizing the AOM-DSS model, Slc7a2-/- mice had significantly increased tumor number, burden, and risk of high-grade dysplasia vs. WT mice. Tumors from Slc7a2-/- mice exhibited significantly increased levels of the proinflammatory cytokines/chemokines IL-1beta, CXCL1, CXCL5, IL-3, CXCL2, CCL3, and CCL4, but decreased levels of IL-4, CXCL9, and CXCL10 compared to tumors from WT mice. This was accompanied by a shift toward pro-tumorigenic M2 macrophage activation in Slc7a2-deficient mice, as marked by increased colonic CD11b+F4/80+ARG1+ cells with no alteration in CD11b+F4/80+NOS2+ cells by flow cytometry and immunofluorescence microscopy. The shift toward M2 macrophage activation was confirmed in bone marrow-derived macrophages from Slc7a2-/- mice. In bone marrow chimeras between Slc7a2-/- and WT mice, the recipient genotype drove the CAC phenotype, suggesting the importance of epithelial SLC7A2 in abrogating neoplastic risk. These data reveal that SLC7A2 has a significant role in the protection from CAC in the setting of chronic colitis, and suggest that the decreased SLC7A2 in inflammatory bowel disease (IBD) may contribute to CAC risk. Strategies to enhance L-Arg availability by supplementing L-Arg and/or increasing L-Arg uptake could represent a therapeutic approach in IBD to reduce the substantial long-term risk of colorectal carcinoma.
30202097	8	40	solute carrier family 7 member 2	Gene	11988(Species:10090)
30202097	98	130	Solute carrier family 7 member 2	Gene	11988(Species:10090)
30202097	132	138	SLC7A2	Gene	11988(Species:10090)
30202097	154	158	CAT2	Gene	11988(Species:10090)
30202097	311	317	SLC7A2	Gene	6542(Species:9606)
30202097	417	425	patients	Species	Species:9606
30202097	435	439	mice	Species	Species:10090
30202097	448	454	Slc7a2	Gene	11988(Species:10090)
30202097	564	568	mice	Species	Species:10090
30202097	601	607	SLC7A2	Gene	11988(Species:10090)
30202097	735	741	SLC7A2	Gene	11988(Species:10090)
30202097	804	808	mice	Species	Species:10090
30202097	839	845	Slc7a2	Gene	11988(Species:10090)
30202097	849	853	mice	Species	Species:10090
30202097	944	948	mice	Species	Species:10090
30202097	962	968	Slc7a2	Gene	11988(Species:10090)
30202097	972	976	mice	Species	Species:10090
30202097	1041	1050	cytokines	Gene	14825(Species:10090),15945(Species:10090),16176(Species:10090),16187(Species:10090),16189(Species:10090),17329(Species:10090),20302(Species:10090),20303(Species:10090),20310(Species:10090),20311(Species:10090),3684(Species:9606)
30202097	1051	1061	chemokines	Gene	14825(Species:10090),15945(Species:10090),17329(Species:10090),20302(Species:10090),20303(Species:10090),20310(Species:10090),20311(Species:10090)
30202097	1062	1070	IL-1beta	Gene	16176(Species:10090)
30202097	1072	1077	CXCL1	Gene	14825(Species:10090)
30202097	1079	1084	CXCL5	Gene	20311(Species:10090)
30202097	1086	1090	IL-3	Gene	16187(Species:10090)
30202097	1092	1097	CXCL2	Gene	20310(Species:10090)
30202097	1099	1103	CCL3	Gene	20302(Species:10090)
30202097	1109	1113	CCL4	Gene	20303(Species:10090)
30202097	1139	1143	IL-4	Gene	16189(Species:10090)
30202097	1145	1150	CXCL9	Gene	17329(Species:10090)
30202097	1156	1162	CXCL10	Gene	15945(Species:10090)
30202097	1190	1194	mice	Species	Species:10090
30202097	1279	1285	Slc7a2	Gene	11988(Species:10090)
30202097	1296	1300	mice	Species	Species:10090
30202097	1333	1338	CD11b	Gene	3684(Species:9606)
30202097	1339	1344	F4/80	Species	Species:10090
30202097	1345	1349	ARG1	Gene	11846(Species:10090)
30202097	1379	1384	CD11b	Gene	3684(Species:9606)
30202097	1385	1390	F4/80	Species	Species:10090
30202097	1552	1558	Slc7a2	Gene	11988(Species:10090)
30202097	1562	1566	mice	Species	Species:10090
30202097	1600	1606	Slc7a2	Gene	11988(Species:10090)
30202097	1617	1621	mice	Species	Species:10090
30202097	1711	1717	SLC7A2	Gene	11988(Species:10090)
30202097	1772	1778	SLC7A2	Gene	11988(Species:10090)
30202097	1895	1901	SLC7A2	Gene	11988(Species:10090)

27502584|t|MicroRNA-203 mimics age-related aortic smooth muscle dysfunction of cytoskeletal pathways.
27502584|a|Increased aortic stiffness is a biomarker for subsequent adverse cardiovascular events. We have previously reported that vascular smooth muscle Src-dependent cytoskeletal remodelling, which contributes to aortic plasticity, is impaired with ageing. Here, we use a multi-scale approach to determine the molecular mechanisms behind defective Src-dependent signalling in an aged C57BL/6 male mouse model. Increased aortic stiffness, as measured in vivo by pulse wave velocity, was found to have a comparable time course to that in humans. Bioinformatic analyses predicted several miRs to regulate Src-dependent cytoskeletal remodelling. qRT-PCR was used to determine the relative levels of predicted miRs in aortas and, notably, the expression of miR-203 increased almost twofold in aged aorta. Increased miR-203 expression was associated with a decrease in both mRNA and protein expression of Src, caveolin-1 and paxillin in aged aorta. Probing with phospho-specific antibodies confirmed that overexpression of miR-203 significantly attenuated Src and extracellular signal regulated kinase (ERK) signalling, which we have previously found to regulate vascular smooth muscle stiffness. In addition, transfection of miR-203 into aortic tissue from young mice increased phenylephrine-induced aortic stiffness ex vivo, mimicking the aged phenotype. Upstream of miR-203, we found that DNA methyltransferases (DNMT) 1, 3a, and 3b are also significantly decreased in the aged mouse aorta and that DNMT inhibition significantly increases miR-203 expression. Thus, the age-induced increase in miR-203 may be caused by epigenetic promoter hypomethylation in the aorta. These findings indicate that miR-203 promotes a re-programming of Src/ERK signalling pathways in vascular smooth muscle, impairing the regulation of stiffness in aged aorta.
27502584	0	12	MicroRNA-203	Gene	387199(Species:10090)
27502584	235	238	Src	Gene	20779(Species:10090)
27502584	431	434	Src	Gene	20779(Species:10090)
27502584	480	485	mouse	Species	Species:10090
27502584	619	625	humans	Species	Species:9606
27502584	685	688	Src	Gene	20779(Species:10090)
27502584	835	842	miR-203	Gene	387199(Species:10090)
27502584	893	900	miR-203	Gene	387199(Species:10090)
27502584	982	985	Src	Gene	20779(Species:10090)
27502584	987	997	caveolin-1	Gene	12389(Species:10090)
27502584	1002	1010	paxillin	Gene	19303(Species:10090)
27502584	1100	1107	miR-203	Gene	387199(Species:10090)
27502584	1133	1136	Src	Gene	20779(Species:10090)
27502584	1141	1178	extracellular signal regulated kinase	Gene	26413(Species:10090)
27502584	1180	1183	ERK	Gene	26413(Species:10090)
27502584	1303	1310	miR-203	Gene	387199(Species:10090)
27502584	1341	1345	mice	Species	Species:10090
27502584	1446	1453	miR-203	Gene	387199(Species:10090)
27502584	1469	1512	DNA methyltransferases (DNMT) 1, 3a, and 3b	Gene	13435(Species:10090),13433(Species:10090),13436(Species:10090)
27502584	1558	1563	mouse	Species	Species:10090
27502584	1579	1583	DNMT	Gene	13435(Species:10090),13433(Species:10090),13436(Species:10090)
27502584	1619	1626	miR-203	Gene	387199(Species:10090)
27502584	1673	1680	miR-203	Gene	387199(Species:10090)
27502584	1777	1784	miR-203	Gene	387199(Species:10090)
27502584	1814	1817	Src	Gene	20779(Species:10090)
27502584	1818	1821	ERK	Gene	26413(Species:10090)

22369755|t|Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells.
22369755|a|AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation. MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively. KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1. Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only). NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1. NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells. These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3. SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.
22369755	30	37	SLURP-1	Gene	57152(Species:9606)
22369755	116	149	nicotinic acetylcholine receptors	Gene	1136(Species:9606)
22369755	215	222	tobacco	Species	Species:4097
22369755	425	434	mammalian	Species	Species:9606
22369755	435	498	Ly-6/urokinase plasminogen activator receptor related protein-1	Gene	57152(Species:9606)
22369755	500	507	SLURP-1	Gene	57152(Species:9606)
22369755	556	563	SLURP-1	Gene	57152(Species:9606)
22369755	619	624	human	Species	Species:9606
22369755	781	784	MYB	Gene	4602(Species:9606)
22369755	789	795	PIK3CA	Gene	5290(Species:9606)
22369755	806	810	ETS1	Gene	2113(Species:9606)
22369755	812	816	NRAS	Gene	4893(Species:9606)
22369755	821	824	SRC	Gene	6714(Species:9606)
22369755	828	834	Het-1A	Species	Species:9606
22369755	840	844	AKT1	Gene	207(Species:9606)
22369755	846	849	KIT	Gene	3815(Species:9606)
22369755	854	857	RB1	Gene	5925(Species:9606)
22369755	923	930	SLURP-1	Gene	57152(Species:9606)
22369755	1005	1012	SLURP-1	Gene	57152(Species:9606)
22369755	1022	1036	growth factors	Gene	1950(Species:9606),3082(Species:9606)
22369755	1037	1040	EGF	Gene	1950(Species:9606)
22369755	1044	1049	BEP2D	Species	Species:9606
22369755	1060	1063	HGF	Gene	3082(Species:9606)
22369755	1067	1073	Het-1A	Species	Species:9606
22369755	1089	1110	transcription factors	Gene	6774(Species:9606)
22369755	1111	1117	CDKN2A	Gene	1029(Species:9606)
22369755	1122	1127	STAT3	Gene	6774(Species:9606)
22369755	1183	1187	BCL2	Gene	596(Species:9606)
22369755	1233	1236	TNF	Gene	7124(Species:9606)
22369755	1247	1250	BAX	Gene	581(Species:9606)
22369755	1255	1260	CASP8	Gene	841(Species:9606)
22369755	1315	1323	rSLURP-1	Gene	57152(Species:9606)
22369755	1357	1363	CTNNB1	Gene	1499(Species:9606)
22369755	1414	1426	beta-catenin	Gene	1499(Species:9606)
22369755	1465	1470	CDKN3	Gene	1033(Species:9606)
22369755	1475	1480	FOXD3	Gene	27022(Species:9606)
22369755	1484	1489	BEP2D	Species	Species:9606
22369755	1500	1508	SERPINB5	Gene	5268(Species:9606)
22369755	1512	1518	Het-1A	Species	Species:9606
22369755	1579	1587	rSLURP-1	Gene	57152(Species:9606)
22369755	1610	1615	RUNX3	Gene	864(Species:9606)
22369755	1693	1700	SLURP-1	Gene	57152(Species:9606)

24914936|t|Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
24914936|a|A new genetic disorder has been identified that results from mutation of THRA, encoding thyroid hormone receptor a1 (TRa1). Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia. In an attempt to improve developmental delay and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of T4 treatment, but responses have been inconsistent so far. Thra1(PV/+) mice express a similar potent dominant-negative mutant TRa1 to affected individuals, and thus represent an excellent disease model. We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities. Adult female Thra1(PV/+) mice had short stature, grossly abnormal bone morphology but normal bone strength despite high bone mass. Although T4 treatment suppressed TSH secretion, it had no effect on skeletal maturation, linear growth, or bone mineralization, thus demonstrating profound tissue resistance to thyroid hormone. Despite this, prolonged T4 treatment abnormally increased bone stiffness and strength, suggesting the potential for detrimental consequences in the long term. Our studies establish that TRa1 has an essential role in the developing and adult skeleton and predict that patients with different THRA mutations will display variable responses to T4 treatment, which depend on the severity of the causative mutation.
24914936	0	26	Thyroid hormone receptor a	Gene	21833(Species:10090)
24914936	105	109	mice	Species	Species:10090
24914936	184	188	THRA	Gene	7067(Species:9606)
24914936	199	226	thyroid hormone receptor a1	Gene	7067(Species:9606)
24914936	228	232	TRa1	Gene	7067(Species:9606)
24914936	244	252	children	Species	Species:9606
24914936	486	494	patients	Species	Species:9606
24914936	599	604	Thra1	Gene	21833(Species:10090)
24914936	611	615	mice	Species	Species:10090
24914936	666	670	TRa1	Gene	21833(Species:10090)
24914936	764	769	Thra1	Gene	21833(Species:10090)
24914936	776	780	mice	Species	Species:10090
24914936	830	835	human	Species	Species:9606
24914936	836	840	THRA	Gene	7067(Species:9606)
24914936	983	988	Thra1	Gene	21833(Species:10090)
24914936	995	999	mice	Species	Species:10090
24914936	1134	1137	TSH	Gene	22094(Species:10090),12640(Species:10090)
24914936	1481	1485	TRa1	Gene	21833(Species:10090)
24914936	1562	1570	patients	Species	Species:9606
24914936	1586	1590	THRA	Gene	7067(Species:9606)

23966295|t|Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
23966295|a|Basal-like breast cancer (BLBC) is an aggressive disease that lacks a clinically approved targeted therapy. Traditional chemotherapy is effective in BLBC, but it spares the cancer stem cell (CSC)-like population, which is likely to contribute to cancer recurrence after the initial treatment. Dual specificity phosphatase-4 (DUSP4) is a negative regulator of the mitogen-activated protein kinase (MAPK) pathway that is deficient in highly aggressive BLBCs treated with chemotherapy, leading to aberrant MAPK activation and resistance to taxane-induced apoptosis. Herein, we investigated how DUSP4 regulates the MAP-ERK kinase (MEK) and c-jun-NH2-kinase (JNK) pathways in modifying CSC-like behavior. DUSP4 loss increased mammosphere formation and the expression of the CSC-promoting cytokines interleukin (IL)-6 and IL-8. These effects were caused in part by loss of control of the MEK and JNK pathways and involved downstream activation of the ETS-1 and c-JUN transcription factors. Enforced expression of DUSP4 reduced the CD44(+)/CD24(-) population in multiple BLBC cell lines in a MEK-dependent manner, limiting tumor formation of claudin-low SUM159PT cells in mice. Our findings support the evaluation of MEK and JNK pathway inhibitors as therapeutic agents in BLBC to eliminate the CSC population.
23966295	14	18	MAPK	Gene	5599(Species:9606),5609(Species:9606)
23966295	35	40	DUSP4	Gene	1846(Species:9606)
23966295	410	440	Dual specificity phosphatase-4	Gene	1846(Species:9606)
23966295	442	447	DUSP4	Gene	1846(Species:9606)
23966295	480	512	mitogen-activated protein kinase	Gene	5599(Species:9606),5609(Species:9606)
23966295	514	518	MAPK	Gene	5599(Species:9606),5609(Species:9606)
23966295	620	624	MAPK	Gene	5599(Species:9606),5609(Species:9606)
23966295	708	713	DUSP4	Gene	1846(Species:9606)
23966295	728	742	MAP-ERK kinase	Gene	5609(Species:9606)
23966295	744	747	MEK	Gene	5609(Species:9606)
23966295	753	769	c-jun-NH2-kinase	Gene	5599(Species:9606)
23966295	771	774	JNK	Gene	5599(Species:9606)
23966295	817	822	DUSP4	Gene	1846(Species:9606)
23966295	900	909	cytokines	Gene	3569(Species:9606),3576(Species:9606)
23966295	910	928	interleukin (IL)-6	Gene	3569(Species:9606)
23966295	933	937	IL-8	Gene	3576(Species:9606)
23966295	999	1002	MEK	Gene	5609(Species:9606)
23966295	1007	1010	JNK	Gene	5599(Species:9606)
23966295	1062	1067	ETS-1	Gene	2113(Species:9606)
23966295	1072	1077	c-JUN	Gene	3725(Species:9606)
23966295	1124	1129	DUSP4	Gene	1846(Species:9606)
23966295	1142	1146	CD44	Gene	960(Species:9606)
23966295	1150	1154	CD24	Gene	100133941(Species:9606)
23966295	1202	1205	MEK	Gene	5609(Species:9606)
23966295	1252	1259	claudin	Gene	9076(Species:9606)
23966295	1264	1272	SUM159PT	Species	Species:9606
23966295	1282	1286	mice	Species	Species:10090
23966295	1327	1330	MEK	Gene	5609(Species:9606)
23966295	1335	1338	JNK	Gene	5599(Species:9606)

28228553|t|The novel mitochondrial matrix protease Ste23 is required for efficient presequence degradation and processing.
28228553|a|Around 70% of mitochondrial precursor proteins are imported from the cytosol via N-terminal presequences, which are cleaved upon exposure to the mitochondrial processing protease MPP in the matrix. Cleaved presequence peptides then need to be efficiently degraded and impairment of this clearance step e.g. by amyloid beta peptides causes a feedback inhibition of MPP leading ultimately to accumulation of immature precursor proteins within mitochondria. Degradation of mitochondrial peptides is performed by Cym1 in yeast and its homolog PreP in humans. Here we identify the novel mitochondrial matrix protease Ste23 in yeast, a homolog of human insulin degrading enzyme, which is required for efficient peptide degradation. Ste23 and Cym1 tightly cooperate to ensure the correct functioning of the essential presequence processing machinery.
28228553	10	39	mitochondrial matrix protease	Gene	851105(Species:559292)
28228553	40	45	Ste23	Gene	851105(Species:559292)
28228553	257	290	mitochondrial processing protease	Gene	856419(Species:559292)
28228553	291	294	MPP	Gene	850860(Species:559292),856419(Species:559292)
28228553	422	434	amyloid beta	Gene	351(Species:9606)
28228553	476	479	MPP	Gene	850860(Species:559292),856419(Species:559292)
28228553	621	625	Cym1	Gene	852041(Species:559292)
28228553	629	634	yeast	Species	Species:559292
28228553	651	655	PreP	Gene	10531(Species:9606)
28228553	659	665	humans	Species	Species:9606
28228553	694	723	mitochondrial matrix protease	Gene	851105(Species:559292)
28228553	724	729	Ste23	Gene	851105(Species:559292)
28228553	733	738	yeast	Species	Species:559292
28228553	753	758	human	Species	Species:9606
28228553	759	783	insulin degrading enzyme	Gene	3416(Species:9606)
28228553	838	843	Ste23	Gene	851105(Species:559292)
28228553	848	852	Cym1	Gene	852041(Species:559292)

21124868|t|Localization of a guanylyl cyclase to chemosensory cilia requires the novel ciliary MYND domain protein DAF-25.
21124868|a|In harsh conditions, Caenorhabditis elegans arrests development to enter a non-aging, resistant diapause state called the dauer larva. Olfactory sensation modulates the TGF-beta and insulin signaling pathways to control this developmental decision. Four mutant alleles of daf-25 (abnormal DAuer Formation) were isolated from screens for mutants exhibiting constitutive dauer formation and found to be defective in olfaction. The daf-25 dauer phenotype is suppressed by daf-10/IFT122 mutations (which disrupt ciliogenesis), but not by daf-6/PTCHD3 mutations (which prevent environmental exposure of sensory cilia), implying that DAF-25 functions in the cilia themselves. daf-25 encodes the C. elegans ortholog of mammalian Ankmy2, a MYND domain protein of unknown function. Disruption of DAF-25, which localizes to sensory cilia, produces no apparent cilia structure anomalies, as determined by light and electron microscopy. Hinting at its potential function, the dauer phenotype, epistatic order, and expression profile of daf-25 are similar to daf-11, which encodes a cilium-localized guanylyl cyclase. Indeed, we demonstrate that DAF-25 is required for proper DAF-11 ciliary localization. Furthermore, the functional interaction is evolutionarily conserved, as mouse Ankmy2 interacts with guanylyl cyclase GC1 from ciliary photoreceptors. The interaction may be specific because daf-25 mutants have normally-localized OSM-9/TRPV4, TAX-4/CNGA1, CHE-2/IFT80, CHE-11/IFT140, CHE-13/IFT57, BBS-8, OSM-5/IFT88, and XBX-1/D2LIC in the cilia. Intraflagellar transport (IFT) (required to build cilia) is not defective in daf-25 mutants, although the ciliary localization of DAF-25 itself is influenced in che-11 mutants, which are defective in retrograde IFT. In summary, we have discovered a novel ciliary protein that plays an important role in cGMP signaling by localizing a guanylyl cyclase to the sensory organelle.
21124868	18	34	guanylyl cyclase	Gene	14919(Species:10090),179605(Species:6239)
21124868	104	110	DAF-25	Gene	171623(Species:6239)
21124868	133	155	Caenorhabditis elegans	Species	Species:6239
21124868	281	289	TGF-beta	Gene	175237(Species:6239)
21124868	294	301	insulin	Gene	191688(Species:6239)
21124868	384	390	daf-25	Gene	171623(Species:6239)
21124868	541	547	daf-25	Gene	171623(Species:6239)
21124868	581	587	daf-10	Gene	184883(Species:6239)
21124868	588	594	IFT122	Gene	184883(Species:6239)
21124868	646	651	daf-6	Gene	181584(Species:6239)
21124868	652	658	PTCHD3	Gene	181584(Species:6239)
21124868	740	746	DAF-25	Gene	171623(Species:6239)
21124868	782	788	daf-25	Gene	171623(Species:6239)
21124868	801	811	C. elegans	Species	Species:6239
21124868	824	833	mammalian	Species	Species:9606
21124868	834	840	Ankmy2	Gene	217473(Species:10090)
21124868	899	905	DAF-25	Gene	171623(Species:6239)
21124868	1136	1142	daf-25	Gene	171623(Species:6239)
21124868	1158	1164	daf-11	Gene	179605(Species:6239)
21124868	1199	1215	guanylyl cyclase	Gene	14919(Species:10090),179605(Species:6239)
21124868	1245	1251	DAF-25	Gene	171623(Species:6239)
21124868	1275	1281	DAF-11	Gene	179605(Species:6239)
21124868	1376	1381	mouse	Species	Species:10090
21124868	1382	1388	Ankmy2	Gene	217473(Species:10090)
21124868	1404	1420	guanylyl cyclase	Gene	14919(Species:10090)
21124868	1421	1424	GC1	Gene	14919(Species:10090)
21124868	1494	1500	daf-25	Gene	171623(Species:6239)
21124868	1533	1538	OSM-9	Gene	177117(Species:6239)
21124868	1539	1544	TRPV4	Gene	177117(Species:6239)
21124868	1546	1551	TAX-4	Gene	176297(Species:6239)
21124868	1552	1557	CNGA1	Gene	176297(Species:6239)
21124868	1559	1564	CHE-2	Gene	180401(Species:6239)
21124868	1565	1570	IFT80	Gene	180401(Species:6239)
21124868	1572	1578	CHE-11	Gene	179666(Species:6239)
21124868	1579	1585	IFT140	Gene	179666(Species:6239)
21124868	1587	1593	CHE-13	Gene	186607(Species:6239)
21124868	1594	1599	IFT57	Gene	186607(Species:6239)
21124868	1601	1606	BBS-8	Gene	188904(Species:6239)
21124868	1608	1613	OSM-5	Gene	180585(Species:6239)
21124868	1614	1619	IFT88	Gene	180585(Species:6239)
21124868	1625	1630	XBX-1	Gene	184080(Species:6239)
21124868	1631	1636	D2LIC	Gene	184080(Species:6239)
21124868	1728	1734	daf-25	Gene	171623(Species:6239)
21124868	1781	1787	DAF-25	Gene	171623(Species:6239)
21124868	1812	1818	che-11	Gene	179666(Species:6239)
21124868	1985	2001	guanylyl cyclase	Gene	14919(Species:10090),179605(Species:6239)

27941998|t|Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.
27941998|a|Desminopathies caused by the mutation in the gene coding for desmin are genetically protein aggregation myopathies. Mitochondrial dysfunction is one of pathological changes in the desminopathies at the earliest stage. The molecular mechanisms of mitochondria dysfunction in desminopathies remain exclusive. VDAC1 regulates mitochondrial uptake across the outer membrane and mitochondrial outer membrane permeabilization (MOMP). Relationships between desminopathies and Voltage-dependent anion channel 1 (VDAC1) remain unclear. Here we successfully constructed the desminopathy rat model, evaluated with conventional stains, containing hematoxylin and eosin (HE), Gomori Trichrome (MGT), (PAS), red oil (ORO), NADH-TR, SDH staining and immunohistochemistry. Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones. Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever. Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2. This pathological analysis presents the correlation between VDAC1 and desmin, and apoptosis related proteins are correlated in the desminopathy. Furthermore, we provide a rat model of desminopathy for the investigation of desmin related myopathy.
27941998	0	33	Voltage-Dependent Anion Channel 1	Gene	7416(Species:9606),83529(Species:10116)
27941998	34	39	VDAC1	Gene	7416(Species:9606),83529(Species:10116)
27941998	179	185	desmin	Gene	1674(Species:9606)
27941998	425	430	VDAC1	Gene	7416(Species:9606)
27941998	587	620	Voltage-dependent anion channel 1	Gene	7416(Species:9606)
27941998	622	627	VDAC1	Gene	7416(Species:9606)
27941998	695	698	rat	Species	Species:10116
27941998	914	919	VDAC1	Gene	7416(Species:9606),83529(Species:10116)
27941998	943	949	desmin	Gene	1674(Species:9606),64362(Species:10116)
27941998	1003	1011	patients	Species	Species:9606
27941998	1028	1031	rat	Species	Species:10116
27941998	1104	1107	bax	Gene	24887(Species:10116),581(Species:9606)
27941998	1112	1116	ATF2	Gene	1386(Species:9606),81647(Species:10116)
27941998	1147	1155	patients	Species	Species:9606
27941998	1173	1176	rat	Species	Species:10116
27941998	1192	1197	bcl-2	Gene	24224(Species:10116),596(Species:9606)
27941998	1199	1205	bcl-xl	Gene	24888(Species:10116),598(Species:9606)
27941998	1209	1212	HK2	Gene	25059(Species:10116),3099(Species:9606)
27941998	1213	1218	VDAC1	Gene	7416(Species:9606),83529(Species:10116)
27941998	1223	1229	desmin	Gene	1674(Species:9606),64362(Species:10116)
27941998	1290	1298	patients	Species	Species:9606
27941998	1303	1307	rats	Species	Species:10116
27941998	1419	1422	bax	Gene	24887(Species:10116),581(Species:9606)
27941998	1424	1428	ATF2	Gene	1386(Species:9606),81647(Species:10116)
27941998	1438	1443	bcl-2	Gene	24224(Species:10116),596(Species:9606)
27941998	1445	1451	bcl-xl	Gene	24888(Species:10116),598(Species:9606)
27941998	1455	1458	HK2	Gene	25059(Species:10116),3099(Species:9606)
27941998	1520	1525	VDAC1	Gene	7416(Species:9606),83529(Species:10116)
27941998	1530	1536	desmin	Gene	1674(Species:9606),64362(Species:10116)
27941998	1631	1634	rat	Species	Species:10116
27941998	1682	1688	desmin	Gene	64362(Species:10116)

28481876|t|Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies.
28481876|a|Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation. MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies. The gain of MCM8 is associated with aggressive clinical features of several human cancers. Increased expression of MCM8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells. As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.
28481876	32	66	miniature chromosome maintenance 8	Gene	84515(Species:9606)
28481876	70	75	human	Species	Species:9606
28481876	90	122	Miniature chromosome maintenance	Gene	84515(Species:9606)
28481876	124	127	MCM	Gene	84515(Species:9606)
28481876	215	219	MCM8	Gene	84515(Species:9606)
28481876	232	235	MCM	Gene	84515(Species:9606)
28481876	384	389	human	Species	Species:9606
28481876	416	420	MCM8	Gene	84515(Species:9606)
28481876	480	485	human	Species	Species:9606
28481876	519	523	MCM8	Gene	84515(Species:9606)
28481876	602	606	MCM8	Gene	84515(Species:9606)
28481876	610	615	RWPE1	Species	Species:9606
28481876	660	684	prostate epithelial cell	Species	Species:9606
28481876	758	762	MCM8	Gene	84515(Species:9606)
28481876	771	776	DU145	Species	Species:9606
28481876	781	786	LNCaP	Species	Species:9606
28481876	900	904	mice	Species	Species:10090
28481876	930	935	DU145	Species	Species:9606
28481876	943	947	MCM8	Gene	84515(Species:9606)
28481876	954	963	cyclin D1	Gene	595(Species:9606)
28481876	978	980	Rb	Gene	5925(Species:9606)
28481876	1008	1033	cyclin-dependent kinase 4	Gene	1019(Species:9606)
28481876	1060	1069	cyclin D1	Gene	595(Species:9606)
28481876	1070	1074	MCM8	Gene	84515(Species:9606)
28481876	1103	1105	Rb	Gene	5925(Species:9606)
28481876	1235	1239	MCM8	Gene	84515(Species:9606)
28481876	1267	1272	human	Species	Species:9606

24643644|t|Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans.
24643644|a|C-reactive protein (CRP) is a heritable biomarker of systemic inflammation and a predictor of cardiovascular disease (CVD). Large-scale genetic association studies for CRP have largely focused on individuals of European descent. We sought to uncover novel genetic variants for CRP in a multiethnic sample using the ITMAT Broad-CARe (IBC) array, a custom 50,000 SNP gene-centric array having dense coverage of over 2,000 candidate CVD genes. We performed analyses on 7,570 African Americans (AA) from the Candidate gene Association Resource (CARe) study and race-combined meta-analyses that included 29,939 additional individuals of European descent from CARe, the Women's Health Initiative (WHI) and KORA studies. We observed array-wide significance (p < 2.2 x 10(-6)) for four loci in AA, three of which have been reported previously in individuals of European descent (IL6R, p = 2.0 x 10(-6); CRP, p = 4.2 x 10(-71); APOE, p = 1.6 x 10(-6)). The fourth significant locus, CD36 (p = 1.6 x 10(-6)), was observed at a functional variant (rs3211938) that is extremely rare in individuals of European descent. We replicated the CD36 finding (p = 1.8 x 10(-5)) in an independent sample of 8,041 AA women from WHI; a meta-analysis combining the CARe and WHI AA results at rs3211938 reached genome-wide significance (p = 1.5 x 10(-10)). In the race-combined meta-analyses, 13 loci reached significance, including ten (CRP, TOMM40/APOE/APOC1, HNF1A, LEPR, GCKR, IL6R, IL1RN, NLRP3, HNF4A and BAZ1B/BCL7B) previously associated with CRP, and one (ARNTL) previously reported to be nominally associated with CRP. Two novel loci were also detected (RPS6KB1, p = 2.0 x 10(-6); CD36, p = 1.4 x 10(-6)). These results highlight both shared and unique genetic risk factors for CRP in AA compared to populations of European descent.
24643644	43	61	C-reactive protein	Gene	1401(Species:9606)
24643644	111	115	CD36	Species	Species:42374
24643644	111	115	CD36	Gene	948(Species:9606)
24643644	138	156	C-reactive protein	Gene	1401(Species:9606)
24643644	158	161	CRP	Gene	1401(Species:9606)
24643644	306	309	CRP	Gene	1401(Species:9606)
24643644	415	418	CRP	Gene	1401(Species:9606)
24643644	802	807	Women	Species	Species:9606
24643644	1009	1013	IL6R	Gene	3570(Species:9606)
24643644	1033	1036	CRP	Gene	1401(Species:9606)
24643644	1057	1061	APOE	Gene	348(Species:9606)
24643644	1112	1116	CD36	Species	Species:42374
24643644	1112	1116	CD36	Gene	948(Species:9606)
24643644	1263	1267	CD36	Gene	948(Species:9606)
24643644	1263	1267	CD36	Species	Species:42374
24643644	1332	1337	women	Species	Species:9606
24643644	1550	1553	CRP	Gene	1401(Species:9606)
24643644	1555	1561	TOMM40	Gene	10452(Species:9606)
24643644	1562	1566	APOE	Gene	348(Species:9606)
24643644	1567	1572	APOC1	Gene	341(Species:9606)
24643644	1574	1579	HNF1A	Gene	6927(Species:9606)
24643644	1581	1585	LEPR	Gene	3953(Species:9606)
24643644	1587	1591	GCKR	Gene	2646(Species:9606)
24643644	1593	1597	IL6R	Gene	3570(Species:9606)
24643644	1599	1604	IL1RN	Gene	3557(Species:9606)
24643644	1606	1611	NLRP3	Gene	114548(Species:9606)
24643644	1613	1618	HNF4A	Gene	3172(Species:9606)
24643644	1623	1628	BAZ1B	Gene	9031(Species:9606)
24643644	1629	1634	BCL7B	Gene	9275(Species:9606)
24643644	1663	1666	CRP	Gene	1401(Species:9606)
24643644	1677	1682	ARNTL	Gene	406(Species:9606)
24643644	1736	1739	CRP	Gene	1401(Species:9606)
24643644	1776	1783	RPS6KB1	Gene	6198(Species:9606)
24643644	1803	1807	CD36	Gene	948(Species:9606)
24643644	1803	1807	CD36	Species	Species:42374
24643644	1900	1903	CRP	Gene	1401(Species:9606)

23934545|t|Loss of PPARg expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment.
23934545|a|Breast cancer is the leading cause of new cancer diagnoses among women. Using peroxisome proliferator-activated receptor (PPAR)g((+/-)) mice, we showed normal expression of PPARg was critical to stop 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumorigenesis. PPARg is expressed in many breast cell types including mammary secretory epithelial (MSE) cells. MSEs proliferate as required during pregnancy, and undergo apoptosis or reversible transdifferentiation during involution once lactation is complete. Thus, MSE-specific loss of PPARg was hypothesized to enhance DMBA-mediated breast tumorigenesis. To test this, MSE cell-specific PPARg knockout (PPARg-MSE KO) and control (PPARg-WT) mice were generated, mated and allowed to nurse for three days. One week after involution, dams were treated with DMBA to initiate breast tumors, and randomized on week 7 to continue receiving a normal chow diet (DMBA Only: PPARg-WT, n = 15; PPARg-MSE KO, n = 25) or one supplemented with a PPARg activating drug (DMBA + ROSI: PPARg-WT, n = 17; PPARg-MSE KO, n = 24), and monitored for changes in breast tumor outcomes. PPARg-MSE KOs had significantly lower overall survival and decreased mammary tumor latency as compared to PPARg-WT controls. PPARg activation significantly reduced DMBA-mediated malignant mammary tumor volumes irrespective of genotype. MSE-specific PPARg loss resulted in decreased mammary gland expression of PTEN and Bax, increased superoxide anion production, and elevated serum eotaxin and RANTES, creating a protumorigenic environment. Moreover, PPARg activation in MSEs delayed mammary tumor growth in part by down-regulating Cox-1, Cox-2 and cyclin D1. Collectively, these studies highlight a protective role of MSE-specific PPARg during breast tumorigenesis, and support a novel chemotherapeutic role of PPARg activation in breast cancer.
23934545	8	13	PPARg	Gene	19016(Species:10090)
23934545	174	179	women	Species	Species:9606
23934545	187	237	peroxisome proliferator-activated receptor (PPAR)g	Gene	19016(Species:10090)
23934545	245	249	mice	Species	Species:10090
23934545	282	287	PPARg	Gene	19016(Species:10090)
23934545	377	382	PPARg	Gene	19016(Species:10090)
23934545	651	656	PPARg	Gene	19016(Species:10090)
23934545	753	758	PPARg	Gene	19016(Species:10090)
23934545	769	774	PPARg	Gene	19016(Species:10090)
23934545	796	801	PPARg	Gene	19016(Species:10090)
23934545	806	810	mice	Species	Species:10090
23934545	1030	1035	PPARg	Gene	19016(Species:10090)
23934545	1048	1053	PPARg	Gene	19016(Species:10090)
23934545	1097	1102	PPARg	Gene	19016(Species:10090)
23934545	1133	1138	PPARg	Gene	19016(Species:10090)
23934545	1151	1156	PPARg	Gene	19016(Species:10090)
23934545	1226	1231	PPARg	Gene	19016(Species:10090)
23934545	1332	1337	PPARg	Gene	19016(Species:10090)
23934545	1351	1356	PPARg	Gene	19016(Species:10090)
23934545	1475	1480	PPARg	Gene	19016(Species:10090)
23934545	1536	1540	PTEN	Gene	19211(Species:10090)
23934545	1545	1548	Bax	Gene	12028(Species:10090)
23934545	1608	1615	eotaxin	Gene	20292(Species:10090)
23934545	1620	1626	RANTES	Gene	20304(Species:10090)
23934545	1677	1682	PPARg	Gene	19016(Species:10090)
23934545	1758	1763	Cox-1	Gene	19224(Species:10090)
23934545	1765	1770	Cox-2	Gene	19225(Species:10090)
23934545	1775	1784	cyclin D1	Gene	12443(Species:10090)
23934545	1858	1863	PPARg	Gene	19016(Species:10090)
23934545	1938	1943	PPARg	Gene	19016(Species:10090)

28368403|t|HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
28368403|a|Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a ligand for the EGF receptor (EGFR), one of the most commonly amplified receptor tyrosine kinases (RTKs) in glioblastoma (GBM). While HBEGF has been found to be expressed in a subset of malignant gliomas, its sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that HBEGF can initiate GBM in mice in the context of Ink4a/Arf and Pten loss, and that these tumors are similar to the classical GBM subtype observed in patients. Isogenic astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in response to HBEGF stimulation. Deletion of either Egfr or Axl decreased the tumorigenic properties of HBEGF-transformed cells; however, only EGFR was able to rescue the phenotype in cells lacking both RTKs indicating that Egfr is required for activation of Axl in this context. Silencing of HBEGF in vivo resulted in tumor regression and significantly increased survival, suggesting that HBEGF may be a clinically relevant target.
28368403	0	5	HBEGF	Gene	15200(Species:10090)
28368403	47	56	Ink4a/Arf	Gene	12578(Species:10090)
28368403	61	65	Pten	Gene	19211(Species:10090)
28368403	72	136	Heparin-binding epidermal growth factor (EGF)-like growth factor	Gene	1839(Species:9606)
28368403	138	143	HBEGF	Gene	1839(Species:9606)
28368403	165	177	EGF receptor	Gene	1956(Species:9606)
28368403	179	183	EGFR	Gene	1956(Species:9606)
28368403	221	246	receptor tyrosine kinases	Gene	13649(Species:10090),26362(Species:10090),1956(Species:9606)
28368403	248	252	RTKs	Gene	13649(Species:10090),26362(Species:10090),1956(Species:9606)
28368403	283	288	HBEGF	Gene	1839(Species:9606)
28368403	451	456	HBEGF	Gene	15200(Species:10090)
28368403	477	481	mice	Species	Species:10090
28368403	500	509	Ink4a/Arf	Gene	12578(Species:10090)
28368403	514	518	Pten	Gene	19211(Species:10090)
28368403	600	608	patients	Species	Species:9606
28368403	641	645	mice	Species	Species:10090
28368403	676	680	Egfr	Gene	13649(Species:10090)
28368403	694	697	RTK	Gene	13649(Species:10090),26362(Species:10090)
28368403	698	701	Axl	Gene	26362(Species:10090)
28368403	717	722	HBEGF	Gene	15200(Species:10090)
28368403	755	759	Egfr	Gene	13649(Species:10090)
28368403	763	766	Axl	Gene	26362(Species:10090)
28368403	807	812	HBEGF	Gene	15200(Species:10090)
28368403	846	850	EGFR	Gene	13649(Species:10090)
28368403	906	910	RTKs	Gene	13649(Species:10090),26362(Species:10090)
28368403	927	931	Egfr	Gene	13649(Species:10090)
28368403	962	965	Axl	Gene	26362(Species:10090)
28368403	996	1001	HBEGF	Gene	15200(Species:10090)
28368403	1093	1098	HBEGF	Gene	1839(Species:9606)

28968468|t|IRF-8 regulates expansion of myeloid-derived suppressor cells and Foxp3+ regulatory T cells and modulates Th2 immune responses to gastrointestinal nematode infection.
28968468|a|Interferon regulatory factor-8 (IRF-8) is critical for Th1 cell differentiation and negatively regulates myeloid cell development including myeloid-derived suppressor cells (MDSC). MDSC expand during infection with various pathogens including the gastrointestinal (GI) nematode Heligmosomoides polygyrus bakeri (Hpb). We investigated if IRF-8 contributes to Th2 immunity to Hpb infection. Irf8 expression was down-regulated in MDSC from Hpb-infected C57BL/6 (B6) mice. IRF-8 deficient Irf8-/- and BXH-2 mice had significantly higher adult worm burdens than B6 mice after primary or challenge Hpb infection. During primary infection, MDSC expanded to a significantly greater extent in mesenteric lymph nodes (MLN) and spleens of Irf8-/- and BXH-2 than B6 mice. CD4+GATA3+ T cells numbers were comparable in MLN of infected B6 and IRF-8 deficient mice, but MLN cells from infected IRF-8 deficient mice secreted significantly less parasite-specific IL-4 ex vivo. The numbers of alternatively activated macrophages in MLN and serum levels of Hpb-specific IgG1 and IgE were also significantly less in infected Irf8-/- than B6 mice. The frequencies of antigen-experienced CD4+CD11ahiCD49dhi cells that were CD44hiCD62L- were similar in MLN of infected Irf8-/- and B6 mice, but the proportions of CD4+GATA3+ and CD4+IL-4+ T cells were lower in infected Irf8-/- mice. CD11b+Gr1+ cells from naive or infected Irf8-/- mice suppressed CD4+ T cell proliferation and parasite-specific IL-4 secretion in vitro albeit less efficiently than B6 mice. Surprisingly, there were significantly more CD4+ T cells in infected Irf8-/- mice, with a higher frequency of CD4+CD25+Foxp3+ T (Tregs) cells and significantly higher numbers of Tregs than B6 mice. In vivo depletion of MDSC and/or Tregs in Irf8-/- mice did not affect adult worm burdens, but Treg depletion resulted in higher egg production and enhanced parasite-specific IL-5, IL-13, and IL-6 secretion ex vivo. Our data thus provide a previously unrecognized role for IRF-8 in Th2 immunity to a GI nematode.
28968468	0	5	IRF-8	Gene	15900(Species:10090)
28968468	66	71	Foxp3	Gene	20371(Species:10090)
28968468	167	197	Interferon regulatory factor-8	Gene	15900(Species:10090)
28968468	199	204	IRF-8	Gene	15900(Species:10090)
28968468	445	477	Heligmosomoides polygyrus bakeri	Species	Species:375939
28968468	479	482	Hpb	Species	Species:375939
28968468	504	509	IRF-8	Gene	15900(Species:10090)
28968468	541	544	Hpb	Species	Species:375939
28968468	556	560	Irf8	Gene	15900(Species:10090)
28968468	604	607	Hpb	Species	Species:375939
28968468	630	634	mice	Species	Species:10090
28968468	636	641	IRF-8	Gene	15900(Species:10090)
28968468	652	656	Irf8	Gene	15900(Species:10090)
28968468	670	674	mice	Species	Species:10090
28968468	727	731	mice	Species	Species:10090
28968468	759	762	Hpb	Species	Species:375939
28968468	895	899	Irf8	Gene	15900(Species:10090)
28968468	921	925	mice	Species	Species:10090
28968468	927	930	CD4	Gene	12504(Species:10090)
28968468	931	936	GATA3	Gene	14462(Species:10090)
28968468	996	1001	IRF-8	Gene	15900(Species:10090)
28968468	1012	1016	mice	Species	Species:10090
28968468	1046	1051	IRF-8	Gene	15900(Species:10090)
28968468	1062	1066	mice	Species	Species:10090
28968468	1113	1117	IL-4	Gene	16189(Species:10090)
28968468	1205	1208	Hpb	Species	Species:375939
28968468	1218	1222	IgG1	Gene	16017(Species:10090)
28968468	1227	1230	IgE	Gene	16020(Species:10090)
28968468	1272	1276	Irf8	Gene	15900(Species:10090)
28968468	1288	1292	mice	Species	Species:10090
28968468	1333	1336	CD4	Gene	12504(Species:10090)
28968468	1337	1342	CD11a	Gene	16408(Species:10090)
28968468	1344	1349	CD49d	Gene	16401(Species:10090)
28968468	1368	1372	CD44	Gene	12505(Species:10090)
28968468	1374	1379	CD62L	Gene	20343(Species:10090)
28968468	1413	1417	Irf8	Gene	15900(Species:10090)
28968468	1428	1432	mice	Species	Species:10090
28968468	1457	1460	CD4	Gene	12504(Species:10090)
28968468	1461	1466	GATA3	Gene	14462(Species:10090)
28968468	1472	1475	CD4	Gene	12504(Species:10090)
28968468	1476	1480	IL-4	Gene	16189(Species:10090)
28968468	1513	1517	Irf8	Gene	15900(Species:10090)
28968468	1521	1525	mice	Species	Species:10090
28968468	1527	1532	CD11b	Gene	16409(Species:10090)
28968468	1533	1536	Gr1	Gene	546644(Species:10090)
28968468	1567	1571	Irf8	Gene	15900(Species:10090)
28968468	1575	1579	mice	Species	Species:10090
28968468	1591	1594	CD4	Gene	12504(Species:10090)
28968468	1639	1643	IL-4	Gene	16189(Species:10090)
28968468	1695	1699	mice	Species	Species:10090
28968468	1745	1748	CD4	Gene	12504(Species:10090)
28968468	1770	1774	Irf8	Gene	15900(Species:10090)
28968468	1778	1782	mice	Species	Species:10090
28968468	1811	1814	CD4	Gene	12504(Species:10090)
28968468	1815	1819	CD25	Gene	16184(Species:10090)
28968468	1820	1825	Foxp3	Gene	20371(Species:10090)
28968468	1893	1897	mice	Species	Species:10090
28968468	1941	1945	Irf8	Gene	15900(Species:10090)
28968468	1949	1953	mice	Species	Species:10090
28968468	2073	2077	IL-5	Gene	16191(Species:10090)
28968468	2079	2084	IL-13	Gene	16163(Species:10090)
28968468	2090	2094	IL-6	Gene	16193(Species:10090)
28968468	2171	2176	IRF-8	Gene	15900(Species:10090)

28186140|t|Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gbg/PKC/ERK1/2 pathway and heterologous receptor desensitization.
28186140|a|The niacin receptor HCA2 is implicated in controlling inflammatory host responses with yet poorly understood mechanistic basis. We previously reported that HCA2 in A431 epithelial cells transduced Gbg-protein kinase C- and Gbg-metalloproteinase/EGFR-dependent MAPK/ERK signaling cascades. Here, we investigated the role of HCA2 in macrophage-mediated inflammation and the underlying mechanisms. We found that proinflammatory stimulants LPS, IL-6 and IL-1b up-regulated the expression of HCA2 on macrophages. Niacin significantly inhibited macrophage chemotaxis in response to chemoattractants fMLF and CCL2 by disrupting polarized distribution of F-actin and Gb protein. Niacin showed a selected additive effect on chemoattractant-induced activation of ERK1/2, JNK and PI3K pathways, but only the MEK inhibitor UO126 reduced niacin-mediated inhibition of macrophage chemotaxis, while activation of ERK1/2 by EGF alone did not inhibit fMLF-mediated migration of HEK293T cells co-expressing HCA2 and fMLF receptor FPR1. In addition, niacin induced heterologous desensitization and internalization of FPR1. Furthermore, niacin rescued mice from septic shock by diminishing inflammatory symptoms and the effect was abrogated in HCA2(-/-) mice. These results suggest that Gbg/PKC-dependent ERK1/2 activation and heterologous desensitization of chemoattractant receptors are involved in the inhibition of chemoattractant-induced migration of macrophages by niacin. Thus, HCA2 plays a critical role in host protection against pro-inflammatory insults.
28186140	10	25	niacin receptor	Gene	80885(Species:10090)
28186140	26	30	HCA2	Gene	80885(Species:10090)
28186140	90	93	Gbg	Gene	14688(Species:10090),14702(Species:10090)
28186140	94	97	PKC	Gene	18750(Species:10090)
28186140	98	104	ERK1/2	Gene	26417(Species:10090),26413(Species:10090)
28186140	160	175	niacin receptor	Gene	80885(Species:10090)
28186140	176	180	HCA2	Gene	80885(Species:10090)
28186140	312	316	HCA2	Gene	338442(Species:9606)
28186140	353	356	Gbg	Gene	2782(Species:9606),54331(Species:9606)
28186140	357	373	protein kinase C	Gene	5580(Species:9606)
28186140	379	382	Gbg	Gene	2782(Species:9606),54331(Species:9606)
28186140	383	400	metalloproteinase	Gene	4314(Species:9606)
28186140	401	405	EGFR	Gene	1956(Species:9606)
28186140	416	420	MAPK	Gene	5594(Species:9606),5595(Species:9606)
28186140	421	424	ERK	Gene	5594(Species:9606),5595(Species:9606)
28186140	479	483	HCA2	Gene	80885(Species:10090)
28186140	597	601	IL-6	Gene	16193(Species:10090)
28186140	606	611	IL-1b	Gene	16176(Species:10090)
28186140	643	647	HCA2	Gene	80885(Species:10090)
28186140	758	762	CCL2	Gene	20296(Species:10090)
28186140	803	810	F-actin	Gene	11461(Species:10090)
28186140	815	817	Gb	Gene	14688(Species:10090)
28186140	909	915	ERK1/2	Gene	26417(Species:10090),26413(Species:10090)
28186140	917	920	JNK	Gene	26419(Species:10090)
28186140	925	929	PI3K	Gene	18708(Species:10090)
28186140	953	956	MEK	Gene	26396(Species:10090)
28186140	1054	1060	ERK1/2	Gene	26417(Species:10090),26413(Species:10090)
28186140	1117	1124	HEK293T	Species	Species:9606
28186140	1145	1149	HCA2	Gene	338442(Species:9606)
28186140	1154	1167	fMLF receptor	Gene	2357(Species:9606)
28186140	1168	1172	FPR1	Gene	2357(Species:9606)
28186140	1254	1258	FPR1	Gene	2357(Species:9606)
28186140	1288	1292	mice	Species	Species:10090
28186140	1380	1384	HCA2	Gene	80885(Species:10090)
28186140	1390	1394	mice	Species	Species:10090
28186140	1423	1426	Gbg	Gene	14688(Species:10090),14702(Species:10090)
28186140	1427	1430	PKC	Gene	18750(Species:10090)
28186140	1441	1447	ERK1/2	Gene	26413(Species:10090),26417(Species:10090)
28186140	1621	1625	HCA2	Gene	80885(Species:10090)

28148261|t|Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
28148261|a|BACKGROUND: More than 80% of intestinal neoplasia is associated with the adenomatous polyposis coli (APC) mutation. Doublecortin-like kinase 1 (Dclk1), a kinase protein, is overexpressed in colorectal cancer and specifically marks tumor stem cells (TSCs) that self-renew and increased the tumor progeny in Apc (Min/+) mice. However, the role of Dclk1 expression and its contribution to regulating pro-survival signaling for tumor progression in Apc mutant cancer is poorly understood. METHODS: We analyzed DCLK1 and pro-survival signaling gene expression datasets of 329 specimens from TCGA Colon Adenocarcinoma Cancer Data. The network of DCLK1 and pro-survival signaling was analyzed utilizing the GeneMANIA database. We examined the expression levels of Dclk1 and other stem cell-associated markers, pro-survival signaling pathways, cell self-renewal in the isolated intestinal epithelial cells of Apc (Min/+) mice with high-grade dysplasia and adenocarcinoma. To determine the functional role of Dclk1 for tumor progression, we knocked down Dclk1 and determined the pro-survival signaling pathways and stemness. We used siRNA technology to gene silence pro-survival signaling in colon cancer cells in vitro. We utilized FACS, IHC, western blot, RT-PCR, and clonogenic (self-renewal) assays. RESULTS: We found a correlation between DCLK1 and pro-survival signaling expression. The expression of Dclk1 and stem cell-associated markers Lgr5, Bmi1, and Musashi1 were significantly higher in the intestinal epithelial cells of Apc (Min/+) mice than in wild-type controls. Intestinal epithelial cells of Apc (Min/+) mice showed increased expression of pro-survival signaling, pluripotency and self-renewal ability. Furthermore, the enteroids formed from the intestinal Dclk1(+) cells of Apc (Min/+) mice display higher pluripotency and pro-survival signaling. Dclk1 knockdown in Apc (Min/+) mice attenuates intestinal adenomas and adenocarcinoma, and decreases pro-survival signaling and self-renewal. Knocking down RELA and NOTCH1 pro-survival signaling and DCLK1 in HT29 and DLD1 colon cancer cells in vitro reduced the tumor cells' ability to self-renew and survive. CONCLUSION: Our results indicate that Dclk1 is essential in advancing intestinal tumorigenesis. Knocking down Dclk1 decreases tumor stemness and progression and is thus predicted to regulate pro-survival signaling and tumor cell pluripotency. This study provides a strong rationale to target Dclk1 as a treatment strategy for colorectal cancer.
28148261	0	5	Dclk1	Gene	13175(Species:10090),9201(Species:9606)
28148261	183	209	adenomatous polyposis coli	Gene	324(Species:9606)
28148261	211	214	APC	Gene	324(Species:9606)
28148261	226	252	Doublecortin-like kinase 1	Gene	13175(Species:10090),9201(Species:9606)
28148261	254	259	Dclk1	Gene	13175(Species:10090),9201(Species:9606)
28148261	416	419	Apc	Gene	11789(Species:10090)
28148261	428	432	mice	Species	Species:10090
28148261	455	460	Dclk1	Gene	13175(Species:10090)
28148261	555	558	Apc	Gene	11789(Species:10090)
28148261	616	621	DCLK1	Gene	9201(Species:9606)
28148261	750	755	DCLK1	Gene	9201(Species:9606)
28148261	867	872	Dclk1	Gene	13175(Species:10090)
28148261	1011	1014	Apc	Gene	11789(Species:10090)
28148261	1023	1027	mice	Species	Species:10090
28148261	1110	1115	Dclk1	Gene	13175(Species:10090)
28148261	1155	1160	Dclk1	Gene	13175(Species:10090)
28148261	1445	1450	DCLK1	Gene	9201(Species:9606)
28148261	1508	1513	Dclk1	Gene	13175(Species:10090)
28148261	1547	1551	Lgr5	Gene	14160(Species:10090)
28148261	1553	1557	Bmi1	Gene	12151(Species:10090)
28148261	1563	1571	Musashi1	Gene	17690(Species:10090)
28148261	1636	1639	Apc	Gene	11789(Species:10090)
28148261	1648	1652	mice	Species	Species:10090
28148261	1712	1715	Apc	Gene	11789(Species:10090)
28148261	1724	1728	mice	Species	Species:10090
28148261	1877	1882	Dclk1	Gene	13175(Species:10090)
28148261	1895	1898	Apc	Gene	11789(Species:10090)
28148261	1907	1911	mice	Species	Species:10090
28148261	1968	1973	Dclk1	Gene	13175(Species:10090)
28148261	1987	1990	Apc	Gene	11789(Species:10090)
28148261	1999	2003	mice	Species	Species:10090
28148261	2124	2128	RELA	Gene	5970(Species:9606)
28148261	2133	2139	NOTCH1	Gene	4851(Species:9606)
28148261	2167	2172	DCLK1	Gene	9201(Species:9606)
28148261	2176	2180	HT29	Species	Species:9606
28148261	2185	2189	DLD1	Species	Species:9606
28148261	2316	2321	Dclk1	Gene	13175(Species:10090),9201(Species:9606)
28148261	2388	2393	Dclk1	Gene	13175(Species:10090),9201(Species:9606)
28148261	2570	2575	Dclk1	Gene	9201(Species:9606)

26640231|t|Search for regulatory factors of the pituitary-specific transcription factor PROP1 gene.
26640231|a|Pituitary-specific transcription factor PROP1, a factor important for pituitary organogenesis, appears on rat embryonic day 11.5 (E11.5) in SOX2-expressing stem/progenitor cells and always coexists with SOX2 throughout life. PROP1-positive cells at one point occupy all cells in Rathke's pouch, followed by a rapid decrease in their number. Their regulatory factors, except for RBP-J, have not yet been clarified. This study aimed to use the 3 kb upstream region and 1st intron of mouse prop1 to pinpoint a group of factors selected on the basis of expression in the early pituitary gland for expression of Prop1. Reporter assays for SOX2 and RBP-J showed that the stem/progenitor marker SOX2 has cell type-dependent inhibitory and activating functions through the proximal and distal upstream regions of Prop1, respectively, while RBP-J had small regulatory activity in some cell lines. Reporter assays for another 39 factors using the 3 kb upstream regions in CHO cells ultimately revealed that 8 factors, MSX2, PAX6, PIT1, PITX1, PITX2, RPF1, SOX8 and SOX11, but not RBP-J, regulate Prop1 expression. Furthermore, a synergy effect with SOX2 was observed for an additional 10 factors, FOXJ1, HES1, HEY1, HEY2, KLF6, MSX1, RUNX1, TEAD2, YBX2 and ZFP36Ll, which did not show substantial independent action. Thus, we demonstrated 19 candidates, including SOX2, to be regulatory factors of Prop1 expression.
26640231	77	82	PROP1	Gene	19127(Species:10090)
26640231	129	134	PROP1	Gene	266738(Species:10116)
26640231	195	198	rat	Species	Species:10116
26640231	229	233	SOX2	Gene	499593(Species:10116)
26640231	292	296	SOX2	Gene	499593(Species:10116)
26640231	314	319	PROP1	Gene	266738(Species:10116)
26640231	467	472	RBP-J	Gene	679028(Species:10116)
26640231	570	575	mouse	Species	Species:10090
26640231	576	581	prop1	Gene	19127(Species:10090)
26640231	696	701	Prop1	Gene	19127(Species:10090)
26640231	723	727	SOX2	Gene	499593(Species:10116)
26640231	732	737	RBP-J	Gene	679028(Species:10116)
26640231	777	781	SOX2	Gene	499593(Species:10116)
26640231	894	899	Prop1	Gene	19127(Species:10090)
26640231	921	926	RBP-J	Gene	19664(Species:10090)
26640231	1051	1054	CHO	Species	Species:10029
26640231	1097	1101	MSX2	Gene	100761249(Species:10029)
26640231	1103	1107	PAX6	Gene	100766953(Species:10029)
26640231	1109	1113	PIT1	Gene	100773365(Species:10029)
26640231	1115	1120	PITX1	Gene	100762112(Species:10029)
26640231	1122	1127	PITX2	Gene	100755816(Species:10029)
26640231	1129	1133	RPF1	Gene	100767673(Species:10029)
26640231	1135	1139	SOX8	Gene	100774670(Species:10029)
26640231	1144	1149	SOX11	Gene	84046(Species:10116)
26640231	1159	1164	RBP-J	Gene	100774626(Species:10029)
26640231	1175	1180	Prop1	Gene	19127(Species:10090)
26640231	1228	1232	SOX2	Gene	499593(Species:10116)
26640231	1276	1281	FOXJ1	Gene	100755106(Species:10029)
26640231	1283	1287	HES1	Gene	100752756(Species:10029)
26640231	1289	1293	HEY1	Gene	100752534(Species:10029)
26640231	1295	1299	HEY2	Gene	100755611(Species:10029)
26640231	1301	1305	KLF6	Gene	100750724(Species:10029)
26640231	1307	1311	MSX1	Gene	100752378(Species:10029)
26640231	1313	1318	RUNX1	Gene	100758283(Species:10029)
26640231	1320	1325	TEAD2	Gene	100755590(Species:10029)
26640231	1327	1331	YBX2	Gene	100761419(Species:10029)
26640231	1336	1343	ZFP36Ll	Gene	12192(Species:10090)
26640231	1443	1447	SOX2	Gene	499593(Species:10116)
26640231	1477	1482	Prop1	Gene	19127(Species:10090)

25874935|t|Neuroprotective effect of neuroserpin in oxygen-glucose deprivation- and reoxygenation-treated rat astrocytes in vitro.
25874935|a|Neuroserpin (NSP) reportedly exerts neuroprotective effects in cerebral ischemic animal models and patients; however, the mechanism of protection is poorly understood. We thus attempted to confirm neuroprotective effects of NSP on astrocytes in the ischemic state and then explored the relative mechanisms. Astrocytes from neonatal rats were treated with oxygen-glucose deprivation (OGD) followed by reoxygenation (OGD/R). To confirm the neuroprotective effects of NSP, we measured the cell survival rate, relative lactate dehydrogenase (LDH) release; we also performed morphological methods, namely Hoechst 33342 staining and Annexin V assay. To explore the potential mechanisms of NSP, the release of nitric oxide (NO) and TNF-alpha related to NSP administration were measured by enzyme-linked immunosorbent assay. The proteins related to the NF-kappaB, ERK1/2, and PI3K/Akt pathways were investigated by Western blotting. To verify the cause-and-effect relationship between neuroprotection and the NF-kappaB pathway, a NF-kappaB pathway inhibitor sc3060 was employed to observe the effects of NSP-induced neuroprotection. We found that NSP significantly increased the cell survival rate and reduced LDH release in OGD/R-treated astrocytes. It also reduced NO/TNF-alpha release. Western blotting showed that the protein levels of p-IKKBalpha/beta and P65 were upregulated by the OGD/R treatment and such effects were significantly inhibited by NSP administration. The NSP-induced inhibition could be significantly reversed by administration of the NF-kappaB pathway inhibitor sc3060, whereas, expressions of p-ERK1, p-ERK2, and p-AKT were upregulated by the OGD/R treatment; however, their levels were unchanged by NSP administration. Our results thus verified the neuroprotective effects of NSP in ischemic astrocytes. The potential mechanisms include inhibition of the release of NO/TNF-alpha and repression of the NF-kappaB signaling pathways. Our data also indicated that NSP has little influence on the MAPK and PI3K/Akt pathways. 
25874935	95	98	rat	Species	Species:10116
25874935	219	227	patients	Species	Species:9606
25874935	452	456	rats	Species	Species:10116
25874935	635	656	lactate dehydrogenase	Gene	24533(Species:10116)
25874935	658	661	LDH	Gene	24533(Species:10116)
25874935	747	756	Annexin V	Gene	25673(Species:10116)
25874935	845	854	TNF-alpha	Gene	24835(Species:10116)
25874935	965	974	NF-kappaB	Gene	309165(Species:10116)
25874935	976	982	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
25874935	988	992	PI3K	Gene	298947(Species:10116)
25874935	993	996	Akt	Gene	24185(Species:10116)
25874935	1121	1130	NF-kappaB	Gene	309165(Species:10116)
25874935	1142	1151	NF-kappaB	Gene	309165(Species:10116)
25874935	1322	1325	LDH	Gene	24533(Species:10116)
25874935	1382	1391	TNF-alpha	Gene	24835(Species:10116)
25874935	1454	1468	IKKBalpha/beta	Gene	309361(Species:10116),84351(Species:10116)
25874935	1473	1476	P65	Gene	309165(Species:10116)
25874935	1670	1679	NF-kappaB	Gene	309165(Species:10116)
25874935	1732	1736	ERK1	Gene	50689(Species:10116)
25874935	1740	1744	ERK2	Gene	116590(Species:10116)
25874935	1752	1755	AKT	Gene	24185(Species:10116)
25874935	2007	2016	TNF-alpha	Gene	24835(Species:10116)
25874935	2039	2048	NF-kappaB	Gene	309165(Species:10116)
25874935	2130	2134	MAPK	Gene	50689(Species:10116),116590(Species:10116),50689(Species:10116)
25874935	2139	2143	PI3K	Gene	298947(Species:10116)
25874935	2144	2147	Akt	Gene	24185(Species:10116)

18627611|t|Transcriptional profiling in C. elegans suggests DNA damage dependent apoptosis as an ancient function of the p53 family.
18627611|a|BACKGROUND: In contrast to the three mammalian p53 family members, p53, which is generally involved in DNA damage responses, and p63 and p73 which are primarily needed for developmental regulation, cep-1 encodes for the single C. elegans p53-like gene. cep-1 acts as a transcription activator in a primordial p53 pathway that involves CEP-1 activation and the CEP-1 dependent transcriptional induction of the worm BH3 only domain encoding genes egl-1 and ced-13 to induce germ cell apoptosis. EGL-1 and CED-13 proteins inactivate Bcl-2 like CED-9 to trigger CED-4 and CED-3 caspase dependent germ cell apoptosis. To address the function of p53 in global transcriptional regulation we investigate genome-wide transcriptional responses upon DNA damage and cep-1 deficiency. RESULTS: Examining C. elegans expression profiles using whole genome Affymetrix GeneChip arrays, we found that 83 genes were induced more than two fold upon ionizing radiation (IR). None of these genes, with exception of an ATP ribosylase homolog, encode for known DNA repair genes. Using two independent cep-1 loss of function alleles we did not find genes regulated by cep-1 in the absence of IR. Among the IR-induced genes only three are dependent on cep-1, namely egl-1, ced-13 and a novel C. elegans specific gene. The majority of IR-induced genes appear to be involved in general stress responses, and qRT-PCR experiments indicate that they are mainly expressed in somatic tissues. Interestingly, we reveal an extensive overlap of gene expression changes occurring in response to DNA damage and in response to bacterial infection. Furthermore, many genes induced by IR are also transcriptionally regulated in longevity mutants suggesting that DNA damage and aging induce an overlapping stress response. CONCLUSION: We performed genome-wide gene expression analyses which indicate that only a surprisingly small number of genes are regulated by CEP-1 and that DNA damage induced apoptosis via the transcriptional induction of BH3 domain proteins is likely to be an ancient DNA damage response function of the p53 family. Interestingly, although the apoptotic response to DNA damage is regulated through the transcriptional activity of CEP-1, other DNA damage responses do not appear to be regulated on the transcriptional level and do not require the p53 like gene cep-1.
18627611	29	39	C. elegans	Species	Species:6239
18627611	110	113	p53	Gene	172616(Species:6239)
18627611	159	168	mammalian	Species	Species:9606
18627611	169	179	p53 family	Gene	7157(Species:9606)
18627611	189	192	p53	Gene	7157(Species:9606)
18627611	251	254	p63	Gene	8626(Species:9606)
18627611	259	262	p73	Gene	7161(Species:9606)
18627611	320	325	cep-1	Gene	172616(Species:6239)
18627611	349	359	C. elegans	Species	Species:6239
18627611	360	363	p53	Gene	172616(Species:6239)
18627611	375	380	cep-1	Gene	172616(Species:6239)
18627611	431	434	p53	Gene	7157(Species:9606)
18627611	457	462	CEP-1	Gene	172616(Species:6239)
18627611	482	487	CEP-1	Gene	172616(Species:6239)
18627611	567	572	egl-1	Gene	179943(Species:6239)
18627611	577	583	ced-13	Gene	191625(Species:6239)
18627611	615	620	EGL-1	Gene	179943(Species:6239)
18627611	625	631	CED-13	Gene	191625(Species:6239)
18627611	663	668	CED-9	Gene	3565776(Species:6239)
18627611	680	685	CED-4	Gene	175643(Species:6239)
18627611	690	703	CED-3 caspase	Gene	178272(Species:6239)
18627611	762	765	p53	Gene	7157(Species:9606)
18627611	876	881	cep-1	Gene	172616(Species:6239)
18627611	913	923	C. elegans	Species	Species:6239
18627611	1199	1204	cep-1	Gene	172616(Species:6239)
18627611	1265	1270	cep-1	Gene	172616(Species:6239)
18627611	1348	1353	cep-1	Gene	172616(Species:6239)
18627611	1362	1367	egl-1	Gene	179943(Species:6239)
18627611	1369	1375	ced-13	Gene	191625(Species:6239)
18627611	1388	1398	C. elegans	Species	Species:6239
18627611	2044	2049	CEP-1	Gene	172616(Species:6239)
18627611	2208	2211	p53	Gene	172616(Species:6239)
18627611	2334	2339	CEP-1	Gene	172616(Species:6239)
18627611	2450	2453	p53	Gene	172616(Species:6239)
18627611	2464	2469	cep-1	Gene	172616(Species:6239)

29136006|t|Lipopolysaccharide potentiates platelet responses via toll-like receptor 4-stimulated Akt-Erk-PLA2 signalling.
29136006|a|Lipopolysaccharide (LPS) from the cell envelope of Gram-negative bacteria is a principal cause of the symptoms of sepsis. LPS has been reported to modulate the function of platelets although the underlying mechanisms of LPS action in these cells remain unclear. Platelets express the Toll-like receptor 4 (TLR4) which serves as a receptor for LPS, although the potential role of TLR4 and associated cell signalling in controlling platelet responses to LPS has not been extensively explored. In this study, we therefore investigated the actions of LPS prepared from different strains of Escherichia coli on platelet function, the underlying signalling mechanisms, and the potential role of TLR4 in orchestrating these. We report that LPS increased the aggregation of washed platelets stimulated by thromboxane (U46619) or GPVI collagen receptor agonists, effects that were prevented by a TLR4 antagonist. Associated with this, LPS enhanced fibrinogen binding, P-selectin exposure and reactive oxygen species (ROS) release. Increase of ROS was found to be important for the actions of LPS on platelets, since these were inhibited in the presence of superoxide dismutase or catalase. The effects of LPS were associated with phosphorylation of Akt, ERK1/2 and PLA2 in stimulated platelets, and inhibitors of PI3-kinase, Akt and ERK1/2 reduced significantly LPS enhanced platelet function and associated ROS production. Furthermore, inhibition of platelet cyclooxygenase or the thromboxane receptor, revealed an important role for thromboxane A2. We therefore conclude that LPS increases human platelet activation through a TLR4-PI3K-Akt-ERK1/2-PLA2 -dependent pathway that is dependent on ROS and TXA2 formation.
29136006	54	74	toll-like receptor 4	Gene	7099(Species:9606)
29136006	86	89	Akt	Gene	207(Species:9606)
29136006	90	93	Erk	Gene	5594(Species:9606),5595(Species:9606)
29136006	94	98	PLA2	Gene	5320(Species:9606)
29136006	395	415	Toll-like receptor 4	Gene	7099(Species:9606)
29136006	417	421	TLR4	Gene	7099(Species:9606)
29136006	490	494	TLR4	Gene	7099(Species:9606)
29136006	697	713	Escherichia coli	Species	Species:562
29136006	800	804	TLR4	Gene	7099(Species:9606)
29136006	932	954	GPVI collagen receptor	Gene	51206(Species:9606)
29136006	998	1002	TLR4	Gene	7099(Species:9606)
29136006	1050	1060	fibrinogen	Gene	2244(Species:9606)
29136006	1070	1080	P-selectin	Gene	6403(Species:9606)
29136006	1258	1278	superoxide dismutase	Gene	6647(Species:9606)
29136006	1282	1290	catalase	Gene	847(Species:9606)
29136006	1351	1354	Akt	Gene	207(Species:9606)
29136006	1356	1362	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
29136006	1367	1371	PLA2	Gene	5320(Species:9606)
29136006	1415	1425	PI3-kinase	Gene	5290(Species:9606)
29136006	1427	1430	Akt	Gene	207(Species:9606)
29136006	1435	1441	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
29136006	1562	1576	cyclooxygenase	Gene	5743(Species:9606)
29136006	1584	1604	thromboxane receptor	Gene	6915(Species:9606)
29136006	1694	1699	human	Species	Species:9606
29136006	1730	1734	TLR4	Gene	7099(Species:9606)
29136006	1735	1739	PI3K	Gene	5290(Species:9606)
29136006	1740	1743	Akt	Gene	207(Species:9606)
29136006	1744	1750	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
29136006	1751	1755	PLA2	Gene	5320(Species:9606)

26450454|t|Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival.
26450454|a|Bcl2 family proteins control mitochondrial apoptosis and its members exert critical cell type and differentiation stage-specific functions, acting as barriers against autoimmunity or transformation. Anti-apoptotic Bcl2a1/Bfl1/A1 is frequently deregulated in different types of blood cancers in humans but its physiological role is poorly understood as quadruplication of the Bcl2a1 gene locus in mice hampers conventional gene targeting strategies. Transgenic overexpression of A1, deletion of the A1-a paralogue or constitutive knockdown in the hematopoietic compartment of mice by RNAi suggested rate-limiting roles in lymphocyte development, granulopoiesis and mast cell activation. Here we report on the consequences of conditional knockdown of A1 protein expression using a reverse transactivator (rtTA)-driven approach that highlights a critical role for this Bcl2 family member in the maintenance of mature B-cell homeostasis. Furthermore, we define the A1/Bim (Bcl-2 interacting mediator of cell death) axis as a target of key kinases mediating B-cell receptor (BCR)-dependent survival signals, such as, spleen tyrosine kinase (Syk) and Brutons tyrosine kinase (Btk). As such, A1 represents a putative target for the treatment of B-cell-related pathologies depending on hyperactivation of BCR-emanating survival signals and loss of A1 expression accounts, in part, for the pro-apoptotic effects of Syk- or Btk inhibitors that rely on the 'BH3-only' protein Bim for cell killing.
26450454	25	31	BCL2A1	Gene	12044(Species:10090)
26450454	63	66	BCR	Gene	111507(Species:10090)
26450454	94	98	Bcl2	Gene	12044(Species:10090),597(Species:9606)
26450454	308	314	Bcl2a1	Gene	597(Species:9606)
26450454	315	319	Bfl1	Gene	597(Species:9606)
26450454	320	322	A1	Gene	597(Species:9606)
26450454	388	394	humans	Species	Species:9606
26450454	469	475	Bcl2a1	Gene	12044(Species:10090)
26450454	490	494	mice	Species	Species:10090
26450454	572	574	A1	Gene	12044(Species:10090)
26450454	592	594	A1	Gene	12044(Species:10090)
26450454	669	673	mice	Species	Species:10090
26450454	843	845	A1	Gene	12044(Species:10090)
26450454	960	964	Bcl2	Gene	12044(Species:10090),597(Species:9606)
26450454	1055	1057	A1	Gene	12044(Species:10090)
26450454	1058	1061	Bim	Gene	12125(Species:10090)
26450454	1063	1103	Bcl-2 interacting mediator of cell death	Gene	12125(Species:10090)
26450454	1147	1162	B-cell receptor	Gene	111507(Species:10090)
26450454	1164	1167	BCR	Gene	111507(Species:10090)
26450454	1206	1228	spleen tyrosine kinase	Gene	20963(Species:10090)
26450454	1230	1233	Syk	Gene	20963(Species:10090)
26450454	1239	1262	Brutons tyrosine kinase	Gene	12229(Species:10090)
26450454	1264	1267	Btk	Gene	12229(Species:10090)
26450454	1279	1281	A1	Gene	597(Species:9606)
26450454	1434	1436	A1	Gene	12044(Species:10090)
26450454	1500	1503	Syk	Gene	20963(Species:10090)
26450454	1508	1511	Btk	Gene	12229(Species:10090)
26450454	1559	1562	Bim	Gene	12125(Species:10090)

27385779|t|A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.
27385779|a|CD200 is a cell surface glycoprotein that functions through engaging CD200R on cells of the myeloid lineage and inhibits their functions. Expression of CD200 was implicated in a variety of human cancer cells, including melanoma cells; however, its roles in tumor growth and immunity are not clearly understood. In this study, we used CD200R-deficient mice and the B16 tumor model to evaluate this issue. We found that CD200R-deficient mice exhibited accelerated growth of CD200(+), but not CD200(-), B16 tumors. Strikingly, CD200R-deficient mice receiving CD200(+) B16 cells i.v. exhibited massive tumor growth in multiple organs, including liver, lung, kidney, and peritoneal cavity, whereas the growth of the same tumors in wild-type mice was limited. CD200(+) tumors grown in CD200R-deficient mice contained higher numbers of CD11b(+)Ly6C(+) myeloid cells, exhibited increased expression of VEGF and HIF1a genes with increased angiogenesis, and showed significantly reduced infiltration of CD4(+) and CD8(+) T cells, presumably as the result of reduced expression of T cell chemokines, such as CXCL9 and CXCL16. The liver from CD200R-deficient mice, under metastatic growth of CD200(+) tumors, contained significantly increased numbers of CD11b(+)Gr1(-) myeloid cells and Foxp3(+) regulatory T cells and reduced numbers of NK cells. Liver T cells also had a reduced capacity to produce IFN-g or TNF-a. Taken together, we revealed a critical role for CD200R signaling in limiting the growth and metastasis of CD200(+) tumors. Thus, targeting CD200R signaling may potentially interfere with the metastatic growth of CD200(+) tumors, like melanoma.
27385779	20	26	CD200R	Gene	57781(Species:10090)
27385779	78	83	CD200	Gene	17470(Species:10090)
27385779	95	100	CD200	Gene	4345(Species:9606)
27385779	164	170	CD200R	Gene	131450(Species:9606)
27385779	247	252	CD200	Gene	4345(Species:9606)
27385779	284	289	human	Species	Species:9606
27385779	429	435	CD200R	Gene	57781(Species:10090)
27385779	446	450	mice	Species	Species:10090
27385779	513	519	CD200R	Gene	57781(Species:10090)
27385779	530	534	mice	Species	Species:10090
27385779	567	572	CD200	Gene	17470(Species:10090)
27385779	585	590	CD200	Gene	17470(Species:10090)
27385779	619	625	CD200R	Gene	57781(Species:10090)
27385779	636	640	mice	Species	Species:10090
27385779	651	656	CD200	Gene	17470(Species:10090)
27385779	831	835	mice	Species	Species:10090
27385779	849	854	CD200	Gene	17470(Species:10090)
27385779	874	880	CD200R	Gene	57781(Species:10090)
27385779	891	895	mice	Species	Species:10090
27385779	924	929	CD11b	Gene	16409(Species:10090)
27385779	932	936	Ly6C	Gene	17067(Species:10090)
27385779	989	993	VEGF	Gene	22339(Species:10090)
27385779	998	1003	HIF1a	Gene	15251(Species:10090)
27385779	1088	1091	CD4	Gene	12504(Species:10090)
27385779	1099	1102	CD8	Gene	12525(Species:10090),12526(Species:10090)
27385779	1172	1182	chemokines	Gene	17329(Species:10090),66102(Species:10090)
27385779	1192	1197	CXCL9	Gene	17329(Species:10090)
27385779	1202	1208	CXCL16	Gene	66102(Species:10090)
27385779	1225	1231	CD200R	Gene	57781(Species:10090)
27385779	1242	1246	mice	Species	Species:10090
27385779	1275	1280	CD200	Gene	17470(Species:10090)
27385779	1337	1342	CD11b	Gene	16409(Species:10090)
27385779	1345	1348	Gr1	Gene	546644(Species:10090)
27385779	1370	1375	Foxp3	Gene	20371(Species:10090)
27385779	1484	1489	IFN-g	Gene	15978(Species:10090)
27385779	1493	1498	TNF-a	Gene	21926(Species:10090)
27385779	1548	1554	CD200R	Gene	57781(Species:10090)
27385779	1606	1611	CD200	Gene	17470(Species:10090)
27385779	1639	1645	CD200R	Gene	57781(Species:10090)
27385779	1712	1717	CD200	Gene	17470(Species:10090)

23750584|t|Arabidopsis CHROMOSOME TRANSMISSION FIDELITY 7 (AtCTF7/ECO1) is required for DNA repair, mitosis and meiosis.
23750584|a|The proper transmission of DNA in dividing cells is crucial for the survival of eukaryotic organisms. During cell division, faithful segregation of replicated chromosomes requires their tight attachment, known as sister chromatid cohesion, until anaphase. Sister chromatid cohesion is established during S-phase in a process requiring an acetyltransferase that in yeast is known as Establishment of cohesion 1 (Eco1). Inactivation of Eco1 typically disrupts chromosome segregation and homologous recombination-dependent DNA repair in dividing cells, ultimately resulting in lethality. We report here the isolation and detailed characterization of two homozygous T-DNA insertion mutants for the Arabidopsis thaliana Eco1 homolog, CHROMOSOME TRANSMISSION FIDELITY 7/ESTABLISHMENT OF COHESION 1 (CTF7/ECO1), called ctf7-1 and ctf7-2. Mutants exhibited dwarfism, poor anther development and sterility. Analysis of somatic tissues by flow cytometry, scanning electron microscopy and quantitative real-time PCR identified defects in DNA repair and cell division, including an increase in the area of leaf epidermal cells, an increase in DNA content and the upregulation of genes involved in DNA repair including BRCA1 and PARP2. No significant change was observed in the expression of genes that influence entry into the endocycle. Analysis of meiocytes identified changes in chromosome morphology and defective segregation; the abundance of chromosomal-bound cohesion subunits was also reduced. Transcript levels for several meiotic genes, including the recombinase genes DMC1 and RAD51C and the S-phase licensing factor CDC45 were elevated in mutant anthers. Taken together our results demonstrate that Arabidopsis CTF7/ECO1 plays important roles in the preservation of genome integrity and meiosis.
23750584	0	11	Arabidopsis	Species	Species:3702
23750584	12	46	CHROMOSOME TRANSMISSION FIDELITY 7	Gene	829267(Species:3702)
23750584	48	54	AtCTF7	Gene	829267(Species:3702)
23750584	55	59	ECO1	Gene	829267(Species:3702)
23750584	448	465	acetyltransferase	Gene	850584(Species:559292)
23750584	474	479	yeast	Species	Species:559292
23750584	492	519	Establishment of cohesion 1	Gene	850584(Species:559292)
23750584	521	525	Eco1	Gene	850584(Species:559292)
23750584	544	548	Eco1	Gene	850584(Species:559292)
23750584	804	824	Arabidopsis thaliana	Species	Species:3702
23750584	825	829	Eco1	Gene	829267(Species:3702)
23750584	839	901	CHROMOSOME TRANSMISSION FIDELITY 7/ESTABLISHMENT OF COHESION 1	Gene	829267(Species:3702)
23750584	903	907	CTF7	Gene	829267(Species:3702)
23750584	908	912	ECO1	Gene	829267(Species:3702)
23750584	922	928	ctf7-1	Gene	829267(Species:3702)
23750584	933	939	ctf7-2	Gene	829267(Species:3702)
23750584	1316	1321	BRCA1	Gene	827854(Species:3702)
23750584	1326	1331	PARP2	Gene	828049(Species:3702)
23750584	1677	1681	DMC1	Gene	821860(Species:3702)
23750584	1686	1692	RAD51C	Gene	819136(Species:3702)
23750584	1726	1731	CDC45	Gene	822101(Species:3702)
23750584	1809	1820	Arabidopsis	Species	Species:3702
23750584	1821	1825	CTF7	Gene	829267(Species:3702)
23750584	1826	1830	ECO1	Gene	829267(Species:3702)

26969755|t|Bacterial DNA Protects Monocytic Cells against HIV-Vpr-Induced Mitochondrial Membrane Depolarization.
26969755|a|Monocytes and macrophages are important HIV reservoirs, as they exhibit marked resistance to apoptosis upon infection. However, the mechanism underlying resistance to apoptosis in these cells is poorly understood. Using HIV-viral protein R-52-96 aa peptide (Vpr), we show that primary monocytes and THP-1 cells treated with Vpr are highly susceptible to mitochondrial depolarization, but develop resistance following stimulation with bacterial DNA or CpG oligodeoxynucleotide. We have shown that Vpr-induced mitochondrial depolarization is mediated by TNFR-associated factor-1 (TRAF-1) and TRAF-2 degradation and subsequent activation of caspase-8, Bid, and Bax. To provide the mechanism governing such resistance to mitochondrial depolarization, our results show that prior stimulation with CpG oligodeoxynucleotide or Escherichia coli DNA prevented: 1) TRAF-1/2 downregulation; 2) activation of caspase-8, Bid, and Bax; and 3) subsequent mitochondrial depolarization and release of apoptosis-inducing factor and cytochrome c Furthermore, this protection was mediated by upregulation of antiapoptotic protein (c-IAP-2) through calmodulin-dependent kinase-II activation. Thus, c-IAP-2 may prevent Vpr-mediated mitochondrial depolarization through stabilizing TRAF-1/2 expression and sequential inhibition of caspase-8, Bid, and Bax.
26969755	401	406	THP-1	Species	Species:9606
26969755	654	678	TNFR-associated factor-1	Gene	7185(Species:9606)
26969755	680	686	TRAF-1	Gene	7185(Species:9606)
26969755	692	698	TRAF-2	Gene	7186(Species:9606)
26969755	740	749	caspase-8	Gene	841(Species:9606)
26969755	751	754	Bid	Gene	637(Species:9606)
26969755	760	763	Bax	Gene	581(Species:9606)
26969755	922	938	Escherichia coli	Species	Species:562
26969755	957	965	TRAF-1/2	Gene	7185(Species:9606),7186(Species:9606)
26969755	999	1008	caspase-8	Gene	841(Species:9606)
26969755	1010	1013	Bid	Gene	637(Species:9606)
26969755	1019	1022	Bax	Gene	581(Species:9606)
26969755	1086	1111	apoptosis-inducing factor	Gene	9131(Species:9606)
26969755	1116	1128	cytochrome c	Gene	54205(Species:9606)
26969755	1190	1211	antiapoptotic protein	Gene	330(Species:9606)
26969755	1213	1220	c-IAP-2	Gene	330(Species:9606)
26969755	1230	1260	calmodulin-dependent kinase-II	Gene	815(Species:9606)
26969755	1279	1286	c-IAP-2	Gene	330(Species:9606)
26969755	1361	1369	TRAF-1/2	Gene	7185(Species:9606),7186(Species:9606)
26969755	1410	1419	caspase-8	Gene	841(Species:9606)
26969755	1421	1424	Bid	Gene	637(Species:9606)
26969755	1430	1433	Bax	Gene	581(Species:9606)

23220172|t|Overexpression of human selenoprotein H in neuronal cells enhances mitochondrial biogenesis and function through activation of protein kinase A, protein kinase B, and cyclic adenosine monophosphate response element-binding protein pathway.
23220172|a|Mitochondrial biogenesis is activated by nuclear encoded transcription co-activator peroxisome proliferator-activated receptor g coactivator-1a (PGC-1a), which is regulated by several upstream factors including protein kinase A and Akt/protein kinase B. We have previously shown that selenoprotein H enhances the levels of nuclear regulators for mitochondrial biogenesis, increases mitochondrial mass and improves mitochondrial respiratory rate, under physiological condition. Furthermore, overexpression of selenoprotein H protects neuronal HT22 cells from ultraviolet B irradiation-induced cell damage by lowering reactive oxygen species production, and inhibiting activation of caspase-3 and -9, as well as p53. The objective of this study is to identify the cell signaling pathways by which selenoprotein H initiates mitochondrial biogenesis. We first confirmed our previous observation that selenoprotein H transfected HT22 cells increased the protein levels of nuclear-encoded mitochondrial biogenesis factors, peroxisome proliferator-activated receptor g coactivator-1a, nuclear respiratory factor 1 and mitochondrial transcription factor A. We then observed that total and phosphorylation of protein kinase A, Akt/protein kinase B and cyclic adenosine monophosphate response element-binding protein (CREB) were significantly increased in selenoprotein H transfected cells compared to vector transfected HT22 cells. To verify whether the observed stimulating effects on mitochondrial biogenesis pathways are caused by selenoprotein H and mediated through CREB, we knocked down selenoprotein H mRNA level using siRNA and inhibited CREB with napthol AS-E phosphate in selenoprotein H transfected cells and repeated the measurements of the aforementioned biomarkers. Our results revealed that silencing of selenoprotein H not only decreased the protein levels of PGC-1a, nuclear respiratory factor 1 and mitochondrial transcription factor A, but also decreased the total and phosphorylation levels of protein kinase A, protein kinase B, and CREB. Similarly, CREB inhibition reduced CREB activation and PGC-1a protein levels in selenoprotein H transfected cells. Moreover, selenoprotein H transfection increased the activity of mitochondrial complexes and prevented the ultraviolet B induced fall of mitochondrial membrane potential. We conclude that the effects of selenoprotein H on mitochondrial biogenesis and mitochondrial function are probably mediated through protein kinase A-CREB-PGC-1a and Akt/protein kinase B-CREB-PGC-1a pathways.
23220172	18	23	human	Species	Species:9606
23220172	24	39	selenoprotein H	Gene	280636(Species:9606)
23220172	127	143	protein kinase A	Gene	18747(Species:10090)
23220172	145	161	protein kinase B	Gene	11651(Species:10090)
23220172	167	230	cyclic adenosine monophosphate response element-binding protein	Gene	12912(Species:10090)
23220172	281	383	nuclear encoded transcription co-activator peroxisome proliferator-activated receptor g coactivator-1a	Gene	19017(Species:10090)
23220172	324	383	peroxisome proliferator-activated receptor g coactivator-1a	Gene	19017(Species:10090)
23220172	385	391	PGC-1a	Gene	19017(Species:10090)
23220172	451	467	protein kinase A	Gene	18747(Species:10090)
23220172	472	475	Akt	Gene	11651(Species:10090)
23220172	476	492	protein kinase B	Gene	11651(Species:10090)
23220172	524	539	selenoprotein H	Gene	280636(Species:9606)
23220172	748	763	selenoprotein H	Gene	280636(Species:9606)
23220172	782	786	HT22	Species	Species:10090
23220172	921	937	caspase-3 and -9	Gene	12367(Species:10090),12371(Species:10090)
23220172	950	953	p53	Gene	22059(Species:10090)
23220172	1035	1050	selenoprotein H	Gene	280636(Species:9606)
23220172	1136	1151	selenoprotein H	Gene	280636(Species:9606)
23220172	1164	1168	HT22	Species	Species:10090
23220172	1257	1317	peroxisome proliferator-activated receptor g coactivator-1a,	Gene	19017(Species:10090)
23220172	1257	1316	peroxisome proliferator-activated receptor g coactivator-1a	Gene	19017(Species:10090)
23220172	1318	1346	nuclear respiratory factor 1	Gene	18181(Species:10090)
23220172	1351	1387	mitochondrial transcription factor A	Gene	21780(Species:10090)
23220172	1440	1456	protein kinase A	Gene	18747(Species:10090)
23220172	1458	1461	Akt	Gene	11651(Species:10090)
23220172	1462	1478	protein kinase B	Gene	11651(Species:10090)
23220172	1483	1546	cyclic adenosine monophosphate response element-binding protein	Gene	12912(Species:10090)
23220172	1548	1552	CREB	Gene	12912(Species:10090)
23220172	1586	1601	selenoprotein H	Gene	280636(Species:9606)
23220172	1651	1655	HT22	Species	Species:10090
23220172	1765	1780	selenoprotein H	Gene	280636(Species:9606)
23220172	1802	1806	CREB	Gene	12912(Species:10090)
23220172	1824	1839	selenoprotein H	Gene	280636(Species:9606)
23220172	1877	1881	CREB	Gene	12912(Species:10090)
23220172	1913	1928	selenoprotein H	Gene	280636(Species:9606)
23220172	2050	2065	selenoprotein H	Gene	280636(Species:9606)
23220172	2107	2113	PGC-1a	Gene	19017(Species:10090)
23220172	2115	2143	nuclear respiratory factor 1	Gene	18181(Species:10090)
23220172	2148	2184	mitochondrial transcription factor A	Gene	21780(Species:10090)
23220172	2245	2261	protein kinase A	Gene	18747(Species:10090)
23220172	2263	2279	protein kinase B	Gene	11651(Species:10090)
23220172	2285	2289	CREB	Gene	12912(Species:10090)
23220172	2302	2306	CREB	Gene	12912(Species:10090)
23220172	2326	2330	CREB	Gene	12912(Species:10090)
23220172	2346	2352	PGC-1a	Gene	19017(Species:10090)
23220172	2371	2386	selenoprotein H	Gene	280636(Species:9606)
23220172	2416	2431	selenoprotein H	Gene	280636(Species:9606)
23220172	2609	2624	selenoprotein H	Gene	280636(Species:9606)
23220172	2710	2726	protein kinase A	Gene	18747(Species:10090)
23220172	2727	2731	CREB	Gene	12912(Species:10090)
23220172	2732	2738	PGC-1a	Gene	19017(Species:10090)
23220172	2743	2746	Akt	Gene	11651(Species:10090)
23220172	2747	2763	protein kinase B	Gene	11651(Species:10090)
23220172	2764	2768	CREB	Gene	12912(Species:10090)
23220172	2769	2775	PGC-1a	Gene	10891(Species:9606)

29470556|t|No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations.
29470556|a|BACKGROUND: Human African trypanosomiasis (HAT) manifests as an acute form caused by Trypanosoma brucei rhodesiense (Tbr) and a chronic form caused by Trypanosoma brucei gambiense (Tbg). Previous studies have suggested a host genetic role in infection outcomes, particularly for APOL1. We have undertaken candidate gene association studies (CGAS) in a Ugandan Tbr and a Tbg HAT endemic area, to determine whether polymorphisms in IL10, IL8, IL4, HLAG, TNFA, TNX4LB, IL6, IFNG, MIF, APOL1, HLAA, IL1B, IL4R, IL12B, IL12R, HP, HPR, and CFH have a role in HAT. METHODOLOGY AND RESULTS: We included 238 and 202 participants from the Busoga Tbr and Northwest Uganda Tbg endemic areas respectively. Single Nucleotide Polymorphism (SNP) genotype data were analysed in the CGAS. The study was powered to find odds ratios > 2 but association testing of the SNPs with HAT yielded no positive associations i.e. none significant after correction for multiple testing. However there was strong evidence for no association with Tbr HAT and APOL1 G2 of the size previously reported in the Kabermaido district of Uganda. CONCLUSIONS/SIGNIFICANCE: A recent study in the Soroti and Kaberamaido focus in Central Uganda found that the APOL1 G2 allele was strongly associated with protection against Tbr HAT (odds ratio = 0.2, 95% CI: 0.07 to 0.48, p = 0.0001). However, in our study no effect of G2 on Tbr HAT was found, despite being well powered to find a similar sized effect (OR = 0.9281, 95% CI: 0.482 to 1.788, p = 0.8035). It is possible that the G2 allele is protective from Tbr in the Soroti/Kabermaido focus but not in the Iganga district of Busoga, which differ in ethnicity and infection history. Mechanisms underlying HAT infection outcome and virulence are complex and might differ between populations, and likely involve several host, parasite or even environmental factors.
29470556	36	41	APOL1	Gene	8542(Species:9606)
29470556	74	79	Human	Species	Species:9606
29470556	144	149	Human	Species	Species:9606
29470556	217	247	Trypanosoma brucei rhodesiense	Species	Species:31286
29470556	249	252	Tbr	Species	Species:31286
29470556	283	311	Trypanosoma brucei gambiense	Species	Species:31285
29470556	313	316	Tbg	Species	Species:31285
29470556	411	416	APOL1	Gene	8542(Species:9606)
29470556	492	495	Tbr	Species	Species:31286
29470556	502	505	Tbg	Species	Species:31285
29470556	562	566	IL10	Gene	3586(Species:9606)
29470556	568	571	IL8	Gene	3576(Species:9606)
29470556	573	576	IL4	Gene	3565(Species:9606)
29470556	578	582	HLAG	Gene	3135(Species:9606)
29470556	584	588	TNFA	Gene	7124(Species:9606)
29470556	598	601	IL6	Gene	3569(Species:9606)
29470556	603	607	IFNG	Gene	3458(Species:9606)
29470556	609	612	MIF	Gene	4282(Species:9606)
29470556	614	619	APOL1	Gene	8542(Species:9606)
29470556	621	625	HLAA	Gene	3105(Species:9606)
29470556	627	631	IL1B	Gene	3553(Species:9606)
29470556	633	637	IL4R	Gene	3566(Species:9606)
29470556	639	644	IL12B	Gene	3593(Species:9606)
29470556	646	651	IL12R	Gene	3594(Species:9606),3595(Species:9606)
29470556	653	655	HP	Gene	3240(Species:9606)
29470556	657	660	HPR	Gene	3250(Species:9606)
29470556	666	669	CFH	Gene	3075(Species:9606)
29470556	739	751	participants	Species	Species:9606
29470556	768	771	Tbr	Species	Species:31286
29470556	793	796	Tbg	Species	Species:31285
29470556	1146	1149	Tbr	Species	Species:31286
29470556	1158	1163	APOL1	Gene	8542(Species:9606)
29470556	1347	1352	APOL1	Gene	8542(Species:9606)
29470556	1411	1414	Tbr	Species	Species:31286
29470556	1514	1517	Tbr	Species	Species:31286
29470556	1695	1698	Tbr	Species	Species:31286

26449539|t|The impact of PPARa activation on whole genome gene expression in human precision cut liver slices.
26449539|a|BACKGROUND: Studies in mice have shown that PPARa is an important regulator of lipid metabolism in liver and key transcription factor involved in the adaptive response to fasting. However, much less is known about the role of PPARa in human liver. METHODS: Here we set out to study the function of PPARa in human liver via analysis of whole genome gene regulation in human liver slices treated with the PPARa agonist Wy14643. RESULTS: Quantitative PCR indicated that PPARa is well expressed in human liver and human liver slices and that the classical PPARa targets PLIN2, VLDLR, ANGPTL4, CPT1A and PDK4 are robustly induced by PPARa activation. Transcriptomics analysis indicated that 617 genes were upregulated and 665 genes were downregulated by PPARa activation (q value < 0.05). Many genes induced by PPARa activation were involved in lipid metabolism (ACSL5, AGPAT9, FADS1, SLC27A4), xenobiotic metabolism (POR, ABCC2, CYP3A5) or the unfolded protein response, whereas most of the downregulated genes were involved in immune-related pathways. Among the most highly repressed genes upon PPARa activation were several chemokines (e.g. CXCL9-11, CCL8, CX3CL1, CXCL6), interferon g-induced genes (e.g. IFITM1, IFIT1, IFIT2, IFIT3) and numerous other immune-related genes (e.g. TLR3, NOS2, and LCN2). Comparative analysis of gene regulation by Wy14643 between human liver slices and primary human hepatocytes showed that down-regulation of gene expression by PPARa is much better captured by liver slices as compared to primary hepatocytes. In particular, PPARa activation markedly suppressed immunity/inflammation-related genes in human liver slices but not in primary hepatocytes. Finally, several putative new target genes of PPARa were identified that were commonly induced by PPARa activation in the two human liver model systems, including TSKU, RHOF, CA12 and VSIG10L. CONCLUSION: Our paper demonstrates the suitability and superiority of human liver slices over primary hepatocytes for studying the functional role of PPARa in human liver. Our data underscore the major role of PPARa in regulation of hepatic lipid and xenobiotic metabolism in human liver and reveal a marked immuno-suppressive/anti-inflammatory effect of PPARa in human liver slices that may be therapeutically relevant for non-alcoholic fatty liver disease.
26449539	14	19	PPARa	Gene	5465(Species:9606)
26449539	66	71	human	Species	Species:9606
26449539	123	127	mice	Species	Species:10090
26449539	144	149	PPARa	Gene	19013(Species:10090)
26449539	326	331	PPARa	Gene	5465(Species:9606)
26449539	335	340	human	Species	Species:9606
26449539	398	403	PPARa	Gene	5465(Species:9606)
26449539	407	412	human	Species	Species:9606
26449539	467	472	human	Species	Species:9606
26449539	503	508	PPARa	Gene	5465(Species:9606)
26449539	567	572	PPARa	Gene	5465(Species:9606)
26449539	594	599	human	Species	Species:9606
26449539	610	615	human	Species	Species:9606
26449539	652	657	PPARa	Gene	5465(Species:9606)
26449539	666	671	PLIN2	Gene	123(Species:9606)
26449539	673	678	VLDLR	Gene	7436(Species:9606)
26449539	680	687	ANGPTL4	Gene	51129(Species:9606)
26449539	689	694	CPT1A	Gene	1374(Species:9606)
26449539	699	703	PDK4	Gene	5166(Species:9606)
26449539	728	733	PPARa	Gene	5465(Species:9606)
26449539	849	854	PPARa	Gene	5465(Species:9606)
26449539	906	911	PPARa	Gene	5465(Species:9606)
26449539	958	963	ACSL5	Gene	51703(Species:9606)
26449539	965	971	AGPAT9	Gene	84803(Species:9606)
26449539	973	978	FADS1	Gene	3992(Species:9606)
26449539	980	987	SLC27A4	Gene	10999(Species:9606)
26449539	1013	1016	POR	Gene	5447(Species:9606)
26449539	1018	1023	ABCC2	Gene	1244(Species:9606)
26449539	1025	1031	CYP3A5	Gene	1577(Species:9606)
26449539	1192	1197	PPARa	Gene	5465(Species:9606)
26449539	1239	1247	CXCL9-11	Gene	4283(Species:9606),3627(Species:9606),6373(Species:9606)
26449539	1249	1253	CCL8	Gene	6355(Species:9606)
26449539	1255	1261	CX3CL1	Gene	6376(Species:9606)
26449539	1263	1268	CXCL6	Gene	6372(Species:9606)
26449539	1271	1283	interferon g	Gene	3458(Species:9606)
26449539	1304	1310	IFITM1	Gene	8519(Species:9606)
26449539	1312	1317	IFIT1	Gene	3434(Species:9606)
26449539	1319	1324	IFIT2	Gene	3433(Species:9606)
26449539	1326	1331	IFIT3	Gene	3437(Species:9606)
26449539	1379	1383	TLR3	Gene	7098(Species:9606)
26449539	1385	1389	NOS2	Gene	4843(Species:9606)
26449539	1395	1399	LCN2	Gene	3934(Species:9606)
26449539	1461	1466	human	Species	Species:9606
26449539	1492	1497	human	Species	Species:9606
26449539	1560	1565	PPARa	Gene	5465(Species:9606)
26449539	1657	1662	PPARa	Gene	5465(Species:9606)
26449539	1733	1738	human	Species	Species:9606
26449539	1830	1835	PPARa	Gene	5465(Species:9606)
26449539	1882	1887	PPARa	Gene	5465(Species:9606)
26449539	1910	1915	human	Species	Species:9606
26449539	1947	1951	TSKU	Gene	25987(Species:9606)
26449539	1953	1957	RHOF	Gene	54509(Species:9606)
26449539	1959	1963	CA12	Gene	771(Species:9606)
26449539	1968	1975	VSIG10L	Gene	147645(Species:9606)
26449539	2047	2052	human	Species	Species:9606
26449539	2127	2132	PPARa	Gene	5465(Species:9606)
26449539	2136	2141	human	Species	Species:9606
26449539	2187	2192	PPARa	Gene	5465(Species:9606)
26449539	2253	2258	human	Species	Species:9606
26449539	2332	2337	PPARa	Gene	5465(Species:9606)
26449539	2341	2346	human	Species	Species:9606

19706770|t|Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
19706770|a|To identify genetic events that characterize cancer progression, we conducted a comprehensive genetic evaluation of 161 primary breast tumors. Similar to the "mountain-and-hill" view of mutations, gene amplification also shows high- and low-frequency alterations in breast cancers. The frequently amplified genes include the well-known oncogenes ERBB2, FGFR1, MYC, CCND1, and PIK3CA, whereas other known oncogenes that are amplified, although less frequently, include CCND2, EGFR, FGFR2, and NOTCH3. More importantly, by honing in on minimally amplified regions containing three or fewer genes, we identified six new amplified genes: POLD3, IRAK4, IRX2, TBL1XR1, ASPH, and BRD4. We found that both the IRX2 and TBL1XR1 proteins showed higher expression in the malignant cell lines MCF10CA1h and MCF10CA1a than in their precursor, MCF10A, a normal immortalized mammary epithelial cell line. To study oncogenic roles of TBL1XR1, we performed knockdown experiments using a short hairpin RNA approach and found that depletion of TBL1XR1 in MCF10CA1h cells resulted in reduction of cell migration and invasion as well as suppression of tumorigenesis in mouse xenografts. Intriguingly, our mutation analysis showed the presence of activation mutations in the PIK3CA gene in a subset of tumors that also had DNA copy number increases in the PIK3CA locus, suggesting an additive effect of coexisting activating amino acid substitution and dosage increase from amplification. Our gene amplification and somatic mutation analysis of breast primary tumors provides a coherent picture of genetic events, both corroborating and novel, offering insight into the genetic underpinnings of breast cancer progression.
19706770	130	136	PIK3CA	Gene	5290(Species:9606)
19706770	474	483	oncogenes	Gene	1956(Species:9606),2064(Species:9606),2263(Species:9606),4609(Species:9606),4854(Species:9606),5290(Species:9606),595(Species:9606),79718(Species:9606),894(Species:9606)
19706770	484	489	ERBB2	Gene	2064(Species:9606)
19706770	491	496	FGFR1	Gene	2260(Species:9606)
19706770	498	501	MYC	Gene	4609(Species:9606)
19706770	503	508	CCND1	Gene	595(Species:9606)
19706770	514	520	PIK3CA	Gene	5290(Species:9606)
19706770	542	551	oncogenes	Gene	1956(Species:9606),2064(Species:9606),2263(Species:9606),4609(Species:9606),4854(Species:9606),5290(Species:9606),595(Species:9606),79718(Species:9606),894(Species:9606)
19706770	606	611	CCND2	Gene	894(Species:9606)
19706770	613	617	EGFR	Gene	1956(Species:9606)
19706770	619	624	FGFR2	Gene	2263(Species:9606)
19706770	630	636	NOTCH3	Gene	4854(Species:9606)
19706770	772	777	POLD3	Gene	10714(Species:9606)
19706770	779	784	IRAK4	Gene	51135(Species:9606)
19706770	786	790	IRX2	Gene	153572(Species:9606)
19706770	792	799	TBL1XR1	Gene	79718(Species:9606)
19706770	801	805	ASPH	Gene	444(Species:9606)
19706770	811	815	BRD4	Gene	23476(Species:9606)
19706770	840	844	IRX2	Gene	153572(Species:9606)
19706770	849	856	TBL1XR1	Gene	79718(Species:9606)
19706770	1056	1063	TBL1XR1	Gene	79718(Species:9606)
19706770	1163	1170	TBL1XR1	Gene	79718(Species:9606)
19706770	1174	1183	MCF10CA1h	Species	Species:9606
19706770	1286	1291	mouse	Species	Species:10090
19706770	1391	1397	PIK3CA	Gene	5290(Species:9606)
19706770	1472	1478	PIK3CA	Gene	5290(Species:9606)

24632949|t|Dysregulation of Wnt inhibitory factor 1 (Wif1) expression resulted in aberrant Wnt-b-catenin signaling and cell death of the cloaca endoderm, and anorectal malformations.
24632949|a|In mammalian urorectal development, the urorectal septum (urs) descends from the ventral body wall to the cloaca membrane (cm) to partition the cloaca into urogenital sinus and rectum. Defective urs growth results in human congenital anorectal malformations (ARMs), and their pathogenic mechanisms are unclear. Recent studies only focused on the importance of urs mesenchyme proliferation, which is induced by endoderm-derived Sonic Hedgehog (Shh). Here, we showed that the programmed cell death of the apical urs and proximal cm endoderm is particularly crucial for the growth of urs during septation. The apoptotic endoderm was closely associated with the tempo-spatial expression of Wnt inhibitory factor 1 (Wif1), which is an inhibitor of Wnt-b-catenin signaling. In Wif1(lacZ/lacZ) mutant mice and cultured urorectum with exogenous Wif1, cloaca septation was defective with undescended urs and hypospadias-like phenotypes, and such septation defects were also observed in Shh(-/-) mutants and in endodermal b-catenin gain-of-function (GOF) mutants. In addition, Wif1 and Shh were expressed in a complementary manner in the cloaca endoderm, and Wif1 was ectopically expressed in the urs and cm associated with excessive endodermal apoptosis and septation defects in Shh(-/-) mutants. Furthermore, apoptotic cells were markedly reduced in the endodermal b-catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1. Taken altogether, these data suggest that regulated expression of Wif1 is critical for the growth of the urs during cloaca septation. Hence, Wif1 governs cell apoptosis of urs endoderm by repressing b-catenin signal, which may facilitate the protrusion of the underlying proliferating mesenchymal cells towards the cm for cloaca septation. Dysregulation of this endodermal Shh-Wif1-b-catenin signaling axis contributes to ARM pathogenesis.
24632949	17	40	Wnt inhibitory factor 1	Gene	24117(Species:10090)
24632949	42	46	Wif1	Gene	24117(Species:10090)
24632949	80	83	Wnt	Gene	22408(Species:10090)
24632949	84	93	b-catenin	Gene	12387(Species:10090)
24632949	175	184	mammalian	Species	Species:9606
24632949	389	394	human	Species	Species:9606
24632949	599	613	Sonic Hedgehog	Gene	20423(Species:10090)
24632949	615	618	Shh	Gene	20423(Species:10090)
24632949	858	881	Wnt inhibitory factor 1	Gene	24117(Species:10090)
24632949	883	887	Wif1	Gene	24117(Species:10090)
24632949	915	918	Wnt	Gene	22408(Species:10090)
24632949	919	928	b-catenin	Gene	12387(Species:10090)
24632949	943	947	Wif1	Gene	24117(Species:10090)
24632949	966	970	mice	Species	Species:10090
24632949	1009	1013	Wif1	Gene	24117(Species:10090)
24632949	1149	1152	Shh	Gene	20423(Species:10090)
24632949	1184	1193	b-catenin	Gene	12387(Species:10090)
24632949	1239	1243	Wif1	Gene	24117(Species:10090)
24632949	1248	1251	Shh	Gene	20423(Species:10090)
24632949	1321	1325	Wif1	Gene	24117(Species:10090)
24632949	1442	1445	Shh	Gene	20423(Species:10090)
24632949	1529	1538	b-catenin	Gene	12387(Species:10090)
24632949	1604	1608	Wif1	Gene	24117(Species:10090)
24632949	1676	1680	Wif1	Gene	24117(Species:10090)
24632949	1751	1755	Wif1	Gene	24117(Species:10090)
24632949	1809	1818	b-catenin	Gene	12387(Species:10090)
24632949	1983	1986	Shh	Gene	20423(Species:10090)
24632949	1987	1991	Wif1	Gene	24117(Species:10090)
24632949	1992	2001	b-catenin	Gene	12387(Species:10090)

19672298|t|A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.
19672298|a|BACKGROUND: Stromal-Derived Inducing Activity (SDIA) is one of the most efficient methods of generating dopaminergic (DA) neurons from embryonic stem cells (ESC). DA neuron induction can be achieved by co-culturing ESC with the mouse stromal cell lines PA6 or MS5. The molecular nature of this effect, which has been termed "SDIA" is so far unknown. Recently, we found that factors secreted by PA6 cells provided lineage-specific instructions to induce DA differentiation of human ESC (hESC). METHODOLOGY/PRINCIPAL FINDINGS: In the present study, we compared PA6 cells to various cell lines lacking the SDIA effect, and employed genome expression analysis to identify differentially-expressed signaling molecules. Among the factors highly expressed by PA6 cells, and known to be associated with CNS development, were stromal cell-derived factor 1 (SDF-1/CXCL12), pleiotrophin (PTN), insulin-like growth factor 2 (IGF2), and ephrin B1 (EFNB1). When these four factors, the combination of which was termed SPIE, were applied to hESC, they induced differentiation to TH-positive neurons in vitro. RT-PCR and western blot analysis confirmed the expression of midbrain specific markers, including engrailed 1, Nurr1, Pitx3, and dopamine transporter (DAT) in cultures influenced by these four molecules. Electrophysiological recordings showed that treatment of hESC with SPIE induced differentiation of neurons that were capable of generating action potentials and forming functional synaptic connections. CONCLUSIONS/SIGNIFICANCE: The combination of SDF-1, PTN, IGF2, and EFNB1 mimics the DA phenotype-inducing property of SDIA and was sufficient to promote differentiation of hESC to functional midbrain DA neurons. These findings provide a method for differentiating hESC to form DA neurons, without a requirement for the use of animal-derived cell lines or products.
19672298	39	43	SPIE	Gene	20315(Species:10090),19242(Species:10090),16002(Species:10090),13641(Species:10090)
19672298	101	106	human	Species	Species:9606
19672298	357	362	mouse	Species	Species:10090
19672298	523	526	PA6	Species	Species:10090
19672298	604	609	human	Species	Species:9606
19672298	688	691	PA6	Species	Species:10090
19672298	881	884	PA6	Species	Species:10090
19672298	946	975	stromal cell-derived factor 1	Gene	20315(Species:10090)
19672298	977	982	SDF-1	Gene	20315(Species:10090)
19672298	983	989	CXCL12	Gene	20315(Species:10090)
19672298	992	1004	pleiotrophin	Gene	19242(Species:10090)
19672298	1006	1009	PTN	Gene	19242(Species:10090)
19672298	1012	1040	insulin-like growth factor 2	Gene	16002(Species:10090)
19672298	1042	1046	IGF2	Gene	16002(Species:10090)
19672298	1053	1062	ephrin B1	Gene	13641(Species:10090)
19672298	1064	1069	EFNB1	Gene	13641(Species:10090)
19672298	1133	1137	SPIE	Gene	13641(Species:10090),16002(Species:10090),19242(Species:10090),20315(Species:10090)
19672298	1321	1332	engrailed 1	Gene	2019(Species:9606)
19672298	1334	1339	Nurr1	Gene	4929(Species:9606)
19672298	1341	1346	Pitx3	Gene	5309(Species:9606)
19672298	1352	1372	dopamine transporter	Gene	6531(Species:9606)
19672298	1374	1377	DAT	Gene	6531(Species:9606)
19672298	1494	1498	SPIE	Gene	13641(Species:10090),16002(Species:10090),19242(Species:10090),20315(Species:10090)
19672298	1674	1679	SDF-1	Gene	20315(Species:10090)
19672298	1681	1684	PTN	Gene	19242(Species:10090)
19672298	1686	1690	IGF2	Gene	16002(Species:10090)
19672298	1696	1701	EFNB1	Gene	13641(Species:10090)

28481877|t|CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.
28481877|a|Tumor-associated macrophages (TAMs) play an essential role in metastasis. However, what enables TAMs to have a superior capacity to establish pre-metastatic microenvironment in distant organs is unclear. Here we have begun to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche formation and metastasis. CYP4A(+) TAM infiltration was positively associated with metastasis, pre-metastatic niche formation and poor prognosis in breast cancer patients. The pharmacological inhibition of CYP4A reduced lung pre-metastatic niche formation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)) myeloid cell recruitment and pro-metastatic protein expression) and metastatic burden, accompanied with TAM polarization away from the M2 phenotype in spontaneous metastasis models of 4T1 breast cancer and B16F10 melanoma. Co-implantation of 4T1 cells with CYP4A10(high) macrophages promoted lung pre-metastatic niche formation and metastasis. Depletion of TAMs disrupted lung pre-metastatic niches and thereby prevented metastasis. Treatment with the CM from CYP4A10(high) M2 macrophages (M2) increased pre-metastatic niche formation and metastatic burden in the lungs, whereas CYP4A inhibition attenuated these effects. In vitro TAM polarization away from the M2 phenotype induced by CYP4A inhibition decreased VEGFR1(+) myeloid cell migration and fibronectin expression, accompanied with downregulation of STAT3 signaling. Conversely, overexpression of CYP4A or exogenous addition of 20-hydroxyeicosatetraenoic acid promoted M2 polarization and cytokine production of macrophages and thereby enhanced migration of VEGFR1(+) myeloid cells, which were reversed by siRNA or pharmacological inhibition of STAT3. Importantly, a combined blocking M2 macrophage-derived factors TGF-b, VEGF and SDF-1 abolished VEGFR1(+) myeloid cell migration and fibroblast activation induced by CYP4A. In summary, CYP4A in TAMs is crucial for lung pre-metastatic niche formation and metastasis, and may serve as a potential therapeutic target in human cancer.
28481877	0	5	CYP4A	Gene	1579(Species:9606)
28481877	343	367	cytochrome P450 (CYP) 4A	Gene	13117(Species:10090)
28481877	431	436	CYP4A	Gene	1579(Species:9606)
28481877	567	575	patients	Species	Species:9606
28481877	611	616	CYP4A	Gene	13117(Species:10090)
28481877	689	734	vascular endothelial growth factor receptor 1	Gene	14254(Species:10090)
28481877	745	751	VEGFR1	Gene	14254(Species:10090)
28481877	962	968	B16F10	Species	Species:10090
28481877	998	1001	4T1	Species	Species:10090
28481877	1013	1020	CYP4A10	Gene	13117(Species:10090)
28481877	1216	1223	CYP4A10	Gene	13117(Species:10090)
28481877	1335	1340	CYP4A	Gene	13117(Species:10090)
28481877	1442	1447	CYP4A	Gene	13117(Species:10090),1579(Species:9606)
28481877	1469	1475	VEGFR1	Gene	2321(Species:9606),14254(Species:10090)
28481877	1506	1517	fibronectin	Gene	2335(Species:9606)
28481877	1565	1570	STAT3	Gene	6774(Species:9606),20848(Species:10090)
28481877	1612	1617	CYP4A	Gene	13117(Species:10090),1579(Species:9606)
28481877	1773	1779	VEGFR1	Gene	2321(Species:9606)
28481877	1860	1865	STAT3	Gene	6774(Species:9606)
28481877	1930	1935	TGF-b	Gene	21803(Species:10090)
28481877	1937	1941	VEGF	Gene	22339(Species:10090)
28481877	1946	1951	SDF-1	Gene	20315(Species:10090)
28481877	1962	1968	VEGFR1	Gene	2321(Species:9606)
28481877	2032	2037	CYP4A	Gene	13117(Species:10090)
28481877	2051	2056	CYP4A	Gene	1579(Species:9606)
28481877	2183	2188	human	Species	Species:9606

28398466|t|Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis.
28398466|a|Nesprins-1 and -2 are highly expressed in skeletal and cardiac muscle and together with SUN (Sad1p/UNC84)-domain containing proteins and lamin A/C form the LInker of Nucleoskeleton-and-Cytoskeleton (LINC) bridging complex at the nuclear envelope (NE). Mutations in nesprin-1/2 have previously been found in patients with autosomal dominant Emery-Dreifuss muscular dystrophy (EDMD) as well as dilated cardiomyopathy (DCM). In this study, three novel rare variants (R8272Q, S8381C and N8406K) in the C-terminus of the SYNE1 gene (nesprin-1) were identified in seven DCM patients by mutation screening. Expression of these mutants caused nuclear morphology defects and reduced lamin A/C and SUN2 staining at the NE. GST pull-down indicated that nesprin-1/lamin/SUN interactions were disrupted. Nesprin-1 mutations were also associated with augmented activation of the ERK pathway in vitro and in hearts in vivo. During C2C12 muscle cell differentiation, nesprin-1 levels are increased concomitantly with kinesin light chain (KLC-1/2) and immunoprecipitation and GST pull-down showed that these proteins interacted via a recently identified LEWD domain in the C-terminus of nesprin-1. Expression of nesprin-1 mutants in C2C12 cells caused defects in myoblast differentiation and fusion associated with dysregulation of myogenic transcription factors and disruption of the nesprin-1 and KLC-1/2 interaction at the outer nuclear membrane. Expression of nesprin-1a2 WT and mutants in zebrafish embryos caused heart developmental defects that varied in severity. These findings support a role for nesprin-1 in myogenesis and muscle disease, and uncover a novel mechanism whereby disruption of the LINC complex may contribute to the pathogenesis of DCM.
28398466	6	15	nesprin-1	Gene	23345(Species:9606)
28398466	126	143	Nesprins-1 and -2	Gene	23345(Species:9606),23224(Species:9606)
28398466	263	272	lamin A/C	Gene	4000(Species:9606)
28398466	391	402	nesprin-1/2	Gene	23345(Species:9606),23224(Species:9606)
28398466	433	441	patients	Species	Species:9606
28398466	642	647	SYNE1	Gene	23345(Species:9606)
28398466	654	663	nesprin-1	Gene	23345(Species:9606)
28398466	694	702	patients	Species	Species:9606
28398466	800	809	lamin A/C	Gene	4000(Species:9606)
28398466	814	818	SUN2	Gene	25777(Species:9606)
28398466	868	877	nesprin-1	Gene	23345(Species:9606)
28398466	878	883	lamin	Gene	4000(Species:9606)
28398466	884	887	SUN	Gene	25777(Species:9606)
28398466	917	926	Nesprin-1	Gene	23345(Species:9606)
28398466	991	994	ERK	Gene	5594(Species:9606)
28398466	1042	1047	C2C12	Species	Species:10090
28398466	1077	1086	nesprin-1	Gene	64009(Species:10090)
28398466	1127	1146	kinesin light chain	Gene	16593(Species:10090),16594(Species:10090)
28398466	1148	1155	KLC-1/2	Gene	16593(Species:10090),16594(Species:10090)
28398466	1296	1305	nesprin-1	Gene	64009(Species:10090)
28398466	1321	1330	nesprin-1	Gene	23345(Species:9606)
28398466	1342	1347	C2C12	Species	Species:10090
28398466	1494	1503	nesprin-1	Gene	64009(Species:10090)
28398466	1508	1515	KLC-1/2	Gene	16593(Species:10090),16594(Species:10090)
28398466	1573	1584	nesprin-1a2	Gene	23345(Species:9606)
28398466	1603	1612	zebrafish	Species	Species:7955
28398466	1715	1724	nesprin-1	Gene	23345(Species:9606)

26027517|t|The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair.
26027517|a|In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis. In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB. The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX. In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained. Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair. LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively. Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice. We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha. These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair. 
26027517	4	13	autotaxin	Gene	84050(Species:10116)
26027517	14	18	LPA2	Gene	498609(Species:10116),53978(Species:10090)
26027517	19	23	GPCR	Gene	295589(Species:10116)
26027517	199	208	autotaxin	Gene	84050(Species:10116)
26027517	210	213	ATX	Gene	84050(Species:10116)
26027517	215	219	LPA2	Gene	498609(Species:10116)
26027517	220	224	GPCR	Gene	295589(Species:10116)
26027517	234	239	IEC-6	Species	Species:10116
26027517	344	348	lpa2	Gene	498609(Species:10116)
26027517	420	429	NF-kappaB	Gene	81736(Species:10116)
26027517	442	446	lpa2	Gene	498609(Species:10116)
26027517	476	491	ATM/ATR kinases	Gene	300711(Species:10116),685055(Species:10116)
26027517	522	526	lpa2	Gene	498609(Species:10116)
26027517	572	575	ATM	Gene	300711(Species:10116)
26027517	580	589	NF-kappaB	Gene	81736(Species:10116)
26027517	640	650	gamma-H2AX	Gene	500987(Species:10116)
26027517	654	657	LPA	Gene	53978(Species:10090)
26027517	666	671	IEC-6	Species	Species:10116
26027517	782	786	LPA2	Gene	498609(Species:10116)
26027517	813	823	gamma-H2AX	Gene	500987(Species:10116)
26027517	828	832	LPA2	Gene	53978(Species:10090)
26027517	865	875	LPA1    '3	Gene	14745(Species:10090),65086(Species:10090)
26027517	890	900	gamma-H2AX	Gene	15270(Species:10090)
26027517	990	1000	ERK1    '2	Gene	26417(Species:10090),26413(Species:10090)
26027517	1004	1008	PI3K	Gene	18708(Species:10090)
26027517	1009	1012	AKT	Gene	11651(Species:10090)
26027517	1102	1106	LPA2	Gene	53978(Species:10090)
26027517	1131	1134	LPA	Gene	53978(Species:10090)
26027517	1150	1154	LPA2	Gene	53978(Species:10090)
26027517	1170	1173	Lin	Gene	83557(Species:10090)
26027517	1176	1181	Sca-1	Gene	110454(Species:10090)
26027517	1184	1189	c-Kit	Gene	16590(Species:10090)
26027517	1365	1375	gamma-H2AX	Gene	15270(Species:10090)
26027517	1441	1445	LPA2	Gene	53978(Species:10090)
26027517	1449	1453	mice	Species	Species:10090
26027517	1469	1473	mice	Species	Species:10090
26027517	1524	1527	ATX	Gene	84050(Species:10116)
26027517	1541	1544	LPA	Gene	53978(Species:10090)
26027517	1635	1643	TNFalpha	Gene	21926(Species:10090)
26027517	1669	1672	ATX	Gene	18606(Species:10090),84050(Species:10116)
26027517	1677	1681	LPA2	Gene	498609(Species:10116),53978(Species:10090)

27679980|t|Pannexin3 inhibits TNF-a-induced inflammatory response by suppressing NF-kB signalling pathway in human dental pulp cells.
27679980|a|Human dental pulp cells (HDPCs) play a crucial role in dental pulp inflammation. Pannexin 3 (Panx3), a member of Panxs (Pannexins), has been recently found to be involved in inflammation. However, the mechanism of Panx3 in human dental pulp inflammation remains unclear. In this study, the role of Panx3 in inflammatory response was firstly explored, and its potential mechanism was proposed. Immunohistochemical staining showed that Panx3 levels were diminished in inflamed human and rat dental pulp tissues. In vitro, Panx3 expression was significantly down-regulated in HDPCs following a TNF-a challenge in a concentration-dependent way, which reached the lowest level at 10 ng/ml of TNF-a. Such decrease could be reversed by MG132, a proteasome inhibitor. Unlike MG132, BAY 11-7082, a NF-kB inhibitor, even reinforced the inhibitory effect of TNF-a. Quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used to investigate the role of Panx3 in inflammatory response of HDPCs. TNF-a-induced pro-inflammatory cytokines, interleukin (IL)-1b and IL-6, were significantly lessened when Panx3 was overexpressed in HDPCs. Conversely, Panx3 knockdown exacerbated the expression of pro-inflammatory cytokines. Moreover, Western blot, dual-luciferase reporter assay, immunofluorescence staining, qRT-PCR and ELISA results showed that Panx3 participated in dental pulp inflammation in a NF-kB-dependent manner. These findings suggested that Panx3 has a defensive role in dental pulp inflammation, serving as a potential target to be exploited for the intervention of human dental pulp inflammation.
27679980	0	9	Pannexin3	Gene	116337(Species:9606)
27679980	19	24	TNF-a	Gene	7124(Species:9606)
27679980	70	75	NF-kB	Gene	5970(Species:9606)
27679980	98	103	human	Species	Species:9606
27679980	123	128	Human	Species	Species:9606
27679980	204	214	Pannexin 3	Gene	116337(Species:9606)
27679980	216	221	Panx3	Gene	116337(Species:9606)
27679980	236	241	Panxs	Gene	116337(Species:9606)
27679980	243	252	Pannexins	Gene	116337(Species:9606)
27679980	337	342	Panx3	Gene	116337(Species:9606)
27679980	346	351	human	Species	Species:9606
27679980	421	426	Panx3	Gene	116337(Species:9606)
27679980	557	562	Panx3	Gene	116337(Species:9606)
27679980	598	603	human	Species	Species:9606
27679980	608	611	rat	Species	Species:10116
27679980	643	648	Panx3	Gene	116337(Species:9606)
27679980	714	719	TNF-a	Gene	7124(Species:9606)
27679980	810	815	TNF-a	Gene	7124(Species:9606)
27679980	912	917	NF-kB	Gene	5970(Species:9606)
27679980	970	975	TNF-a	Gene	7124(Species:9606)
27679980	1097	1102	Panx3	Gene	116337(Species:9606)
27679980	1138	1143	TNF-a	Gene	7124(Species:9606)
27679980	1180	1199	interleukin (IL)-1b	Gene	3553(Species:9606)
27679980	1204	1208	IL-6	Gene	3569(Species:9606)
27679980	1243	1248	Panx3	Gene	116337(Species:9606)
27679980	1289	1294	Panx3	Gene	116337(Species:9606)
27679980	1486	1491	Panx3	Gene	116337(Species:9606)
27679980	1538	1543	NF-kB	Gene	5970(Species:9606)
27679980	1592	1597	Panx3	Gene	116337(Species:9606)
27679980	1718	1723	human	Species	Species:9606

22022612|t|Expression of novel opsins and intrinsic light responses in the mammalian retinal ganglion cell line RGC-5. Presence of OPN5 in the rat retina.
22022612|a|The vertebrate retina is known to contain three classes of photoreceptor cells: cones and rods responsible for vision, and intrinsically photoresponsive retinal ganglion cells (RGCs) involved in diverse non-visual functions such as photic entrainment of daily rhythms and pupillary light responses. In this paper we investigated the potential intrinsic photoresponsiveness of the rat RGC line, RGC-5, by testing for the presence of visual and non-visual opsins and assessing expression of the immediate-early gene protein c-Fos and changes in intracellular Ca(2+) mobilization in response to brief light pulses. Cultured RGC-5 cells express a number of photopigment mRNAs such as retinal G protein coupled receptor (RGR), encephalopsin/panopsin (Opn3), neuropsin (Opn5) and cone opsin (Opn1mw) but not melanopsin (Opn4) or rhodopsin. Opn5 immunoreactivity was observed in RGC-5 cells and in the inner retina of rat, mainly localized in the ganglion cell layer (GCL). Furthermore, white light pulses of different intensities and durations elicited changes both in intracellular Ca(2+) levels and in the induction of c-Fos protein in RGC-5 cell cultures. The results demonstrate that RGC-5 cells expressing diverse putative functional photopigments display intrinsic photosensitivity which accounts for the photic induction of c-Fos protein and changes in intracellular Ca(2+) mobilization. The presence of Opn5 in the GCL of the rat retina suggests the existence of a novel type of photoreceptor cell.
22022612	20	26	opsins	Gene	192223(Species:10116),24717(Species:10116),316259(Species:10116),498289(Species:10116),89810(Species:10116)
22022612	64	73	mammalian	Species	Species:9606
22022612	120	124	OPN5	Gene	316259(Species:10116)
22022612	132	135	rat	Species	Species:10116
22022612	524	527	rat	Species	Species:10116
22022612	598	604	opsins	Gene	192223(Species:10116),24717(Species:10116),316259(Species:10116),498289(Species:10116),89810(Species:10116)
22022612	666	671	c-Fos	Gene	314322(Species:10116)
22022612	765	770	RGC-5	Species	Species:10090
22022612	824	858	retinal G protein coupled receptor	Gene	306307(Species:10116)
22022612	860	863	RGR	Gene	306307(Species:10116)
22022612	866	879	encephalopsin	Gene	498289(Species:10116)
22022612	880	888	panopsin	Gene	498289(Species:10116)
22022612	890	894	Opn3	Gene	498289(Species:10116)
22022612	897	906	neuropsin	Gene	316259(Species:10116)
22022612	908	912	Opn5	Gene	316259(Species:10116)
22022612	918	928	cone opsin	Gene	89810(Species:10116)
22022612	930	936	Opn1mw	Gene	89810(Species:10116)
22022612	946	956	melanopsin	Gene	192223(Species:10116)
22022612	958	962	Opn4	Gene	192223(Species:10116)
22022612	967	976	rhodopsin	Gene	24717(Species:10116)
22022612	978	982	Opn5	Gene	316259(Species:10116)
22022612	1016	1021	RGC-5	Species	Species:10090
22022612	1055	1058	rat	Species	Species:10116
22022612	1259	1264	c-Fos	Gene	314322(Species:10116)
22022612	1276	1281	RGC-5	Species	Species:10090
22022612	1326	1331	RGC-5	Species	Species:10090
22022612	1469	1474	c-Fos	Gene	314322(Species:10116)
22022612	1549	1553	Opn5	Gene	316259(Species:10116)
22022612	1572	1575	rat	Species	Species:10116

27640183|t|Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.
27640183|a|BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented. We therefore investigated the effects of acute and prolonged Epo exposure on human WAT in vivo. METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha. Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA. A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA). RESULTS: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.
27640183	33	56	erythropoietin receptor	Gene	2057(Species:9606)
27640183	92	97	human	Species	Species:9606
27640183	229	233	mice	Species	Species:10090
27640183	284	290	humans	Species	Species:9606
27640183	392	397	human	Species	Species:9606
27640183	505	510	human	Species	Species:9606
27640183	782	794	Epo receptor	Gene	2057(Species:9606)
27640183	796	801	Epo-R	Gene	2057(Species:9606)
27640183	894	899	Epo-R	Gene	2057(Species:9606)
27640183	940	945	Epo-R	Gene	2057(Species:9606)
27640183	966	969	Akt	Gene	207(Species:9606)
27640183	971	976	STAT5	Gene	6776(Species:9606)
27640183	978	984	p70s6k	Gene	6198(Species:9606)
27640183	986	989	LYN	Gene	4067(Species:9606)
27640183	995	1002	p38MAPK	Gene	1432(Species:9606)
27640183	1039	1043	ATGL	Gene	57104(Species:9606)
27640183	1045	1048	HSL	Gene	3991(Species:9606)
27640183	1050	1056	CGI-58	Gene	51099(Species:9606)
27640183	1058	1062	G0S2	Gene	50486(Species:9606)
27640183	1064	1073	Perilipin	Gene	5346(Species:9606)
27640183	1075	1080	Cidea	Gene	1149(Species:9606)
27640183	1082	1087	Cidec	Gene	63924(Species:9606)
27640183	1089	1093	AMPK	Gene	5562(Species:9606)
27640183	1099	1102	ACC	Gene	31(Species:9606)
27640183	1135	1139	VDAC	Gene	7416(Species:9606)
27640183	1141	1146	HSP90	Gene	3320(Species:9606)
27640183	1148	1151	PDH	Gene	54704(Species:9606)
27640183	1157	1161	SDHA	Gene	6389(Species:9606)
27640183	1214	1219	Epo-R	Gene	2057(Species:9606)
27640183	1276	1281	Epo-R	Gene	2057(Species:9606)
27640183	1397	1403	humans	Species	Species:9606

22711886|t|TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.
22711886|a|We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al. 2004. Proc. Nat. Acad. Sci. USA 101: 16600-16605). Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN-tg B cells compared with wild-type mice. This was the result of proteasome-dependent degradation, and rendered TRAF2DN B cells as bona fide TRAF2-deficient B cells. Similar to B cells with targeted Traf2 deletion, Traf2DN-tg mice show expanded marginal zone B cell population and have constitutive p100 NF-kappaB2 processing. Also, TRAF3, X-linked inhibitor of apoptosis, and Bcl-X(L) expression levels were increased, whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild-type B cells. Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement. However, TRAF2 was deleterious for BCR-mediated activation of these kinases. In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation. Finally, we further confirm that TRAF2 was required for CD40-mediated proliferation, but its absence relieved B cells of the need for B cell activating factor for survival. Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
22711886	0	24	TNFR-associated factor 2	Gene	22030(Species:10090)
22711886	127	131	mice	Species	Species:10090
22711886	179	183	mice	Species	Species:10090
22711886	217	222	BCL-2	Gene	596(Species:9606)
22711886	229	253	TNFR-associated factor 2	Gene	22030(Species:10090)
22711886	255	260	TRAF2	Gene	22030(Species:10090)
22711886	334	341	TRAF2DN	Gene	7186(Species:9606)
22711886	535	540	TRAF2	Gene	22030(Species:10090)
22711886	545	552	TRAF2DN	Gene	7186(Species:9606)
22711886	621	626	TRAF2	Gene	22030(Species:10090)
22711886	634	641	TRAF2DN	Gene	7186(Species:9606)
22711886	660	667	Traf2DN	Gene	7186(Species:9606)
22711886	703	707	mice	Species	Species:10090
22711886	732	742	proteasome	Gene	16912(Species:10090)
22711886	779	786	TRAF2DN	Gene	7186(Species:9606)
22711886	798	802	bona	Species	Species:9606
22711886	808	813	TRAF2	Gene	22030(Species:10090)
22711886	866	871	Traf2	Gene	22030(Species:10090)
22711886	882	889	Traf2DN	Gene	7186(Species:9606)
22711886	893	897	mice	Species	Species:10090
22711886	966	981	p100 NF-kappaB2	Gene	18034(Species:10090)
22711886	1000	1005	TRAF3	Gene	22031(Species:10090)
22711886	1007	1038	X-linked inhibitor of apoptosis	Gene	11798(Species:10090)
22711886	1044	1052	Bcl-X(L)	Gene	12048(Species:10090)
22711886	1095	1135	cellular inhibitors of apoptosis 1 and 2	Gene	11796(Species:10090),11797(Species:10090)
22711886	1278	1283	TRAF2	Gene	22030(Species:10090)
22711886	1311	1314	JNK	Gene	26419(Species:10090)
22711886	1319	1322	ERK	Gene	26413(Species:10090)
22711886	1349	1353	CD40	Gene	21939(Species:10090)
22711886	1375	1380	TRAF2	Gene	22030(Species:10090)
22711886	1401	1404	BCR	Gene	12518(Species:10090)
22711886	1434	1441	kinases	Gene	26413(Species:10090),26416(Species:10090),26419(Species:10090)
22711886	1456	1461	TRAF2	Gene	22030(Species:10090)
22711886	1490	1494	CD40	Gene	21939(Species:10090)
22711886	1504	1512	p38 MAPK	Gene	26416(Species:10090)
22711886	1550	1553	BCR	Gene	12518(Species:10090)
22711886	1563	1566	p38	Gene	26416(Species:10090)
22711886	1612	1617	TRAF2	Gene	22030(Species:10090)
22711886	1635	1639	CD40	Gene	21939(Species:10090)
22711886	1713	1737	B cell activating factor	Gene	24099(Species:10090)
22711886	1789	1794	TRAF2	Gene	22030(Species:10090)
22711886	1822	1827	BCL-2	Gene	596(Species:9606)
22711886	1900	1904	mice	Species	Species:10090
22711886	1987	2018	X-linked inhibitor of apoptosis	Gene	11798(Species:10090)
22711886	2068	2092	B cell activating factor	Gene	24099(Species:10090)

23374751|t|MyD88 is crucial for the development of a protective CNS immune response to Toxoplasma gondii infection.
23374751|a|BACKGROUND: Toxoplasmosis is one of the most common parasitic infections in humans. It can establish chronic infection and is characterized by the formation of tissue cysts in the brain. The cysts remain largely quiescent for the life of the host, but can reactivate and cause life-threatening toxoplasmic encephalitis in immunocompromised patients, such as those with AIDS, neoplastic diseases and organ transplants. Toll-like receptor (TLR) adaptor MyD88 activation is required for the innate sensing of Toxoplasma gondii. Mice deficient in MyD88 have defective IL-12 and Th1 effector responses, and are highly susceptible to the acute phase of T. gondii infection. However, the role of this signaling pathway during cerebral infection is poorly understood and requires examination. METHOD: MyD88-deficient mice and control mice were orally infected with T. gondii cysts. Cellular and parasite infiltration in the peripheral organs and in the brain were determined by histology and immunohistochemistry. Cytokine levels were determined by ELISA and chemokine mRNA levels were quantified by real-time PCR (qPCR). RESULTS: Thirteen days after infection, a higher parasite burden was observed but there was no histological change in the liver, heart, lungs and small intestine of MyD88-/- and MyD88+/+ mice. However, MyD88-/- mice compared to MyD88+/+ mice were highly susceptible to cerebral infection, displayed high parasite migration to the brain, severe neuropathological signs of encephalitis and succumbed within 2 weeks of oral infection. Susceptibility was primarily associated with lower expression of Th1 cytokines, especially IL-12, IFN-g and TNF-a, significant decrease in the expression of CCL3, CCL5, CCL7 and CCL19 chemokines, marked defect of CD8+ T cells, and infiltration of CD11b+ and F4/80+ cells in the brain. CONCLUSION: MyD88 is essential for the protection of mice during the cerebral installation of T. gondii infection. These results establish a role for MyD88 in T cell-mediated control of T. gondii in the central nervous system (CNS).
23374751	0	5	MyD88	Gene	17874(Species:10090)
23374751	76	93	Toxoplasma gondii	Species	Species:5811
23374751	181	187	humans	Species	Species:9606
23374751	445	453	patients	Species	Species:9606
23374751	523	541	Toll-like receptor	Gene	24088(Species:10090)
23374751	543	546	TLR	Gene	24088(Species:10090)
23374751	556	561	MyD88	Gene	17874(Species:10090)
23374751	611	628	Toxoplasma gondii	Species	Species:5811
23374751	630	634	Mice	Species	Species:10090
23374751	648	653	MyD88	Gene	17874(Species:10090)
23374751	669	674	IL-12	Gene	16159(Species:10090),16160(Species:10090)
23374751	752	761	T. gondii	Species	Species:5811
23374751	898	903	MyD88	Gene	17874(Species:10090)
23374751	914	918	mice	Species	Species:10090
23374751	931	935	mice	Species	Species:10090
23374751	962	971	T. gondii	Species	Species:5811
23374751	1111	1119	Cytokine	Gene	15978(Species:10090),16159(Species:10090),16160(Species:10090),21926(Species:10090)
23374751	1156	1165	chemokine	Gene	20302(Species:10090),20304(Species:10090),20306(Species:10090),24047(Species:10090)
23374751	1384	1389	MyD88	Gene	17874(Species:10090)
23374751	1397	1402	MyD88	Gene	17874(Species:10090)
23374751	1406	1410	mice	Species	Species:10090
23374751	1421	1426	MyD88	Gene	17874(Species:10090)
23374751	1430	1434	mice	Species	Species:10090
23374751	1447	1452	MyD88	Gene	17874(Species:10090)
23374751	1456	1460	mice	Species	Species:10090
23374751	1716	1729	Th1 cytokines	Gene	15978(Species:10090),16159(Species:10090),16160(Species:10090),21926(Species:10090)
23374751	1720	1729	cytokines	Gene	15978(Species:10090),16159(Species:10090),16160(Species:10090),21926(Species:10090)
23374751	1742	1747	IL-12	Gene	16159(Species:10090),16160(Species:10090)
23374751	1749	1754	IFN-g	Gene	15978(Species:10090)
23374751	1759	1764	TNF-a	Gene	21926(Species:10090)
23374751	1808	1812	CCL3	Gene	20302(Species:10090)
23374751	1814	1818	CCL5	Gene	20304(Species:10090)
23374751	1820	1824	CCL7	Gene	20306(Species:10090)
23374751	1829	1834	CCL19	Gene	24047(Species:10090)
23374751	1835	1845	chemokines	Gene	20302(Species:10090),20304(Species:10090),20306(Species:10090),24047(Species:10090)
23374751	1898	1903	CD11b	Gene	16409(Species:10090)
23374751	1909	1914	F4/80	Species	Species:10090
23374751	1909	1914	F4/80	Gene	13733(Species:10090)
23374751	1948	1953	MyD88	Gene	17874(Species:10090)
23374751	1989	1993	mice	Species	Species:10090
23374751	2030	2039	T. gondii	Species	Species:5811
23374751	2086	2091	MyD88	Gene	17874(Species:10090)
23374751	2122	2131	T. gondii	Species	Species:5811

25711908|t|Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.
25711908|a|Chronic liver disease mediated by activation of hepatic stellate cells (HSCs) leads to liver fibrosis. Here, we postulated that the immune regulatory properties of HSCs might promote the profibrogenic activity of B cells. Fibrosis is completely attenuated in carbon tetrachloride-treated, B cell-deficient uMT mice, showing that B cells are required. The retinoic acid produced by HSCs augmented B-cell survival, plasma cell marker CD138 expression, and immunoglobulin G production. These activities were reversed following addition of the retinoic acid inhibitor LE540. Transcriptional profiling of fibrotic liver B cells revealed increased expression of genes related to activation of nuclear factor k light chain enhancer of activated B cells, proinflammatory cytokine production, and CD40 signaling, suggesting that these B cells are activated and may be acting as inflammatory cells. Biological validation experiments also revealed increased activation (CD44 and CD86 expression), constitutive immunoglobulin G production, and secretion of the proinflammatory cytokines tumor necrosis factor-a, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1a. Likewise, targeted deletion of B-cell-intrinsic myeloid differentiation primary response gene 88 signaling, an innate adaptor with involvement in retinoic acid signaling, resulted in reduced infiltration of migratory CD11c(+) dendritic cells and Ly6C(++) monocytes and, hence, reduced liver pathology. CONCLUSION: Liver fibrosis occurs through a mechanism of HSC-mediated augmentation of innate B-cell activity. These findings highlight B cells as important "first responders" of the intrahepatic immune environment.
25711908	47	52	MyD88	Gene	17874(Species:10090)
25711908	397	401	mice	Species	Species:10090
25711908	519	524	CD138	Gene	20969(Species:10090)
25711908	541	557	immunoglobulin G	Gene	668542(Species:10090)
25711908	774	832	nuclear factor k light chain enhancer of activated B cells	Species	Focus:9606
25711908	774	832	nuclear factor k light chain enhancer of activated B cells	Gene	19697(Species:10090)
25711908	850	858	cytokine	Gene	20296(Species:10090),20302(Species:10090),21926(Species:10090)
25711908	875	879	CD40	Gene	21939(Species:10090)
25711908	1046	1050	CD44	Gene	12505(Species:10090)
25711908	1055	1059	CD86	Gene	12524(Species:10090)
25711908	1086	1102	immunoglobulin G	Gene	668542(Species:10090)
25711908	1136	1161	proinflammatory cytokines	Gene	20296(Species:10090),20302(Species:10090),21926(Species:10090)
25711908	1152	1161	cytokines	Gene	20296(Species:10090),20302(Species:10090),21926(Species:10090)
25711908	1162	1185	tumor necrosis factor-a	Gene	21926(Species:10090)
25711908	1187	1221	monocyte chemoattractant protein-1	Gene	20296(Species:10090)
25711908	1227	1261	macrophage inflammatory protein-1a	Gene	20302(Species:10090)
25711908	1311	1359	myeloid differentiation primary response gene 88	Gene	17874(Species:10090)
25711908	1480	1485	CD11c	Gene	16411(Species:10090)
25711908	1509	1513	Ly6C	Gene	17067(Species:10090)

22964642|t|Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity.
22964642|a|Identification of regulatable mechanisms by which transcription factor NF-E2 p45-related factor 2 (Nrf2) is repressed will allow strategies to be designed that counter drug resistance associated with its upregulation in tumours that harbour somatic mutations in Kelch-like ECH-associated protein-1 (Keap1), a gene that encodes a joint adaptor and substrate receptor for the Cul3-Rbx1/Roc1 ubiquitin ligase. We now show that mouse Nrf2 contains two binding sites for beta-transducin repeat-containing protein (beta-TrCP), which acts as a substrate receptor for the Skp1-Cul1-Rbx1/Roc1 ubiquitin ligase complex. Deletion of either binding site in Nrf2 decreased beta-TrCP-mediated ubiquitylation of the transcription factor. The ability of one of the two beta-TrCP-binding sites to serve as a degron could be both increased and decreased by manipulation of glycogen synthase kinase-3 (GSK-3) activity. Biotinylated-peptide pull-down assays identified DSGIS(338) and DSAPGS(378) as the two beta-TrCP-binding motifs in Nrf2. Significantly, our pull-down assays indicated that beta-TrCP binds a phosphorylated version of DSGIS more tightly than its non-phosphorylated counterpart, whereas this was not the case for DSAPGS. These data suggest that DSGIS, but not DSAPGS, contains a functional GSK-3 phosphorylation site. Activation of GSK-3 in Keap1-null mouse embryonic fibroblasts (MEFs), or in human lung A549 cells that contain mutant Keap1, by inhibition of the phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB)/Akt pathway markedly reduced endogenous Nrf2 protein and decreased to 10-50% of normal the levels of mRNA for prototypic Nrf2-regulated enzymes, including the glutamate-cysteine ligase catalytic and modifier subunits, glutathione S-transferases Alpha-1 and Mu-1, haem oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Pre-treatment of Keap1(-/-) MEFs or A549 cells with the LY294002 PI3K inhibitor or the MK-2206 PKB/Akt inhibitor increased their sensitivity to acrolein, chlorambucil and cisplatin between 1.9-fold and 3.1-fold, and this was substantially attenuated by simultaneous pre-treatment with the GSK-3 inhibitor CT99021. 
22964642	0	4	Nrf2	Gene	18024(Species:10090)
22964642	35	44	beta-TrCP	Gene	12234(Species:10090)
22964642	117	122	GSK-3	Gene	606496(Species:10090)
22964642	204	230	NF-E2 p45-related factor 2	Gene	18024(Species:10090)
22964642	232	236	Nrf2	Gene	18024(Species:10090)
22964642	395	430	Kelch-like ECH-associated protein-1	Gene	50868(Species:10090)
22964642	432	437	Keap1	Gene	50868(Species:10090)
22964642	507	511	Cul3	Gene	26554(Species:10090)
22964642	512	516	Rbx1	Gene	56438(Species:10090)
22964642	517	521	Roc1	Gene	56438(Species:10090)
22964642	522	538	ubiquitin ligase	Gene	26554(Species:10090),56438(Species:10090),56438(Species:10090)
22964642	557	562	mouse	Species	Species:10090
22964642	563	567	Nrf2	Gene	18024(Species:10090)
22964642	599	640	beta-transducin repeat-containing protein	Gene	12234(Species:10090)
22964642	642	651	beta-TrCP	Gene	12234(Species:10090)
22964642	697	701	Skp1	Gene	21402(Species:10090)
22964642	702	706	Cul1	Gene	26965(Species:10090)
22964642	707	711	Rbx1	Gene	56438(Species:10090)
22964642	712	716	Roc1	Gene	56438(Species:10090)
22964642	717	741	ubiquitin ligase complex	Gene	21402(Species:10090),26965(Species:10090),56438(Species:10090)
22964642	778	782	Nrf2	Gene	18024(Species:10090)
22964642	793	802	beta-TrCP	Gene	12234(Species:10090)
22964642	886	895	beta-TrCP	Gene	12234(Species:10090)
22964642	988	1014	glycogen synthase kinase-3	Gene	606496(Species:10090)
22964642	1016	1021	GSK-3	Gene	606496(Species:10090)
22964642	1120	1129	beta-TrCP	Gene	12234(Species:10090)
22964642	1148	1152	Nrf2	Gene	18024(Species:10090)
22964642	1205	1214	beta-TrCP	Gene	12234(Species:10090)
22964642	1420	1425	GSK-3	Gene	606496(Species:10090)
22964642	1462	1467	GSK-3	Gene	2931(Species:9606),606496(Species:10090)
22964642	1471	1476	Keap1	Gene	50868(Species:10090)
22964642	1482	1487	mouse	Species	Species:10090
22964642	1524	1529	human	Species	Species:9606
22964642	1566	1571	Keap1	Gene	9817(Species:9606)
22964642	1594	1619	phosphoinositide 3-kinase	Gene	18704(Species:10090),5286(Species:9606)
22964642	1621	1625	PI3K	Gene	18704(Species:10090),5286(Species:9606)
22964642	1627	1643	protein kinase B	Gene	11651(Species:10090),207(Species:9606)
22964642	1645	1648	PKB	Gene	11651(Species:10090),207(Species:9606)
22964642	1650	1653	Akt	Gene	11651(Species:10090),207(Species:9606)
22964642	1690	1694	Nrf2	Gene	18024(Species:10090),4780(Species:9606)
22964642	1771	1775	Nrf2	Gene	18024(Species:10090),4780(Species:9606)
22964642	1868	1911	glutathione S-transferases Alpha-1 and Mu-1	Gene	14857(Species:10090),2938(Species:9606),14862(Species:10090),2944(Species:9606)
22964642	1913	1929	haem oxygenase-1	Gene	15368(Species:10090),3162(Species:9606)
22964642	1934	1966	NAD(P)H:quinone oxidoreductase-1	Gene	1728(Species:9606),18104(Species:10090)
22964642	1985	1990	Keap1	Gene	50868(Species:10090)
22964642	2033	2037	PI3K	Gene	18704(Species:10090)
22964642	2063	2066	PKB	Gene	11651(Species:10090)
22964642	2067	2070	Akt	Gene	11651(Species:10090)
22964642	2257	2262	GSK-3	Gene	606496(Species:10090)

28436950|t|MRE11 stability is regulated by CK2-dependent interaction with R2TP complex.
28436950|a|The MRN (MRE11-RAD50-NBS1) complex is essential for repair of DNA double-strand breaks and stalled replication forks. Mutations of the MRN complex subunit MRE11 cause the hereditary cancer-susceptibility disease ataxia-telangiectasia-like disorder (ATLD). Here we show that MRE11 directly interacts with PIH1D1, a subunit of heat-shock protein 90 cochaperone R2TP complex, which is required for the assembly of large protein complexes, such as RNA polymerase II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1. The MRE11-PIH1D1 interaction is dependent on casein kinase 2 (CK2) phosphorylation of two acidic sequences within the MRE11 C terminus containing serines 558/561 and 688/689. Conversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphorylated by CK2. Consistent with these findings, depletion of PIH1D1 resulted in MRE11 destabilization and affected DNA-damage repair processes dependent on MRE11. Additionally, mutations of serines 688/689, which abolish PIH1D1 binding, also resulted in decreased MRE11 stability. As depletion of R2TP frequently leads to instability of its substrates and as truncation mutation of MRE11 lacking serines 688/689 leads to decreased levels of the MRN complex both in ATLD patients and an ATLD mouse model, our results suggest that the MRN complex is a novel R2TP complex substrate and that their interaction is regulated by CK2 phosphorylation.
28436950	0	5	MRE11	Gene	4361(Species:9606)
28436950	32	35	CK2	Gene	1457(Species:9606)
28436950	63	67	R2TP	Gene	55011(Species:9606)
28436950	81	84	MRN	Gene	4361(Species:9606),10111(Species:9606),4683(Species:9606)
28436950	86	91	MRE11	Gene	4361(Species:9606)
28436950	92	97	RAD50	Gene	10111(Species:9606)
28436950	98	102	NBS1	Gene	4361(Species:9606)
28436950	212	215	MRN	Gene	4361(Species:9606),10111(Species:9606),4683(Species:9606)
28436950	232	237	MRE11	Gene	4361(Species:9606)
28436950	351	356	MRE11	Gene	4361(Species:9606)
28436950	381	387	PIH1D1	Gene	55011(Species:9606)
28436950	436	440	R2TP	Gene	55011(Species:9606),3320(Species:9606)
28436950	521	538	RNA polymerase II	Gene	5430(Species:9606)
28436950	540	574	small nucleolar ribonucleoproteins	Gene	55272(Species:9606)
28436950	579	588	mammalian	Species	Species:9606
28436950	579	618	mammalian target of rapamycin complex 1	Gene	2475(Species:9606)
28436950	624	629	MRE11	Gene	4361(Species:9606)
28436950	630	636	PIH1D1	Gene	55011(Species:9606)
28436950	665	680	casein kinase 2	Gene	1457(Species:9606)
28436950	682	685	CK2	Gene	1457(Species:9606)
28436950	738	743	MRE11	Gene	4361(Species:9606)
28436950	811	817	PIH1D1	Gene	55011(Species:9606)
28436950	880	885	MRE11	Gene	4361(Species:9606)
28436950	904	907	CK2	Gene	1457(Species:9606)
28436950	954	960	PIH1D1	Gene	55011(Species:9606)
28436950	973	978	MRE11	Gene	4361(Species:9606)
28436950	1049	1054	MRE11	Gene	4361(Species:9606)
28436950	1114	1120	PIH1D1	Gene	55011(Species:9606)
28436950	1157	1162	MRE11	Gene	4361(Species:9606)
28436950	1190	1194	R2TP	Gene	55011(Species:9606)
28436950	1275	1280	MRE11	Gene	4361(Species:9606)
28436950	1338	1341	MRN	Gene	17535(Species:10090)
28436950	1363	1371	patients	Species	Species:9606
28436950	1384	1389	mouse	Species	Species:10090
28436950	1426	1429	MRN	Gene	4361(Species:9606),10111(Species:9606),4683(Species:9606)
28436950	1449	1453	R2TP	Gene	55011(Species:9606)
28436950	1515	1518	CK2	Gene	1457(Species:9606)

22027689|t|MUC13 mucin augments pancreatic tumorigenesis.
22027689|a|The high death rate of pancreatic cancer is attributed to the lack of reliable methods for early detection and underlying molecular mechanisms of its aggressive pathogenesis. Although MUC13, a newly identified transmembrane mucin, is known to be aberrantly expressed in ovarian and gastro-intestinal cancers, its role in pancreatic cancer is unknown. Herein, we investigated the expression profile and functions of MUC13 in pancreatic cancer progression. The expression profile of MUC13 in pancreatic cancer was investigated using a recently generated monoclonal antibody (clone PPZ0020) and pancreatic tissue microarrays. The expression of MUC13 was significantly (P < 0.005) higher in cancer samples compared with normal/nonneoplastic pancreatic tissues. For functional analyses, full-length MUC13 was expressed in MUC13 null pancreatic cancer cell lines, MiaPaca and Panc1. MUC13 overexpression caused a significant (P < 0.05) increase in cell motility, invasion, proliferation, and anchorage-dependent or -independent clonogenicity while decreasing cell-cell and cell-substratum adhesion. Exogenous MUC13 expression significantly (P < 0.05) enhanced pancreatic tumor growth and reduced animal survival in a xenograft mouse model. These tumorigenic characteristics correlated with the upregulation/phosphorylation of HER2, p21-activated kinase 1 (PAK1), extracellular signal-regulated kinase (ERK), Akt, and metastasin (S100A4), and the suppression of p53. Conversely, suppression of MUC13 in HPAFII pancreatic cancer cells by short hairpin RNA resulted in suppression of tumorigenic characteristics, repression of HER2, PAK1, ERK, and S100A4, and upregulation of p53. MUC13 suppression also significantly (P < 0.05) reduced tumor growth and increased animal survival. These results imply a role of MUC13 in pancreatic cancer and suggest its potential use as a diagnostic and therapeutic target.
22027689	0	5	MUC13	Gene	56667(Species:9606)
22027689	6	11	mucin	Gene	56667(Species:9606)
22027689	231	236	MUC13	Gene	56667(Species:9606)
22027689	271	276	mucin	Gene	56667(Species:9606)
22027689	462	467	MUC13	Gene	56667(Species:9606)
22027689	528	533	MUC13	Gene	56667(Species:9606)
22027689	688	693	MUC13	Gene	56667(Species:9606)
22027689	841	846	MUC13	Gene	56667(Species:9606)
22027689	864	869	MUC13	Gene	56667(Species:9606)
22027689	924	929	MUC13	Gene	56667(Species:9606)
22027689	1150	1155	MUC13	Gene	56667(Species:9606)
22027689	1268	1273	mouse	Species	Species:10090
22027689	1367	1371	HER2	Gene	2064(Species:9606)
22027689	1373	1395	p21-activated kinase 1	Gene	5058(Species:9606)
22027689	1397	1401	PAK1	Gene	5058(Species:9606)
22027689	1404	1441	extracellular signal-regulated kinase	Gene	5594(Species:9606)
22027689	1443	1446	ERK	Gene	5594(Species:9606)
22027689	1449	1452	Akt	Gene	207(Species:9606)
22027689	1458	1468	metastasin	Gene	6275(Species:9606)
22027689	1470	1476	S100A4	Gene	6275(Species:9606)
22027689	1502	1505	p53	Gene	7157(Species:9606)
22027689	1534	1539	MUC13	Gene	56667(Species:9606)
22027689	1543	1549	HPAFII	Species	Species:9606
22027689	1665	1669	HER2	Gene	2064(Species:9606)
22027689	1671	1675	PAK1	Gene	5058(Species:9606)
22027689	1677	1680	ERK	Gene	5594(Species:9606)
22027689	1686	1692	S100A4	Gene	6275(Species:9606)
22027689	1714	1717	p53	Gene	7157(Species:9606)
22027689	1719	1724	MUC13	Gene	56667(Species:9606)
22027689	1849	1854	MUC13	Gene	56667(Species:9606)

26590805|t|A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer.
26590805|a|BACKGROUND: Colorectal cancer (CRC) ranks third among the estimated cancer cases and cancer related mortalities in the Western world. Early detection and efficient therapy of CRC remains a major health challenge. Therefore, there is a need to identify novel tumor markers for early diagnosis and treatment of CRC. METHODS: A-kinase anchor protein 4 (AKAP4) gene and protein expression was monitored by quantitative polymerase chain reaction (qPCR), reverse transcription (RT)-PCR and Western blotting in normal colon tissue lysate, normal colon epithelial cells and in colon cancer cell lines viz., Caco-2, COLO205, COLO320DM, HCT-15, HCT116, HT-29, SW480, and SW620. The effect of AKAP4 on cellular growth, migration and invasion abilities was studied using gene silencing approach. The role of AKAP4 in various pathways involved in cell cycle, apoptosis, senescence was investigated in in vitro and in human xenograft mouse model. RESULTS: Our studies showed that AKAP4 gene and protein expression was expressed in all colon cancer cells while no expression was detectable in normal colon cells. Ablation of AKAP4 led to reduced cellular growth, migration, invasion and increased apoptosis and senescence of CRC cells in in vitro assays and tumor growth in human xenograft mouse. Human colon xenograft studies showed a significant decrease in the levels of cyclins B1, D and E and cyclin dependent kinases such as CDK1, CDK2, CDK4 and CDK6. Interestingly, an up-regulation in the levels of p16 and p21 was also observed. Besides, an increase in the levels of pro-apoptotic molecules AIF, APAF1, BAD, BID, BAK, BAX, PARP1, NOXA, PUMA and cyt-C and Caspase 3, 7, 8 and 9 was also found in cancer cells as well as in xenograft tissue sections. However, anti-apoptotic molecules BCL2, Bcl-xL, cIAP2, XIAP, Axin2 and Survivin were down regulated in these samples. Our data also revealed elevated expression of epithelial marker E-cadherin and down regulation of EMT markers N-cadherin, P-cadherin, SLUG, a-SMA, SNAIL, TWIST and Vimentin. Further ablation of AKAP4 resulted in the down regulation of invasion molecules matrix metalloproteinase MMP2, MMP3 and MMP9. CONCLUSION: AKAP4 appears to be a novel CRC-associated antigen with a potential for developing as a new clinical therapeutic target.
26590805	0	25	A-kinase anchor protein 4	Gene	8852(Species:9606)
26590805	27	32	AKAP4	Gene	8852(Species:9606)
26590805	410	435	A-kinase anchor protein 4	Gene	8852(Species:9606)
26590805	437	442	AKAP4	Gene	8852(Species:9606)
26590805	769	774	AKAP4	Gene	8852(Species:9606)
26590805	883	888	AKAP4	Gene	8852(Species:9606)
26590805	991	996	human	Species	Species:9606
26590805	1007	1012	mouse	Species	Species:10090
26590805	1053	1058	AKAP4	Gene	8852(Species:9606)
26590805	1197	1202	AKAP4	Gene	8852(Species:9606)
26590805	1346	1351	human	Species	Species:9606
26590805	1362	1367	mouse	Species	Species:10090
26590805	1369	1374	Human	Species	Species:9606
26590805	1470	1494	cyclin dependent kinases	Gene	1017(Species:9606),1019(Species:9606),1021(Species:9606),983(Species:9606)
26590805	1503	1507	CDK1	Gene	983(Species:9606)
26590805	1509	1513	CDK2	Gene	1017(Species:9606)
26590805	1515	1519	CDK4	Gene	1019(Species:9606)
26590805	1524	1528	CDK6	Gene	1021(Species:9606)
26590805	1579	1582	p16	Gene	1029(Species:9606)
26590805	1587	1590	p21	Gene	1026(Species:9606)
26590805	1672	1675	AIF	Gene	9131(Species:9606)
26590805	1677	1682	APAF1	Gene	317(Species:9606)
26590805	1684	1687	BAD	Gene	572(Species:9606)
26590805	1689	1692	BID	Gene	637(Species:9606)
26590805	1694	1697	BAK	Gene	578(Species:9606)
26590805	1699	1702	BAX	Gene	581(Species:9606)
26590805	1704	1709	PARP1	Gene	142(Species:9606)
26590805	1711	1715	NOXA	Gene	5366(Species:9606)
26590805	1717	1721	PUMA	Gene	27113(Species:9606)
26590805	1726	1731	cyt-C	Gene	54205(Species:9606)
26590805	1736	1757	Caspase 3, 7, 8 and 9	Gene	836(Species:9606),840(Species:9606),841(Species:9606),842(Species:9606)
26590805	1864	1868	BCL2	Gene	596(Species:9606)
26590805	1870	1876	Bcl-xL	Gene	598(Species:9606)
26590805	1878	1883	cIAP2	Gene	330(Species:9606)
26590805	1885	1889	XIAP	Gene	331(Species:9606)
26590805	1891	1896	Axin2	Gene	8313(Species:9606)
26590805	1901	1909	Survivin	Gene	332(Species:9606)
26590805	2012	2022	E-cadherin	Gene	999(Species:9606)
26590805	2058	2068	N-cadherin	Gene	1000(Species:9606)
26590805	2070	2080	P-cadherin	Gene	1001(Species:9606)
26590805	2082	2086	SLUG	Gene	6591(Species:9606)
26590805	2088	2093	a-SMA	Gene	59(Species:9606)
26590805	2095	2100	SNAIL	Gene	6615(Species:9606)
26590805	2102	2107	TWIST	Gene	7291(Species:9606)
26590805	2112	2120	Vimentin	Gene	7431(Species:9606)
26590805	2142	2147	AKAP4	Gene	8852(Species:9606)
26590805	2202	2226	matrix metalloproteinase	Gene	4313(Species:9606),4314(Species:9606),4318(Species:9606)
26590805	2227	2231	MMP2	Gene	4313(Species:9606)
26590805	2233	2237	MMP3	Gene	4314(Species:9606)
26590805	2242	2246	MMP9	Gene	4318(Species:9606)
26590805	2260	2265	AKAP4	Gene	8852(Species:9606)

24971614|t|Functional characterization of obesity-associated variants involving the a and b isoforms of human SH2B1.
24971614|a|We have previously reported rare variants in sarcoma (Src) homology 2 (SH2) B adaptor protein 1 (SH2B1) in individuals with obesity, insulin resistance, and maladaptive behavior. Here, we identify 4 additional SH2B1 variants by sequencing 500 individuals with severe early-onset obesity. SH2B1 has 4 alternatively spliced isoforms. One variant (T546A) lies within the N-terminal region common to all isoforms. As shown for past variants in this region, T546A impairs SH2B1b enhancement of nerve growth factor-induced neurite outgrowth, and the individual with the T546A variant exhibits mild developmental delay. The other 3 variants (A663V, V695M, and A723V) lie in the C-terminal tail of SH2B1a. SH2B1a variant carriers were hyperinsulinemic but did not exhibit the behavioral phenotype observed in individuals with SH2B1 variants that disrupt all isoforms. In in vitro assays, SH2B1a, like SH2B1b, enhances insulin- and leptin-induced insulin receptor substrate 2 (IRS2) phosphorylation and GH-induced cell motility. None of the variants affect SH2B1a enhancement of insulin- and leptin-induced IRS2 phosphorylation. However, T546A, A663V, and A723V all impair the ability of SH2B1a to enhance GH-induced cell motility. In contrast to SH2B1b, SH2B1a does not enhance nerve growth factor-induced neurite outgrowth. These studies suggest that genetic variants that disrupt isoforms other than SH2B1b may be functionally significant. Further studies are needed to understand the mechanism by which the individual isoforms regulate energy homeostasis and behavior.
24971614	93	98	human	Species	Species:9606
24971614	99	104	SH2B1	Gene	25970(Species:9606)
24971614	159	201	(Src) homology 2 (SH2) B adaptor protein 1	Gene	25970(Species:9606)
24971614	203	208	SH2B1	Gene	25970(Species:9606)
24971614	239	246	insulin	Gene	3630(Species:9606)
24971614	316	321	SH2B1	Gene	25970(Species:9606)
24971614	394	399	SH2B1	Gene	25970(Species:9606)
24971614	573	579	SH2B1b	Gene	25970(Species:9606)
24971614	796	802	SH2B1a	Gene	25970(Species:9606)
24971614	804	810	SH2B1a	Gene	25970(Species:9606)
24971614	924	929	SH2B1	Gene	25970(Species:9606)
24971614	986	992	SH2B1a	Gene	25970(Species:9606)
24971614	986	991	SH2B1	Gene	25970(Species:9606)
24971614	999	1005	SH2B1b	Gene	25970(Species:9606)
24971614	999	1004	SH2B1	Gene	25970(Species:9606)
24971614	1016	1023	insulin	Gene	3630(Species:9606)
24971614	1029	1035	leptin	Gene	3952(Species:9606)
24971614	1044	1072	insulin receptor substrate 2	Gene	8660(Species:9606)
24971614	1074	1078	IRS2	Species	Species:10029
24971614	1074	1078	IRS2	Gene	8660(Species:9606)
24971614	1154	1160	SH2B1a	Gene	25970(Species:9606)
24971614	1176	1183	insulin	Gene	3630(Species:9606)
24971614	1189	1195	leptin	Gene	3952(Species:9606)
24971614	1204	1208	IRS2	Gene	8660(Species:9606)
24971614	1285	1291	SH2B1a	Gene	25970(Species:9606)
24971614	1344	1350	SH2B1b	Gene	25970(Species:9606)
24971614	1352	1358	SH2B1a	Gene	25970(Species:9606)
24971614	1500	1506	SH2B1b	Gene	25970(Species:9606)

28518143|t|Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.
28518143|a|Diabetic cardiomyopathy (DCM) is a major complication and fatal cause of the patients with diabetes. The calcium sensing receptor (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on. In our previous study, we found that CaSR expression, intracellular calcium levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet. The present study revealed the protective role of CaSR in myocardial energy metabolism disorder induced by high glucose (HG) as well as the underlying mechanism. Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration. In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43. Moreover, CaSR agonist and gp78-siRNA significantly reduced the above changes. Taken together, these results suggest that HG induces myocardial energy metabolism disorder via decrease of CaSR expression, and activation of gp78-ubiquitin proteasome system. In turn, these effects disrupt the structure and function of the mitochondria and the cell gap junction, result in the reduced ATP synthesis and the increased ATP leakage. Stimulation of CaSR significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting CaSR would be a promising potential therapeutic target for DCM.
28518143	0	24	Calcium sensing receptor	Gene	24247(Species:10116)
28518143	95	99	gp78	Gene	361367(Species:10116)
28518143	207	215	patients	Species	Species:9606
28518143	235	259	calcium sensing receptor	Gene	24247(Species:10116)
28518143	261	265	CaSR	Gene	24247(Species:10116)
28518143	272	298	G protein-coupled receptor	Gene	24247(Species:10116)
28518143	447	451	CaSR	Gene	24247(Species:10116)
28518143	554	558	rats	Species	Species:10116
28518143	658	662	CaSR	Gene	24247(Species:10116)
28518143	828	832	CaSR	Gene	24247(Species:10116)
28518143	865	869	Mfn1	Gene	192647(Species:10116)
28518143	871	875	Mfn2	Gene	64476(Species:10116)
28518143	914	918	Cx43	Gene	24392(Species:10116)
28518143	920	932	beta-catenin	Gene	84353(Species:10116)
28518143	934	944	N-cadherin	Gene	83501(Species:10116)
28518143	1061	1065	gp78	Gene	361367(Species:10116)
28518143	1099	1103	Fis1	Gene	288584(Species:10116)
28518143	1105	1109	Drp1	Gene	114114(Species:10116)
28518143	1145	1149	Mfn1	Gene	192647(Species:10116)
28518143	1151	1155	Mfn2	Gene	64476(Species:10116)
28518143	1160	1164	Cx43	Gene	24392(Species:10116)
28518143	1176	1180	CaSR	Gene	24247(Species:10116)
28518143	1193	1197	gp78	Gene	361367(Species:10116)
28518143	1353	1357	CaSR	Gene	24247(Species:10116)
28518143	1388	1392	gp78	Gene	361367(Species:10116)
28518143	1609	1613	CaSR	Gene	24247(Species:10116)
28518143	1700	1704	CaSR	Gene	24247(Species:10116)

23028939|t|Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
23028939|a|BACKGROUND: Malignant pleural mesothelioma (MPM) is a devastating disease with an overall poor prognosis. Despite the recent advances in targeted molecular therapies, there is a clear and urgent need for the identification of novel mesothelioma targets for the development of highly efficacious therapeutics. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we report that the expression of Sphingosine Kinase 1 (SphK1) protein was preferentially elevated in MPM tumor tissues (49 epithelioid and 13 sarcomatoid) compared to normal tissue (n = 13). In addition, we also observed significantly elevated levels of SphK1 and SphK2 mRNA and SphK1 protein expression in MPM cell lines such as H2691, H513 and H2461 compared to the non-malignant mesothelial Met5 cells. The underlying mechanism appears to be mediated by SphK1 induced upregulation of select gene transcription programs such as that of CBP/p300 and PCAF, two histone acetyl transferases (HAT), and the down regulation of cell cycle dependent kinase inhibitor genes such as p27Kip1 and p21Cip1. In addition, using immunoprecipitates of anti-acetylated histone antibody from SphK inhibitor, SphK-I2 treated Met5A and H2691 cell lysates, we also showed activation of other cell proliferation related genes, such as Top2A (DNA replication), AKB (chromosome remodeling and mitotic spindle formation), and suppression of p21 CIP1 and p27KIP1. The CDK2, HAT1 and MYST2 were, however, unaffected in the above study. Using SphK inhibitor and specific siRNA targeting either SphK1 or SphK2, we also unequivocally established that SphK1, but not SphK2, promotes H2691 mesothelioma cell proliferation. Using a multi-walled carbon nanotubes induced peritoneal mesothelioma mouse model, we showed that the SphK1-/- null mice exhibited significantly less inflammation and granulamatous nodules compared to their wild type counterparts. CONCLUSIONS/SIGNIFICANCE: The lipid kinase SphK1 plays a positive and essential role in the growth and development of malignant mesothelioma and is therefore a likely therapeutic target.
23028939	0	20	Sphingosine kinase 1	Gene	8877(Species:9606)
23028939	78	85	histone	Gene	3014(Species:9606)
23028939	488	508	Sphingosine Kinase 1	Gene	8877(Species:9606)
23028939	510	515	SphK1	Gene	8877(Species:9606)
23028939	709	714	SphK1	Gene	8877(Species:9606)
23028939	719	724	SphK2	Gene	56848(Species:9606)
23028939	734	739	SphK1	Gene	8877(Species:9606)
23028939	912	917	SphK1	Gene	8877(Species:9606)
23028939	993	1001	CBP/p300	Gene	1385(Species:9606),2033(Species:9606)
23028939	993	996	CBP	Gene	1387(Species:9606)
23028939	997	1001	p300	Gene	2033(Species:9606)
23028939	1006	1010	PCAF	Gene	8850(Species:9606)
23028939	1016	1043	histone acetyl transferases	Gene	1387(Species:9606),2033(Species:9606),8850(Species:9606)
23028939	1045	1048	HAT	Gene	1387(Species:9606),2033(Species:9606),8850(Species:9606)
23028939	1078	1115	cell cycle dependent kinase inhibitor	Gene	1026(Species:9606),1027(Species:9606)
23028939	1130	1137	p27Kip1	Gene	1027(Species:9606)
23028939	1142	1149	p21Cip1	Gene	1026(Species:9606)
23028939	1208	1215	histone	Gene	3014(Species:9606)
23028939	1230	1234	SphK	Gene	56848(Species:9606),8877(Species:9606)
23028939	1246	1250	SphK	Gene	56848(Species:9606),8877(Species:9606)
23028939	1262	1267	Met5A	Species	Species:9606
23028939	1272	1277	H2691	Species	Species:9606
23028939	1369	1374	Top2A	Gene	7153(Species:9606)
23028939	1394	1397	AKB	Gene	9212(Species:9606)
23028939	1472	1480	p21 CIP1	Gene	1026(Species:9606)
23028939	1485	1492	p27KIP1	Gene	1027(Species:9606)
23028939	1498	1502	CDK2	Gene	1017(Species:9606)
23028939	1504	1508	HAT1	Gene	8520(Species:9606)
23028939	1513	1518	MYST2	Gene	11143(Species:9606)
23028939	1571	1575	SphK	Gene	56848(Species:9606),8877(Species:9606)
23028939	1622	1627	SphK1	Gene	8877(Species:9606)
23028939	1631	1636	SphK2	Gene	56848(Species:9606)
23028939	1677	1682	SphK1	Gene	8877(Species:9606)
23028939	1692	1697	SphK2	Gene	56848(Species:9606)
23028939	1708	1713	H2691	Species	Species:9606
23028939	1817	1822	mouse	Species	Species:10090
23028939	1849	1854	SphK1	Gene	20698(Species:10090)
23028939	1863	1867	mice	Species	Species:10090
23028939	2008	2020	lipid kinase	Gene	56848(Species:9606),8877(Species:9606)
23028939	2021	2026	SphK1	Gene	8877(Species:9606)

28468941|t|Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
28468941|a|A heterozygous caveolin-1 c.474delA mutation has been identified in a family with heritable pulmonary arterial hypertension (PAH). This frameshift mutation leads to a caveolin-1 protein that contains all known functional domains but has a change in only the final 20 amino acids of the C-terminus. Here we studied how this mutation alters caveolin-1 function, using patient-derived fibroblasts. Transmission electron microscopy showed that fibroblasts carrying the c.474delA mutation form typical caveolae. Expression of mutated caveolin-1 in caveolin-1-null mouse fibroblasts failed to induce formation of caveolae due to retention of the mutated protein in the endoplasmic reticulum. However, coexpression of wild-type caveolin-1 with mutated caveolin-1 restored the ability to form caveolae. Importantly, fibroblasts carrying the mutation showed twofold increase in proliferation rate associated with hyperphosphorylation of Smad1/5/8. This mutation impaired the antiproliferative function of caveolin-1. Inhibition of type I TGFb receptors ALK1/2/3/6 responsible for phosphorylation of Smad1/5/8 reduced the hyperproliferation seen in c.474delA fibroblasts. These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
28468941	9	19	caveolin-1	Gene	857(Species:9606)
28468941	29	33	Smad	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
28468941	133	140	patient	Species	Species:9606
28468941	231	241	caveolin-1	Gene	857(Species:9606)
28468941	383	393	caveolin-1	Gene	857(Species:9606)
28468941	555	565	caveolin-1	Gene	857(Species:9606)
28468941	582	589	patient	Species	Species:9606
28468941	745	755	caveolin-1	Gene	857(Species:9606)
28468941	759	769	caveolin-1	Gene	12389(Species:10090)
28468941	775	780	mouse	Species	Species:10090
28468941	937	947	caveolin-1	Gene	857(Species:9606)
28468941	961	971	caveolin-1	Gene	857(Species:9606)
28468941	1144	1153	Smad1/5/8	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
28468941	1212	1222	caveolin-1	Gene	857(Species:9606)
28468941	1238	1259	type I TGFb receptors	Gene	94(Species:9606),90(Species:9606),657(Species:9606),658(Species:9606)
28468941	1260	1270	ALK1/2/3/6	Gene	94(Species:9606),90(Species:9606),657(Species:9606),658(Species:9606)
28468941	1306	1315	Smad1/5/8	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
28468941	1453	1463	caveolin-1	Gene	857(Species:9606)
28468941	1516	1520	Smad	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
28468941	1558	1562	Smad	Gene	4086(Species:9606),4090(Species:9606),4093(Species:9606)
28468941	1662	1670	patients	Species	Species:9606
28468941	1676	1686	caveolin-1	Gene	857(Species:9606)

23195221|t|Scribble is required for normal epithelial cell-cell contacts and lumen morphogenesis in the mammalian lung.
23195221|a|During lung development, proper epithelial cell arrangements are critical for the formation of an arborized network of tubes. Each tube requires a lumen, the diameter of which must be tightly regulated to enable optimal lung function. Lung branching and lumen morphogenesis require close epithelial cell-cell contacts that are maintained as a result of adherens junctions, tight junctions and by intact apical-basal (A/B) polarity. However, the molecular mechanisms that maintain epithelial cohesion and lumen diameter in the mammalian lung are unknown. Here we show that Scribble, a protein implicated in planar cell polarity (PCP) signalling, is necessary for normal lung morphogenesis. Lungs of the Scrib mouse mutant Circletail (Crc) are abnormally shaped with fewer airways, and these airways often lack a visible, 'open' lumen. Mechanistically we show that Scrib genetically interacts with the core PCP gene Vangl2 in the developing lung and that the distribution of PCP pathway proteins and Rho mediated cytoskeletal modification is perturbed in Scrib(Crc/Crc) lungs. However A/B polarity, which is disrupted in Drosophila Scrib mutants, is largely unaffected. Notably, we find that Scrib mediates functions not attributed to other PCP proteins in the lung. Specifically, Scrib localises to both adherens and tight junctions of lung epithelia and knockdown of Scrib in lung explants and organotypic cultures leads to reduced cohesion of lung epithelial cells. Live imaging of Scrib knockdown lungs shows that Scrib does not affect bud bifurcation, as previously shown for the PCP protein Celsr1, but is required to maintain epithelial cohesion. To understand the mechanism leading to reduced cell-cell association, we show that Scrib associates with b-catenin in embryonic lung and the sub-cellular distribution of adherens and tight junction proteins is perturbed in mutant lung epithelia. Our data reveal that Scrib is required for normal lung epithelial organisation and lumen morphogenesis by maintaining cell-cell contacts. Thus we reveal novel and important roles for Scrib in lung development operating via the PCP pathway, and in regulating junctional complexes and cell cohesion.
23195221	0	8	Scribble	Gene	105782(Species:10090)
23195221	93	102	mammalian	Species	Species:9606
23195221	635	644	mammalian	Species	Species:9606
23195221	681	689	Scribble	Gene	105782(Species:10090)
23195221	811	816	Scrib	Gene	105782(Species:10090)
23195221	817	822	mouse	Species	Species:10090
23195221	830	846	Circletail (Crc)	Gene	105782(Species:10090)
23195221	972	977	Scrib	Gene	105782(Species:10090)
23195221	1023	1029	Vangl2	Gene	93840(Species:10090)
23195221	1107	1110	Rho	Gene	11848(Species:10090)
23195221	1162	1167	Scrib	Gene	105782(Species:10090)
23195221	1168	1171	Crc	Gene	105782(Species:10090)
23195221	1172	1175	Crc	Gene	105782(Species:10090)
23195221	1228	1238	Drosophila	Species	Species:7227
23195221	1239	1244	Scrib	Gene	44448(Species:7227)
23195221	1299	1304	Scrib	Gene	105782(Species:10090)
23195221	1388	1393	Scrib	Gene	105782(Species:10090)
23195221	1476	1481	Scrib	Gene	105782(Species:10090)
23195221	1592	1597	Scrib	Gene	105782(Species:10090)
23195221	1625	1630	Scrib	Gene	105782(Species:10090)
23195221	1704	1710	Celsr1	Gene	12614(Species:10090)
23195221	1844	1849	Scrib	Gene	105782(Species:10090)
23195221	1866	1875	b-catenin	Gene	12387(Species:10090)
23195221	2028	2033	Scrib	Gene	105782(Species:10090)
23195221	2190	2195	Scrib	Gene	105782(Species:10090)

25882704|t|CCL20 is elevated during obesity and differentially regulated by NF-kB subunits in pancreatic b-cells.
25882704|a|Enhanced leukocytic infiltration into pancreatic islets contributes to inflammation-based diminutions in functional b-cell mass. Insulitis (aka islet inflammation), which can be present in both T1DM and T2DM, is one factor influencing pancreatic b-cell death and dysfunction. IL-1b, an inflammatory mediator in both T1DM and T2DM, acutely (within 1h) induced expression of the CCL20 gene in rat and human islets and clonal b-cell lines. Transcriptional induction of CCL20 required the p65 subunit of NF-kB to replace the p50 subunit at two functional kB sites within the CCL20 proximal gene promoter. The NF-kB p50 subunit prevents CCL20 gene expression during unstimulated conditions and overexpression of p50 reduces CCL20, but enhances cyclooxygenase-2 (COX-2), transcript accumulation after exposure to IL-1b. We also identified differential recruitment of specific co-activator molecules to the CCL20 gene promoter, when compared with the CCL2 and COX2 genes, revealing distinct transcriptional requirements for individual NF-kB responsive genes. Moreover, IL-1b, TNF-a and IFN-g individually increased the expression of CCR6, the receptor for CCL20, on the surface of human neutrophils. We further found that the chemokine CCL20 is elevated in serum from both genetically obese db/db mice and in C57BL6/J mice fed a high-fat diet. Taken together, these results are consistent with a possible activation of the CCL20-CCR6 axis in diseases with inflammatory components. Thus, interfering with this signaling pathway, either at the level of NF-kB-mediated chemokine production, or downstream receptor activation, could be a potential therapeutic target to offset inflammation-associated tissue dysfunction in obesity and diabetes.
25882704	0	5	CCL20	Gene	20297(Species:10090)
25882704	65	70	NF-kB	Gene	309165(Species:10116),81736(Species:10116)
25882704	65	79	NF-kB subunits	Gene	309165(Species:10116),4790(Species:9606),5970(Species:9606),81736(Species:10116)
25882704	379	384	IL-1b	Gene	24494(Species:10116),3553(Species:9606)
25882704	480	485	CCL20	Gene	29538(Species:10116),6364(Species:9606)
25882704	494	497	rat	Species	Species:10116
25882704	502	507	human	Species	Species:9606
25882704	569	574	CCL20	Gene	29538(Species:10116)
25882704	588	608	p65 subunit of NF-kB	Gene	309165(Species:10116)
25882704	624	635	p50 subunit	Gene	81736(Species:10116)
25882704	624	627	p50	Gene	4790(Species:9606),81736(Species:10116)
25882704	674	679	CCL20	Gene	29538(Species:10116),6364(Species:9606)
25882704	708	725	NF-kB p50 subunit	Gene	81736(Species:10116)
25882704	714	717	p50	Gene	4790(Species:9606),81736(Species:10116)
25882704	735	740	CCL20	Gene	29538(Species:10116),6364(Species:9606)
25882704	810	813	p50	Gene	4790(Species:9606),81736(Species:10116)
25882704	822	827	CCL20	Gene	29538(Species:10116),6364(Species:9606)
25882704	842	858	cyclooxygenase-2	Gene	29527(Species:10116)
25882704	860	865	COX-2	Gene	29527(Species:10116)
25882704	910	915	IL-1b	Gene	24494(Species:10116)
25882704	1003	1008	CCL20	Gene	29538(Species:10116),6364(Species:9606)
25882704	1047	1051	CCL2	Gene	24770(Species:10116)
25882704	1056	1060	COX2	Gene	29527(Species:10116)
25882704	1131	1136	NF-kB	Gene	309165(Species:10116),81736(Species:10116)
25882704	1165	1170	IL-1b	Gene	3553(Species:9606)
25882704	1172	1177	TNF-a	Gene	7124(Species:9606)
25882704	1182	1187	IFN-g	Gene	3458(Species:9606)
25882704	1229	1233	CCR6	Gene	1235(Species:9606)
25882704	1252	1257	CCL20	Gene	6364(Species:9606)
25882704	1277	1282	human	Species	Species:9606
25882704	1322	1331	chemokine	Gene	20297(Species:10090),24770(Species:10116),29538(Species:10116),6364(Species:9606)
25882704	1332	1337	CCL20	Gene	20297(Species:10090)
25882704	1393	1397	mice	Species	Species:10090
25882704	1414	1418	mice	Species	Species:10090
25882704	1519	1524	CCL20	Gene	20297(Species:10090)
25882704	1525	1529	CCR6	Gene	12458(Species:10090)
25882704	1647	1652	NF-kB	Gene	309165(Species:10116),81736(Species:10116)
25882704	1662	1671	chemokine	Gene	20296(Species:10090),29538(Species:10116),6364(Species:9606)

25884948|t|Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
25884948|a|BACKGROUND: Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25-30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5-18% of patients. METHODS: The exomes of six responsive prolactinomas and six resistant prolactinomas were analyzed by whole-exome sequencing. RESULTS: Using stringent variant calling and filtering parameters, ten somatic variants that were mainly associated with DNA repair or protein metabolic processes were identified. New resistant variants were identified in multiple genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, and KRTAP10-3. The expression of these genes was then quantified by real-time reverse-transcription PCR (RT-qPCR) in 12 prolactinomas and 3 normal pituitary glands. The mRNA levels of PRDM2 were approximately five-fold lower in resistant prolactinomas than in responsive tumors (p < 0.05). PRDM2 protein levels were lower in resistant prolactinomas than in responsive tumors, as determined by Western blotting and immunohistochemical analysis (p < 0.05). Overexpression of PRDM2 upregulated dopamine receptor D2 (D2DR) and inhibited the phosphorylation of ERK1/2 in MMQ cells. PRDM2 showed a synergistic effect with BRC on the inhibition of prolactin (PRL) secretion and MMQ cell viability, and low PRDM2 expression was associated with tumor recurrence. CONCLUSIONS: PRDM2 downregulation may play a role in dopamine-agonist resistance and tumor recurrence in prolactinomas.
25884948	6	11	PRDM2	Gene	7799(Species:9606)
25884948	379	387	patients	Species	Species:9606
25884948	761	766	PRDM2	Gene	7799(Species:9606)
25884948	768	772	PRG4	Gene	10216(Species:9606)
25884948	774	778	MUC4	Gene	4585(Species:9606)
25884948	780	784	DSPP	Gene	1834(Species:9606)
25884948	786	791	DPCR1	Gene	135656(Species:9606)
25884948	793	798	RP1L1	Gene	94137(Species:9606)
25884948	800	803	MX2	Gene	4600(Species:9606)
25884948	805	810	POTEF	Gene	728378(Species:9606)
25884948	812	820	C1orf170	Gene	84808(Species:9606)
25884948	826	835	KRTAP10-3	Gene	386682(Species:9606)
25884948	1006	1011	PRDM2	Gene	7799(Species:9606)
25884948	1112	1117	PRDM2	Gene	7799(Species:9606)
25884948	1295	1300	PRDM2	Gene	7799(Species:9606)
25884948	1313	1333	dopamine receptor D2	Gene	1813(Species:9606)
25884948	1335	1339	D2DR	Gene	1813(Species:9606)
25884948	1378	1384	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
25884948	1388	1391	MMQ	Species	Species:10116
25884948	1399	1404	PRDM2	Gene	7799(Species:9606)
25884948	1463	1472	prolactin	Gene	5617(Species:9606)
25884948	1474	1477	PRL	Gene	5617(Species:9606)
25884948	1493	1496	MMQ	Species	Species:10116
25884948	1521	1526	PRDM2	Gene	7799(Species:9606)
25884948	1589	1594	PRDM2	Gene	7799(Species:9606)

26479186|t|Leptin Matures Aspects of Lung Structure and Function in the Ovine Fetus.
26479186|a|In human and ovine fetuses, glucocorticoids stimulate leptin secretion, although the extent to which leptin mediates the maturational effects of glucocorticoids on pulmonary development is unclear. This study investigated the effects of leptin administration on indices of lung structure and function before birth. Chronically catheterized singleton sheep fetuses were infused iv for 5 days with either saline or recombinant ovine leptin (0.5 mg/kg . d leptin (LEP), 0.5 LEP or 1.0 mg/kg . d, 1.0 LEP) from 125 days of gestation (term  145 d). Over the infusion, leptin administration increased plasma leptin, but not cortisol, concentrations. On the fifth day of infusion, 0.5 LEP reduced alveolar wall thickness and increased the volume at closing pressure of the pressure-volume deflation curve, interalveolar septal elastin content, secondary septal crest density, and the mRNA abundance of the leptin receptor (Ob-R) and surfactant protein (SP) B. Neither treatment influenced static lung compliance, maximal lung volume at 40 cmH2O, lung compartment volumes, alveolar surface area, pulmonary glycogen, protein content of the long form signaling Ob-Rb or phosphorylated signal transducers and activators of transcription-3, or mRNA levels of SP-A, C, or D, elastin, vascular endothelial growth factor-A, the vascular endothelial growth factor receptor 2, angiotensin-converting enzyme, peroxisome proliferator-activated receptor g, or parathyroid hormone-related peptide. Leptin administration in the ovine fetus during late gestation promotes aspects of lung maturation, including up-regulation of SP-B.
26479186	0	6	Leptin	Gene	443534(Species:9940)
26479186	77	82	human	Species	Species:9606
26479186	128	134	leptin	Gene	443534(Species:9940)
26479186	175	181	leptin	Gene	443534(Species:9940)
26479186	311	317	leptin	Gene	443534(Species:9940)
26479186	424	429	sheep	Species	Species:9940
26479186	505	511	leptin	Gene	443534(Species:9940)
26479186	527	533	leptin	Gene	443534(Species:9940)
26479186	535	538	LEP	Gene	443534(Species:9940)
26479186	545	548	LEP	Gene	443534(Species:9940)
26479186	571	574	LEP	Gene	443534(Species:9940)
26479186	637	643	leptin	Gene	443534(Species:9940)
26479186	676	682	leptin	Gene	443534(Species:9940)
26479186	752	755	LEP	Gene	443534(Species:9940)
26479186	894	901	elastin	Gene	101111152(Species:9940)
26479186	973	988	leptin receptor	Gene	443264(Species:9940)
26479186	990	994	Ob-R	Gene	443264(Species:9940)
26479186	1000	1025	surfactant protein (SP) B	Gene	443043(Species:9940)
26479186	1205	1230	long form signaling Ob-Rb	Gene	443264(Species:9940)
26479186	1249	1301	signal transducers and activators of transcription-3	Gene	100294659(Species:9940)
26479186	1321	1334	SP-A, C, or D	Gene	443033(Species:9940),443034(Species:9940),101106651(Species:9940)
26479186	1336	1343	elastin	Gene	101111152(Species:9940)
26479186	1345	1381	vascular endothelial growth factor-A	Gene	443103(Species:9940)
26479186	1387	1432	vascular endothelial growth factor receptor 2	Gene	443087(Species:9940)
26479186	1434	1463	angiotensin-converting enzyme	Gene	554335(Species:9940)
26479186	1465	1509	peroxisome proliferator-activated receptor g	Gene	443513(Species:9940)
26479186	1514	1549	parathyroid hormone-related peptide	Gene	443135(Species:9940)
26479186	1551	1557	Leptin	Gene	443534(Species:9940)
26479186	1678	1682	SP-B	Gene	443043(Species:9940)

26516699|t|Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
26516699|a|Differential expression of microRNAs (miRNAs) has been demonstrated in various cancers, including pancreatic cancer (PC). Due to the lack of tissue samples from early-stages of PC, the stage-specific alteration of miRNAs during PC initiation and progression is largely unknown. In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model. At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls. Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice. In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice. Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression. Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets. 
26516699	138	143	mouse	Species	Species:10090
26516699	587	592	mouse	Species	Species:10090
26516699	682	689	miR-150	Gene	387168(Species:10090)
26516699	691	698	miR-494	Gene	723878(Species:10090)
26516699	700	707	miR-138	Gene	387156(Species:10090),723956(Species:10090)
26516699	709	717	miR-148a	Gene	387166(Species:10090)
26516699	719	727	miR-216a	Gene	387212(Species:10090)
26516699	733	740	miR-217	Gene	387213(Species:10090)
26516699	761	769	miR-146b	Gene	751550(Species:10090)
26516699	771	778	miR-205	Gene	387201(Species:10090)
26516699	780	786	miR-31	Gene	723895(Species:10090)
26516699	788	795	miR-192	Gene	387187(Species:10090)
26516699	801	807	miR-21	Gene	387140(Species:10090)
26516699	814	818	mice	Species	Species:10090
26516699	903	908	Dicer	Gene	192119(Species:10090)
26516699	910	920	Exportin-5	Gene	72322(Species:10090)
26516699	922	927	TRKRA	Gene	18211(Species:10090)
26516699	933	939	TARBP2	Gene	21357(Species:10090)
26516699	966	971	DGCR8	Gene	94223(Species:10090)
26516699	976	980	Ago2	Gene	239528(Species:10090)
26516699	1004	1008	mice	Species	Species:10090
26516699	1102	1106	mice	Species	Species:10090
26516699	1134	1141	miR-216	Gene	387212(Species:10090)
26516699	1143	1150	miR-217	Gene	387213(Species:10090)
26516699	1152	1159	miR-100	Gene	723892(Species:10090)
26516699	1161	1168	miR-345	Gene	723946(Species:10090)
26516699	1170	1177	miR-141	Gene	387159(Species:10090)
26516699	1179	1189	miR-483-3p	Gene	723874(Species:10090)
26516699	1191	1198	miR-26b	Gene	387219(Species:10090)
26516699	1200	1207	miR-150	Gene	387168(Species:10090)
26516699	1209	1216	miR-195	Gene	387190(Species:10090)
26516699	1218	1224	Let-7b	Gene	387245(Species:10090)
26516699	1256	1262	miR-21	Gene	387140(Species:10090)
26516699	1264	1271	miR-205	Gene	387201(Species:10090)
26516699	1273	1281	miR-146b	Gene	751550(Species:10090)
26516699	1283	1290	miR-34c	Gene	723932(Species:10090)
26516699	1292	1300	miR-1273	Gene	100422821(Species:9606)
26516699	1302	1309	miR-223	Gene	723814(Species:10090)
26516699	1314	1321	miR-195	Gene	387190(Species:10090)
26516699	1342	1346	mice	Species	Species:10090
26516699	1403	1407	mice	Species	Species:10090
26516699	1455	1460	human	Species	Species:9606
26516699	1517	1523	Let-7b	Gene	406884(Species:9606)
26516699	1527	1536	CD18/HPAF	Species	Species:9606
26516699	1527	1531	CD18	Gene	3689(Species:9606)
26516699	1541	1547	Capan1	Species	Species:9606
26516699	1588	1592	KRAS	Gene	3845(Species:9606)

25946186|t|TIPE2 Inhibits Lung Cancer Growth Attributing to Promotion of Apoptosis by Regulating Some Apoptotic Molecules Expression.
25946186|a|Recent studies found that TIPE2 was involved in cancer development. However, little is known about TIPE2 in lung cancer. Our study aims to clarify the role of TIPE2 in lung carcinogenesis. We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues. Overexpression of TIPE2 significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed tumor formation in vivo. Flow cytometry analysis found TIPE2 overexpression promoted apoptosis of H446. In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated. Moreover, coincident results were shown by immunohistochemistry in tumors from nude mice. TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway. Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
25946186	0	5	TIPE2	Gene	79626(Species:9606)
25946186	149	154	TIPE2	Gene	79626(Species:9606)
25946186	222	227	TIPE2	Gene	79626(Species:9606)
25946186	282	287	TIPE2	Gene	79626(Species:9606)
25946186	342	347	TIPE2	Gene	79626(Species:9606)
25946186	455	460	TIPE2	Gene	79626(Species:9606)
25946186	568	573	TIPE2	Gene	79626(Species:9606)
25946186	718	723	TIPE2	Gene	79626(Species:9606)
25946186	761	765	H446	Species	Species:9606
25946186	770	775	TIPE2	Gene	79626(Species:9606)
25946186	799	808	caspase-3	Gene	836(Species:9606)
25946186	810	819	caspase-9	Gene	842(Species:9606)
25946186	825	828	Bax	Gene	581(Species:9606)
25946186	867	872	Bcl-2	Gene	596(Species:9606)
25946186	972	981	nude mice	Species	Species:10090
25946186	983	988	TIPE2	Gene	79626(Species:9606)
25946186	1022	1025	Akt	Gene	207(Species:9606)
25946186	1066	1069	P38	Gene	1432(Species:9606)
25946186	1092	1096	IkBa	Gene	4792(Species:9606)
25946186	1101	1104	ERK	Gene	5594(Species:9606)
25946186	1130	1135	TIPE2	Gene	79626(Species:9606)
25946186	1218	1227	caspase-3	Gene	836(Species:9606)
25946186	1229	1238	caspase-9	Gene	842(Species:9606)
25946186	1240	1245	Bcl-2	Gene	596(Species:9606)
25946186	1250	1253	Bax	Gene	581(Species:9606)
25946186	1279	1282	P38	Gene	1432(Species:9606)
25946186	1287	1290	Akt	Gene	207(Species:9606)
25946186	1317	1322	TIPE2	Gene	79626(Species:9606)

28112376|t|Increased frequency of peripheral blood follicular helper T cells and elevated serum IL-21 levels in patients with knee osteoarthritis.
28112376|a|An aberrant immune response has been implicated in the pathogenesis of osteoarthritis (OA). However, the role of peripheral blood follicular helper T (TFH) cells in the pathogenesis of OA has yet to be elucidated. The purpose of the present study was to examine the role of TFH cells and serum interleukin-21 (IL-21) in the pathogenesis of OA. Frequency of peripheral blood inducible costimulator (ICOS)+, programmed death 1 (PD-1)+, and IL-21+ CXCR5+CD4+ T cells in 40 patients with OA and 13 healthy controls (HCs) were examined by flow cytometry. The disease state in individual patients was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Concentrations of serum IL-21, interferon-g (INF-g), IL-4, IL-17A, and C-reactive protein (CRP) were determined, and the erythrocyte sedimentation rate (ESR) was measured. The percentages of CXCR5+CD4+ cells, PD-1+CXCR5+CD4+, ICOS+CXCR5+CD4+ and IL-21+CXCR5+CD4+ T cells in OA patients were signifcantly higher than those in the HCs. Furthermore, serum IL-21, IL-17A and IFN-g levels in OA patients were significantly higher than those in HCs. Expression of IL-21+TFH cells in OA patients demonstrated a positive correlation with OA disease activity, CRP levels and WOMAC. TFH cells and IL-21 appear to serve an important role in the progression of OA. IL-21+TFH cells may prove to be a marker of OA disease activity.
28112376	85	90	IL-21	Gene	59067(Species:9606)
28112376	101	109	patients	Species	Species:9606
28112376	430	444	interleukin-21	Gene	59067(Species:9606)
28112376	446	451	IL-21	Gene	59067(Species:9606)
28112376	510	532	inducible costimulator	Gene	733597(Species:9823)
28112376	534	538	ICOS	Gene	29851(Species:9606)
28112376	542	560	programmed death 1	Gene	5133(Species:9606)
28112376	562	566	PD-1	Gene	5133(Species:9606)
28112376	562	566	PD-1	Species	Species:9823
28112376	574	579	IL-21	Gene	59067(Species:9606)
28112376	581	586	CXCR5	Gene	643(Species:9606)
28112376	587	590	CD4	Gene	920(Species:9606)
28112376	606	614	patients	Species	Species:9606
28112376	718	726	patients	Species	Species:9606
28112376	846	851	IL-21	Gene	59067(Species:9606)
28112376	853	865	interferon-g	Gene	3458(Species:9606)
28112376	867	872	INF-g	Gene	3458(Species:9606)
28112376	875	879	IL-4	Gene	3565(Species:9606)
28112376	881	887	IL-17A	Gene	3605(Species:9606)
28112376	893	911	C-reactive protein	Gene	1401(Species:9606)
28112376	913	916	CRP	Gene	1401(Species:9606)
28112376	1013	1018	CXCR5	Gene	643(Species:9606)
28112376	1019	1022	CD4	Gene	920(Species:9606)
28112376	1031	1035	PD-1	Gene	5133(Species:9606)
28112376	1036	1041	CXCR5	Gene	643(Species:9606)
28112376	1042	1045	CD4	Gene	920(Species:9606)
28112376	1048	1052	ICOS	Gene	29851(Species:9606)
28112376	1053	1058	CXCR5	Gene	643(Species:9606)
28112376	1059	1062	CD4	Gene	920(Species:9606)
28112376	1068	1073	IL-21	Gene	59067(Species:9606)
28112376	1074	1079	CXCR5	Gene	643(Species:9606)
28112376	1080	1083	CD4	Gene	920(Species:9606)
28112376	1099	1107	patients	Species	Species:9606
28112376	1175	1180	IL-21	Gene	59067(Species:9606)
28112376	1182	1188	IL-17A	Gene	3605(Species:9606)
28112376	1193	1198	IFN-g	Gene	3458(Species:9606)
28112376	1212	1220	patients	Species	Species:9606
28112376	1280	1285	IL-21	Gene	59067(Species:9606)
28112376	1302	1310	patients	Species	Species:9606
28112376	1373	1376	CRP	Gene	1401(Species:9606)
28112376	1409	1414	IL-21	Gene	59067(Species:9606)
28112376	1475	1480	IL-21	Gene	59067(Species:9606)

22208359|t|Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway.
22208359|a|BACKGROUND: Microglia are the principal cells involved in the innate immune response in the CNS. Activated microglia produce a number of proinflammatory cytokines implicated in neurotoxicity but they also are a major source of anti-inflammatory cytokines, antiviral proteins and growth factors. Therefore, an immune therapy aiming at suppressing the proinflammatory phenotype while enhancing the anti-inflammatory, growth promoting phenotype would be of great benefit. In the current study, we tested the hypothesis that interferon regulatory factor 3 (IRF3), a transcription factor required for the induction of IFNbeta following TLR3 or TLR4 activation, is critical to the microglial phenotype change from proinflammatory to anti-inflammatory, and that this phenotype change can be greatly facilitated by IRF3 gene transfer. METHODS: Cultures of primary human fetal microglia were transduced with IRF3 using recombinant adenovirus (Ad-IRF3) and subjected to microarray analysis, real-time PCR, immunoblotting and ELISA to determine inflammatory gene expression. Two different types of immune stimuli were tested, the TLR ligands, poly IC (PIC) and LPS, and the proinflammatory cytokines, IL-1/IFNgamma. In addition, the role of the PI3K/Akt pathway was examined by use of a pharmacological inhibitor, LY294002. RESULTS: Our results show that Ad-IRF3 suppressed proinflammatory genes (IL-1alpha, IL-1beta, TNFalpha, IL-6, IL-8 and CXCL1) and enhanced anti-inflammatory genes (IL-1 receptor antagonist, IL-10 and IFNbeta) in microglia, regardless of the cell stimuli applied. Furthermore, Ad-IRF3 activated Akt, and LY294002 reversed the effects of Ad-IRF3 on microglial inflammatory gene expression. pAkt was critical in LPS- or PIC-induced production of IL-10 and IL-1ra. Significantly, microglial IFNbeta protein production was also dependent on pAkt and required both Ad-IRF3 and immunological stimuli (PIC    > IL-1/IFNgamma). pAkt played much less prominent and variable roles in microglial proinflammatory gene expression. This anti-inflammatory promoting role of PI3K/Akt appeared to be specific to microglia, since astrocyte proinflammatory gene expression (as well as IFNbeta expression) required PI3K/Akt. CONCLUSIONS: Our results show a novel anti-inflammatory role for the PI3K/Akt signaling pathway in microglia. They further suggest that IRF3 gene therapy could facilitate the microglial phenotype switch from proinflammatory ("M1-like") to anti-inflammatory and immunomodulatory ("M2-like"), in part, by augmenting the level of pAkt.
22208359	0	30	Interferon regulatory factor 3	Gene	3661(Species:9606)
22208359	94	98	PI3K	Gene	5290(Species:9606)
22208359	99	102	Akt	Gene	207(Species:9606)
22208359	265	274	cytokines	Gene	2919(Species:9606),3456(Species:9606),3458(Species:9606),3552(Species:9606),3553(Species:9606),3557(Species:9606),3569(Species:9606),3576(Species:9606),3586(Species:9606),7124(Species:9606)
22208359	357	366	cytokines	Gene	2919(Species:9606),3456(Species:9606),3458(Species:9606),3552(Species:9606),3553(Species:9606),3557(Species:9606),3569(Species:9606),3576(Species:9606),3586(Species:9606),7124(Species:9606)
22208359	633	663	interferon regulatory factor 3	Gene	3661(Species:9606)
22208359	665	669	IRF3	Gene	3661(Species:9606)
22208359	674	694	transcription factor	Gene	3661(Species:9606)
22208359	725	732	IFNbeta	Gene	3456(Species:9606)
22208359	743	747	TLR3	Gene	7098(Species:9606)
22208359	751	755	TLR4	Gene	7099(Species:9606)
22208359	919	923	IRF3	Gene	3661(Species:9606)
22208359	968	973	human	Species	Species:9606
22208359	1011	1015	IRF3	Gene	3661(Species:9606)
22208359	1034	1044	adenovirus	Species	Species:10508
22208359	1049	1053	IRF3	Gene	3661(Species:9606)
22208359	1291	1300	cytokines	Gene	2919(Species:9606),3456(Species:9606),3458(Species:9606),3552(Species:9606),3553(Species:9606),3557(Species:9606),3569(Species:9606),3576(Species:9606),3586(Species:9606),7124(Species:9606)
22208359	1302	1306	IL-1	Gene	3552(Species:9606),3553(Species:9606)
22208359	1307	1315	IFNgamma	Gene	3458(Species:9606)
22208359	1346	1350	PI3K	Gene	5290(Species:9606)
22208359	1351	1354	Akt	Gene	207(Species:9606)
22208359	1459	1463	IRF3	Gene	3661(Species:9606)
22208359	1498	1507	IL-1alpha	Gene	3552(Species:9606)
22208359	1509	1517	IL-1beta	Gene	3553(Species:9606)
22208359	1519	1527	TNFalpha	Gene	7124(Species:9606)
22208359	1529	1533	IL-6	Gene	3569(Species:9606)
22208359	1535	1539	IL-8	Gene	3576(Species:9606)
22208359	1544	1549	CXCL1	Gene	2919(Species:9606)
22208359	1589	1613	IL-1 receptor antagonist	Gene	3557(Species:9606)
22208359	1615	1620	IL-10	Gene	3586(Species:9606)
22208359	1625	1632	IFNbeta	Gene	3456(Species:9606)
22208359	1704	1708	IRF3	Gene	3661(Species:9606)
22208359	1719	1722	Akt	Gene	207(Species:9606)
22208359	1764	1768	IRF3	Gene	3661(Species:9606)
22208359	1813	1817	pAkt	Gene	207(Species:9606)
22208359	1868	1873	IL-10	Gene	3586(Species:9606)
22208359	1878	1884	IL-1ra	Gene	3557(Species:9606)
22208359	1912	1919	IFNbeta	Gene	3456(Species:9606)
22208359	1961	1965	pAkt	Gene	207(Species:9606)
22208359	1987	1991	IRF3	Gene	3661(Species:9606)
22208359	2028	2032	IL-1	Gene	3552(Species:9606),3553(Species:9606)
22208359	2033	2041	IFNgamma	Gene	3458(Species:9606)
22208359	2045	2048	Akt	Gene	207(Species:9606)
22208359	2183	2187	PI3K	Gene	5290(Species:9606)
22208359	2188	2191	Akt	Gene	207(Species:9606)
22208359	2290	2297	IFNbeta	Gene	3456(Species:9606)
22208359	2319	2323	PI3K	Gene	5290(Species:9606)
22208359	2324	2327	Akt	Gene	207(Species:9606)
22208359	2398	2402	PI3K	Gene	5290(Species:9606)
22208359	2403	2406	Akt	Gene	207(Species:9606)
22208359	2465	2469	IRF3	Gene	3661(Species:9606)
22208359	2656	2660	pAkt	Gene	207(Species:9606)

28148288|t|Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
28148288|a|BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors. ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers. It is currently unknown whether ADAM12 plays an active role in promoting the CSC phenotype in breast cancer cells. METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression. Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated. RNA sequencing was performed to identify global gene expression changes after ADAM12 knockdown. RESULTS: We found that sorted SUM159PT cell populations with high ADAM12 levels had elevated expression of CSC markers and an increased ability to form mammospheres. ADAM12 knockdown reduced cell migration and invasion, decreased anoikis resistance, and compromised mammosphere formation. ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo. RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor (EGFR)-regulated genes. Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor. Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by ADAM12 knockdown. CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
28148288	0	27	Metalloprotease-disintegrin	Gene	8038(Species:9606)
28148288	28	34	ADAM12	Gene	8038(Species:9606)
28148288	85	92	claudin	Gene	9076(Species:9606)
28148288	124	130	ADAM12	Gene	8038(Species:9606)
28148288	149	154	human	Species	Species:9606
28148288	211	228	estrogen receptor	Gene	2099(Species:9606)
28148288	246	252	ADAM12	Gene	8038(Species:9606)
28148288	335	342	claudin	Gene	9076(Species:9606)
28148288	448	454	ADAM12	Gene	8038(Species:9606)
28148288	540	546	ADAM12	Gene	8038(Species:9606)
28148288	594	601	claudin	Gene	9076(Species:9606)
28148288	852	856	ALDH	Gene	217(Species:9606)
28148288	889	893	CD44	Gene	960(Species:9606)
28148288	898	902	CD24	Gene	100133941(Species:9606)
28148288	957	961	mice	Species	Species:10090
28148288	1104	1110	ADAM12	Gene	8038(Species:9606)
28148288	1152	1160	SUM159PT	Species	Species:9606
28148288	1188	1194	ADAM12	Gene	8038(Species:9606)
28148288	1288	1294	ADAM12	Gene	8038(Species:9606)
28148288	1411	1417	ADAM12	Gene	8038(Species:9606)
28148288	1461	1465	CD44	Gene	960(Species:9606)
28148288	1470	1474	CD24	Gene	100133941(Species:9606)
28148288	1544	1548	mice	Species	Species:10090
28148288	1614	1620	ADAM12	Gene	8038(Species:9606)
28148288	1626	1658	Epidermal Growth Factor Receptor	Gene	1956(Species:9606)
28148288	1660	1664	EGFR	Gene	1956(Species:9606)
28148288	1697	1703	ADAM12	Gene	8038(Species:9606)
28148288	1752	1756	EGFR	Gene	1956(Species:9606)
28148288	1926	1930	CD44	Gene	960(Species:9606)
28148288	1935	1939	CD24	Gene	100133941(Species:9606)
28148288	1965	1971	ADAM12	Gene	8038(Species:9606)
28148288	2024	2030	ADAM12	Gene	8038(Species:9606)
28148288	2070	2077	claudin	Gene	9076(Species:9606)
28148288	2124	2128	EGFR	Gene	1956(Species:9606)

19672862|t|Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
19672862|a|Endometrial cancer is the most common invasive gynecologic malignancy, yet molecular mechanisms and signaling pathways underlying its etiology and pathophysiology remain poorly characterized. We sought to define a functional role for the protein kinase C (PKC) isoform, PKCalpha, in an established cell model of endometrial adenocarcinoma. Ishikawa cells depleted of PKCalpha protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft tumor formation in nude mice. Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27). Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta). PKCalpha knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following EGF stimulation. p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK. Immunohistochemical analysis of Grade 1 endometrioid adenocarcinoma revealed aberrant PKCalpha expression, with foci of elevated PKCalpha staining, not observed in normal endometrium. These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways. Thus, targeting PKCalpha may provide novel therapeutic options in endometrial tumors.
19672862	0	22	Protein kinase C alpha	Gene	5578(Species:9606)
19672862	340	356	protein kinase C	Gene	5578(Species:9606)
19672862	372	380	PKCalpha	Gene	5578(Species:9606)
19672862	442	450	Ishikawa	Species	Species:9606
19672862	469	477	PKCalpha	Gene	5578(Species:9606)
19672862	612	621	nude mice	Species	Species:10090
19672862	656	664	PKCalpha	Gene	5578(Species:9606)
19672862	699	739	cyclin-dependent kinase (CDK) inhibitors	Gene	1026(Species:9606),1027(Species:9606)
19672862	740	754	p21(Cip1/WAF1)	Gene	1026(Species:9606)
19672862	756	759	p21	Gene	1026(Species:9606)
19672862	765	774	p27(Kip1)	Gene	1027(Species:9606)
19672862	776	779	p27	Gene	1027(Species:9606)
19672862	816	846	phosphatase and tensin homolog	Gene	5728(Species:9606)
19672862	848	852	PTEN	Gene	5728(Species:9606)
19672862	865	873	Ishikawa	Species	Species:9606
19672862	881	889	PKCalpha	Gene	5578(Species:9606)
19672862	908	911	Akt	Gene	207(Species:9606)
19672862	993	996	Akt	Gene	207(Species:9606)
19672862	1005	1035	glycogen synthase kinase-3beta	Gene	2932(Species:9606)
19672862	1037	1046	GSK-3beta	Gene	2932(Species:9606)
19672862	1049	1057	PKCalpha	Gene	5578(Species:9606)
19672862	1101	1104	ERK	Gene	5594(Species:9606)
19672862	1136	1139	ERK	Gene	5594(Species:9606)
19672862	1178	1181	p21	Gene	1026(Species:9606)
19672862	1186	1189	p27	Gene	1027(Species:9606)
19672862	1235	1243	Ishikawa	Species	Species:9606
19672862	1255	1258	ERK	Gene	5594(Species:9606)
19672862	1263	1266	Akt	Gene	207(Species:9606)
19672862	1295	1303	PKCalpha	Gene	5578(Species:9606)
19672862	1314	1317	CDK	Gene	1021(Species:9606)
19672862	1346	1349	Akt	Gene	207(Species:9606)
19672862	1354	1357	ERK	Gene	5594(Species:9606)
19672862	1445	1453	PKCalpha	Gene	5578(Species:9606)
19672862	1488	1496	PKCalpha	Gene	5578(Species:9606)
19672862	1589	1597	PKCalpha	Gene	5578(Species:9606)
19672862	1680	1683	p21	Gene	1026(Species:9606)
19672862	1688	1691	p27	Gene	1027(Species:9606)
19672862	1710	1713	Akt	Gene	207(Species:9606)
19672862	1718	1721	ERK	Gene	5594(Species:9606)
19672862	1772	1780	PKCalpha	Gene	5578(Species:9606)

19825989|t|H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
19825989|a|Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4). The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth. We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth. Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured. In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms. Localization of PKCalpha was visualized by immunofluorescence in cell smears and immunoblotting for PKCalpha in cytosol and membrane fractions. Following knockdown of PKCalpha, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. In vivo experiments were done in BALB/c nude mice. Mice were treated with saline or RAMH for 44 days and tumor volume was measured. Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3. HRH3 expression was found in all cells. RAMH inhibited the growth of cholangiocarcinoma cells. RAMH increased IP(3) levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation. RAMH induced a shift in the localization of PKCalpha expression from the cytosolic domain into the membrane region of Mz-ChA-1 cells. Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation. In vivo, RAMH decreased tumor growth and expression of VEGF and its receptors; PKCalpha expression was increased. RAMH inhibits cholangiocarcinoma growth by PKCalpha-dependent ERK1/2 dephosphorylation. Modulation of PKCalpha by histamine receptors may be important in regulating cholangiocarcinoma growth.
19825989	0	21	H3 histamine receptor	Gene	11255(Species:9606)
19825989	45	66	protein kinase Calpha	Gene	5578(Species:9606)
19825989	181	185	HRH1	Gene	3269(Species:9606)
19825989	187	191	HRH2	Gene	3274(Species:9606)
19825989	193	197	HRH3	Gene	11255(Species:9606)
19825989	203	207	HRH4	Gene	59340(Species:9606)
19825989	264	280	protein kinase C	Gene	5578(Species:9606)
19825989	282	285	PKC	Gene	5578(Species:9606)
19825989	287	319	mitogen-activated protein kinase	Gene	5594(Species:9606),5595(Species:9606)
19825989	390	394	HRH3	Gene	11255(Species:9606)
19825989	457	461	HRH3	Gene	11255(Species:9606)
19825989	534	539	human	Species	Species:9606
19825989	571	579	Mz-ChA-1	Species	Species:9606
19825989	746	749	PKC	Gene	5578(Species:9606)
19825989	754	786	mitogen-activated protein kinase	Gene	5594(Species:9606),5595(Species:9606)
19825989	813	821	PKCalpha	Gene	5578(Species:9606)
19825989	897	905	PKCalpha	Gene	5578(Species:9606)
19825989	964	972	PKCalpha	Gene	5578(Species:9606)
19825989	974	982	Mz-ChA-1	Species	Species:9606
19825989	1049	1096	extracellular signal-regulated kinase (ERK)-1/2	Gene	5595(Species:9606),5594(Species:9606)
19825989	1154	1163	nude mice	Species	Species:10090
19825989	1165	1169	Mice	Species	Species:10090
19825989	1328	1336	PKCalpha	Gene	5578(Species:9606)
19825989	1338	1381	vascular endothelial growth factor (VEGF)-A	Gene	7422(Species:9606)
19825989	1338	1372	vascular endothelial growth factor	Gene	7422(Species:9606)
19825989	1374	1381	VEGF)-A	Gene	7422(Species:9606)
19825989	1383	1389	VEGF-C	Gene	7424(Species:9606)
19825989	1391	1406	VEGF receptor 2	Gene	3791(Species:9606)
19825989	1412	1427	VEGF receptor 3	Gene	2324(Species:9606)
19825989	1429	1433	HRH3	Gene	11255(Species:9606)
19825989	1556	1564	PKCalpha	Gene	5578(Species:9606)
19825989	1595	1601	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
19825989	1663	1671	PKCalpha	Gene	5578(Species:9606)
19825989	1737	1745	Mz-ChA-1	Species	Species:9606
19825989	1766	1774	PKCalpha	Gene	5578(Species:9606)
19825989	1804	1812	Mz-ChA-1	Species	Species:9606
19825989	1853	1859	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
19825989	1932	1936	VEGF	Gene	7422(Species:9606),7424(Species:9606)
19825989	1956	1964	PKCalpha	Gene	5578(Species:9606)
19825989	2034	2042	PKCalpha	Gene	5578(Species:9606)
19825989	2053	2059	ERK1/2	Gene	5595(Species:9606),5594(Species:9606)
19825989	2093	2101	PKCalpha	Gene	5578(Species:9606)
19825989	2105	2124	histamine receptors	Gene	11255(Species:9606),3269(Species:9606),3274(Species:9606),59340(Species:9606)

28259923|t|Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
28259923|a|Epithelial-mesenchymal transition (EMT) is a critical step in the acquisition of metastatic and invasive power for tumor cells. Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival. Recent studies show that pleomorphic adenoma gene like-2 (PLAGL2) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer. In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480. We found that PLAGL2 expression was upregulated in the paraffin-embedded CRC tissues compared to borderline or benign tissues. Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin. Subsequently, through western blot assay, we found that PLAGL2 could activate the wnt-signaling component b-catenin in the nuclei. More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group. Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in Wnt/b-catenin signaling pathway.
28259923	0	31	Pleomorphic adenoma gene like-2	Gene	5326(Species:9606)
28259923	78	81	Wnt	Gene	7474(Species:9606)
28259923	82	91	b-catenin	Gene	1499(Species:9606)
28259923	113	118	human	Species	Species:9606
28259923	364	371	patient	Species	Species:9606
28259923	407	438	pleomorphic adenoma gene like-2	Gene	5326(Species:9606)
28259923	440	446	PLAGL2	Gene	5326(Species:9606)
28259923	600	606	PLAGL2	Gene	5326(Species:9606)
28259923	631	639	patients	Species	Species:9606
28259923	674	680	PLAGL2	Gene	5326(Species:9606)
28259923	732	738	PLAGL2	Gene	5326(Species:9606)
28259923	873	879	PLAGL2	Gene	5326(Species:9606)
28259923	908	914	PLAGL2	Gene	5326(Species:9606)
28259923	1064	1074	N-cadherin	Gene	1000(Species:9606)
28259923	1079	1087	vimentin	Gene	7431(Species:9606)
28259923	1140	1150	E-cadherin	Gene	999(Species:9606)
28259923	1208	1214	PLAGL2	Gene	5326(Species:9606)
28259923	1234	1237	wnt	Gene	7474(Species:9606)
28259923	1258	1267	b-catenin	Gene	1499(Species:9606)
28259923	1343	1349	PLAGL2	Gene	5326(Species:9606)
28259923	1365	1370	SW480	Species	Species:9606
28259923	1413	1417	rats	Species	Species:10116
28259923	1454	1460	PLAGL2	Gene	5326(Species:9606)
28259923	1504	1510	PLAGL2	Gene	5326(Species:9606)
28259923	1576	1579	Wnt	Gene	7474(Species:9606)
28259923	1580	1589	b-catenin	Gene	1499(Species:9606)

17397547|t|Regulatory network of inflammation downstream of proteinase-activated receptors.
17397547|a|BACKGROUND: Protease-activated receptors (PAR) are present in the urinary bladder, and their expression is altered in response to inflammation. PARs are a unique class of G protein-coupled that carry their own ligands, which remain cryptic until unmasked by proteolytic cleavage. Although the canonical signal transduction pathway downstream of PAR activation and coupling with various G proteins is known and leads to the rapid transcription of genes involved in inflammation, the effect of PAR activation on the downstream transcriptome is unknown. We have shown that intravesical administration of PAR-activating peptides leads to an inflammatory reaction characterized by edema and granulocyte infiltration. Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency. RESULTS: Here, cDNA array experiments determined inflammatory genes whose expression is dependent on PAR1 activation. For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen). 75 transcripts were considered to be dependent on PAR-1 activation and further annotated in silico by Ingenuity Pathways Analysis (IPA) and gene ontology (GO). Selected transcripts were target validated by quantitative PCR (Q-PCR). Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2. However, a balanced response to signals of injury requires a transient cellular activation of a panel of genes together with inhibitory systems that temper the overwhelming inflammation. In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production. In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli. CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of PAR1 in bladder inflammation, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation. It remains to be determined whether or not mechanisms targeting PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestation of cystitis.
17397547	49	79	proteinase-activated receptors	Gene	14062(Species:10090)
17397547	93	121	Protease-activated receptors	Gene	14062(Species:10090)
17397547	123	126	PAR	Gene	14062(Species:10090)
17397547	426	429	PAR	Gene	14062(Species:10090)
17397547	573	576	PAR	Gene	14062(Species:10090)
17397547	682	685	PAR	Gene	14062(Species:10090)
17397547	900	907	E. coli	Species	Species:562
17397547	944	950	P (SP)	Species	Species:59823
17397547	991	995	PAR1	Gene	14062(Species:10090)
17397547	1023	1027	PAR2	Gene	14063(Species:10090)
17397547	1141	1145	PAR1	Gene	14062(Species:10090)
17397547	1239	1243	PAR1	Gene	14062(Species:10090)
17397547	1247	1251	mice	Species	Species:10090
17397547	1372	1377	PAR-1	Gene	14062(Species:10090)
17397547	1560	1564	PAR1	Gene	14062(Species:10090)
17397547	1652	1655	b2m	Gene	12010(Species:10090)
17397547	1657	1661	ccl7	Gene	20306(Species:10090)
17397547	1663	1668	cd200	Gene	17470(Species:10090)
17397547	1670	1674	cd63	Gene	12512(Species:10090)
17397547	1683	1687	cfl1	Gene	12631(Species:10090)
17397547	1689	1694	dusp1	Gene	19252(Species:10090)
17397547	1696	1702	fkbp1a	Gene	14225(Species:10090)
17397547	1704	1708	fth1	Gene	14319(Species:10090)
17397547	1710	1715	hspb1	Gene	15507(Species:10090)
17397547	1717	1725	marcksl1	Gene	17357(Species:10090)
17397547	1727	1731	mmp2	Gene	17390(Species:10090)
17397547	1733	1738	myo5a	Gene	17918(Species:10090)
17397547	1740	1746	nfkbia	Gene	18035(Species:10090)
17397547	1748	1752	pax1	Gene	18503(Species:10090)
17397547	1754	1759	plaur	Gene	18793(Species:10090)
17397547	1761	1765	ppia	Gene	268373(Species:10090)
17397547	1767	1772	ptpn1	Gene	19246(Species:10090)
17397547	1774	1781	ptprcap	Gene	19265(Species:10090)
17397547	1783	1790	s100a10	Gene	20194(Species:10090)
17397547	1792	1796	sim2	Gene	20465(Species:10090)
17397547	1802	1809	tnfaip2	Gene	21928(Species:10090)
17397547	2047	2052	dusp1	Gene	19252(Species:10090)
17397547	2057	2063	nfkbia	Gene	18035(Species:10090)
17397547	2118	2121	PAR	Gene	14062(Species:10090)
17397547	2169	2177	p38 MAPK	Gene	26416(Species:10090)
17397547	2246	2250	arf6	Gene	11845(Species:10090)
17397547	2255	2260	dcnt1	Gene	13426(Species:10090)
17397547	2299	2302	PAR	Gene	14062(Species:10090)
17397547	2529	2533	PAR1	Gene	14062(Species:10090)
17397547	2702	2706	PAR1	Gene	14062(Species:10090)
17397547	2783	2787	PAR1	Gene	14062(Species:10090)
17397547	2806	2810	PAR1	Gene	14062(Species:10090)

18489763|t|Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India.
18489763|a|BACKGROUND: Plasmodium falciparum in a subset of patients can lead to cerebral malaria (CM), a major contributor to malaria-associated mortality. Despite treatment, CM mortality can be as high as 30%, while 10% of survivors of the disease may experience short- and long-term neurological complications. The pathogenesis of CM is mediated by alterations in cytokine and chemokine homeostasis, inflammation as well as vascular injury and repair processes although their roles are not fully understood. The hypothesis for this study is that CM-induced changes in inflammatory, apoptotic and angiogenic factors mediate severity of CM and that their identification will enable development of new prognostic markers and adjunctive therapies for preventing CM mortalities. METHODS: Plasma samples (133) were obtained from healthy controls (HC, 25), mild malaria (MM, 48), cerebral malaria survivors (CMS, 48), and cerebral malaria non-survivors (CMNS, 12) at admission to the hospital in Jabalpur, India. Plasma levels of 30 biomarkers ((IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic protein, G-CSF, GM-CSF, IFN-gamma, IP-10, MCP-1 (MCAF), MIP-1alpha, MIP-1beta, RANTES, TNF-alpha, Fas-ligand (Fas-L), soluble Fas (sFas), soluble TNF receptor 1 (sTNF-R1) and soluble TNF receptor 2 (sTNFR-2), PDGF bb and VEGF)) were simultaneously measured in an initial subset of ten samples from each group. Only those biomarkers which showed significant differences in the pilot analysis were chosen for testing on all remaining samples. The results were then compared between the four groups to determine their role in CM severity. RESULTS: IP-10, sTNF-R2 and sFas were independently associated with increased risk of CM associated mortality. CMNS patients had a significantly lower level of the neuroprotective factor VEGF when compared to other groups (P    < 0.0045). The ratios of VEGF to IP-10, sTNF-R2, and sFas distinguished CM survivors from non survivors (P    < 0.0001). CONCLUSION: The results suggest that plasma levels of IP-10, sTNF-R2 and sFas may be potential biomarkers of CM severity and mortality. VEGF was found to be protective against CM associated mortality and may be considered for adjunctive therapy to improve the treatment outcome in CM patients.
18489763	7	12	IP-10	Gene	3627(Species:9606)
18489763	108	129	Plasmodium falciparum	Species	Species:5833
18489763	145	153	patients	Species	Species:9606
18489763	1127	1135	IL-1beta	Gene	3553(Species:9606)
18489763	1137	1143	IL-1ra	Gene	3557(Species:9606)
18489763	1145	1149	IL-2	Gene	3558(Species:9606)
18489763	1151	1155	IL-4	Gene	3565(Species:9606)
18489763	1157	1161	IL-5	Gene	3567(Species:9606)
18489763	1163	1167	IL-6	Gene	3569(Species:9606)
18489763	1169	1173	IL-8	Gene	3576(Species:9606)
18489763	1175	1179	IL-9	Gene	3578(Species:9606)
18489763	1181	1186	IL-10	Gene	3586(Species:9606)
18489763	1188	1199	IL-12 (p70)	Gene	3592(Species:9606),3593(Species:9606)
18489763	1201	1206	IL-13	Gene	3596(Species:9606)
18489763	1208	1213	IL-15	Gene	3600(Species:9606)
18489763	1215	1220	IL-17	Gene	3605(Species:9606)
18489763	1222	1229	Eotaxin	Gene	6356(Species:9606)
18489763	1231	1248	FGF basic protein	Gene	2247(Species:9606)
18489763	1250	1255	G-CSF	Gene	1440(Species:9606)
18489763	1257	1263	GM-CSF	Gene	1437(Species:9606)
18489763	1265	1274	IFN-gamma	Gene	3458(Species:9606)
18489763	1276	1281	IP-10	Gene	3627(Species:9606)
18489763	1283	1288	MCP-1	Gene	6347(Species:9606)
18489763	1290	1294	MCAF	Gene	6347(Species:9606)
18489763	1297	1307	MIP-1alpha	Gene	6348(Species:9606)
18489763	1309	1318	MIP-1beta	Gene	6351(Species:9606)
18489763	1320	1326	RANTES	Gene	6352(Species:9606)
18489763	1328	1337	TNF-alpha	Gene	7124(Species:9606)
18489763	1339	1349	Fas-ligand	Gene	356(Species:9606)
18489763	1351	1356	Fas-L	Gene	356(Species:9606)
18489763	1367	1370	Fas	Gene	355(Species:9606)
18489763	1372	1376	sFas	Gene	355(Species:9606)
18489763	1387	1401	TNF receptor 1	Gene	7132(Species:9606)
18489763	1403	1410	sTNF-R1	Gene	7132(Species:9606)
18489763	1424	1438	TNF receptor 2	Gene	7133(Species:9606)
18489763	1440	1447	sTNFR-2	Gene	7133(Species:9606)
18489763	1450	1457	PDGF bb	Gene	5155(Species:9606)
18489763	1462	1466	VEGF	Gene	7422(Species:9606)
18489763	1786	1791	IP-10	Gene	3627(Species:9606)
18489763	1793	1800	sTNF-R2	Gene	7133(Species:9606)
18489763	1805	1809	sFas	Gene	355(Species:9606)
18489763	1893	1901	patients	Species	Species:9606
18489763	1964	1968	VEGF	Gene	7422(Species:9606)
18489763	2030	2034	VEGF	Gene	7422(Species:9606)
18489763	2038	2043	IP-10	Gene	3627(Species:9606)
18489763	2045	2052	sTNF-R2	Gene	7133(Species:9606)
18489763	2058	2062	sFas	Gene	355(Species:9606)
18489763	2180	2185	IP-10	Gene	3627(Species:9606)
18489763	2187	2194	sTNF-R2	Gene	7133(Species:9606)
18489763	2199	2203	sFas	Gene	355(Species:9606)
18489763	2262	2266	VEGF	Gene	7422(Species:9606)
18489763	2410	2418	patients	Species	Species:9606

21075137|t|Phylogenetic and developmental study of CD4, CD8 alpha and beta T cell co-receptor homologs in two amphibian species, Xenopus tropicalis and Xenopus laevis.
21075137|a|CD4 and CD8 co-receptors play critical roles in T cell development and activation by interacting both with T cell receptors and MHC molecules. Although homologs of these genes have been identified in many jawed vertebrates, there are still unresolved gaps concerning their evolution and specialization in MHC interaction and T cell function. Using experimental and computational procedures we identified CD4, CD8alpha and CD8beta gene homologs both in Xenopus tropicalis, whose full genome has been sequenced, and its sister species Xenopus laevis. Multiple alignments of deduced amino acid sequences reveal a poor conservation of the residues involved in binding of CD4 to MHC class II, and CD8alpha to class I in non-mammalian species, presumably related to the co-evolutionary pressure of MHC I and II genes. Phylogenetic study suggests that Xenopodinae co-receptor genes are more closely related to their homologs in other tetrapods than those of bony fish. Furthermore, the developmental and cell-specific expression patterns of these genes in X. laevis are very similar to that of mammals. X. laevis CD4 is mainly expressed by peripheral non-CD8 T cells and detected in the thymus as early as four days post-fertilization (dpf) at the onset of thymic organogenesis. CD8beta expression is specific to adult surface CD8(+) T cells and thymocytes, and is first detected in the thymus at 5 dpf in parallel with productive TCRgamma transrcipts, whereas productive TCRbeta and alpha rearrangements are not detected before 7-9 dpf.
21075137	40	43	CD4	Gene	100491070(Species:8364),100653504(Species:8355)
21075137	45	63	CD8 alpha and beta	Gene	100489117(Species:8364),100653505(Species:8355),100529233(Species:8355),101733278(Species:8364)
21075137	118	136	Xenopus tropicalis	Species	Species:8364
21075137	141	155	Xenopus laevis	Species	Species:8355
21075137	157	160	CD4	Gene	100491070(Species:8364)
21075137	165	168	CD8	Gene	100489117(Species:8364)
21075137	264	280	T cell receptors	Gene	100381039(Species:8355),493253(Species:8364)
21075137	285	288	MHC	Gene	100127725(Species:8364),447287(Species:8355)
21075137	362	379	jawed vertebrates	Species	Species:7776
21075137	462	465	MHC	Gene	100127725(Species:8364),447287(Species:8355)
21075137	561	564	CD4	Gene	100491070(Species:8364),100653504(Species:8355)
21075137	566	574	CD8alpha	Gene	100489117(Species:8364),100653505(Species:8355)
21075137	579	586	CD8beta	Gene	100529233(Species:8355),101733278(Species:8364)
21075137	609	627	Xenopus tropicalis	Species	Species:8364
21075137	690	704	Xenopus laevis	Species	Species:8355
21075137	824	827	CD4	Gene	100491070(Species:8364),100653504(Species:8355)
21075137	831	843	MHC class II	Gene	100127727(Species:8364),379662(Species:8355)
21075137	849	857	CD8alpha	Gene	100489117(Species:8364),100653505(Species:8355)
21075137	861	868	class I	Gene	100127725(Species:8364),447287(Species:8355)
21075137	876	885	mammalian	Species	Species:9606
21075137	949	961	MHC I and II	Gene	100127725(Species:8364),447287(Species:8355),100127727(Species:8364),379662(Species:8355)
21075137	1084	1093	tetrapods	Species	Species:32523
21075137	1206	1215	X. laevis	Species	Species:8355
21075137	1253	1262	X. laevis	Species	Species:8355
21075137	1263	1266	CD4	Gene	100653504(Species:8355)
21075137	1305	1308	CD8	Gene	100529233(Species:8355),100653505(Species:8355)
21075137	1429	1436	CD8beta	Gene	100529233(Species:8355)
21075137	1477	1480	CD8	Gene	100529233(Species:8355),100653505(Species:8355)
21075137	1581	1589	TCRgamma	Gene	398311(Species:8355)
21075137	1622	1639	TCRbeta and alpha	Gene	378564(Species:8355),373849(Species:8355)

20454457|t|HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors.
20454457|a|BACKGROUND: A hallmark of cancer cells is hypermethylation of CpG islands (CGIs), which probably arises from upregulation of one or more DNA methyltransferases. The purpose of this study was to identify the targets of DNMT3B, an essential DNA methyltransferase in mammals, in colon cancer. METHODOLOGY/PRINCIPAL FINDINGS: Chromatin immunoprecipitation with DNMT3B specific antibody followed by CGI microarray identified genes with or without CGIs, repeat elements and genomic contigs in RKO cells. ChIP-Chop analysis showed that the majority of the target genes including P16, DCC, DISC1, SLIT1, CAVEOLIN1, GNA11, TBX5, TBX18, HOXB13 and some histone variants, that harbor CGI in their promoters, were methylated in multiple colon cancer cell lines but not in normal colon epithelial cells. Further, these genes were reactivated in RKO cells after treatment with 5-aza-2'-deoxycytidine, a DNA hypomethylating agent. COBRA showed that the CGIs encompassing the promoter and/or coding region of DCC, TBX5, TBX18, SLIT1 were methylated in primary colorectal tumors but not in matching normal colon tissues whereas GNA11 was methylated in both. MassARRAY analysis demonstrated that the CGI located approximately 4.5 kb upstream of HOXB13 +1 site was tumor-specifically hypermethylated in primary colorectal cancers and cancer cell lines. HOXB13 upstream CGI was partially hypomethylated in DNMT1(-/-) HCT cells but was almost methylation free in cells lacking both DNMT1 and DNMT3B. Analysis of tumor suppressor properties of two aberrantly methylated transcription factors, HOXB13 and TBX18, revealed that both inhibited growth and clonogenic survival of colon cancer cells in vitro, but only HOXB13 abolished tumor growth in nude mice. CONCLUSIONS/SIGNIFICANCE: This is the first report that identifies several important tumor suppressors and transcription factors as direct DNMT3B targets in colon cancer and as potential biomarkers for this cancer. Further, this study shows that methylation at an upstream CGI of HOXB13 is unique to colon cancer.
20454457	0	6	HOXB13	Gene	10481(Species:9606)
20454457	20	26	DNMT3B	Gene	1789(Species:9606)
20454457	272	294	DNA methyltransferases	Gene	1786(Species:9606),1789(Species:9606)
20454457	353	359	DNMT3B	Gene	1789(Species:9606)
20454457	374	395	DNA methyltransferase	Gene	1786(Species:9606),1789(Species:9606)
20454457	492	498	DNMT3B	Gene	1789(Species:9606)
20454457	622	625	RKO	Species	Species:9606
20454457	707	710	P16	Gene	1029(Species:9606)
20454457	712	715	DCC	Gene	1630(Species:9606)
20454457	717	722	DISC1	Gene	27185(Species:9606)
20454457	724	729	SLIT1	Gene	6585(Species:9606)
20454457	731	740	CAVEOLIN1	Gene	857(Species:9606)
20454457	742	747	GNA11	Gene	2767(Species:9606)
20454457	749	753	TBX5	Gene	6910(Species:9606)
20454457	755	760	TBX18	Gene	9096(Species:9606)
20454457	762	768	HOXB13	Gene	10481(Species:9606)
20454457	967	970	RKO	Species	Species:9606
20454457	1128	1131	DCC	Gene	1630(Species:9606)
20454457	1133	1137	TBX5	Gene	6910(Species:9606)
20454457	1139	1144	TBX18	Gene	9096(Species:9606)
20454457	1146	1151	SLIT1	Gene	6585(Species:9606)
20454457	1246	1251	GNA11	Gene	2767(Species:9606)
20454457	1362	1368	HOXB13	Gene	10481(Species:9606)
20454457	1469	1475	HOXB13	Gene	10481(Species:9606)
20454457	1521	1526	DNMT1	Gene	1786(Species:9606)
20454457	1596	1601	DNMT1	Gene	1786(Species:9606)
20454457	1606	1612	DNMT3B	Gene	1789(Species:9606)
20454457	1706	1712	HOXB13	Gene	10481(Species:9606)
20454457	1717	1722	TBX18	Gene	9096(Species:9606)
20454457	1825	1831	HOXB13	Gene	10481(Species:9606)
20454457	1858	1867	nude mice	Species	Species:10090
20454457	2008	2014	DNMT3B	Gene	1789(Species:9606)
20454457	2149	2155	HOXB13	Gene	10481(Species:9606)

27110091|t|The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride-induced murine dry eye model.
27110091|a|PURPOSE: In this study, the beneficial effects of the oral administration of ethanol extract of Diospyros kaki (EEDK) were tested on a mouse dry eye model induced by benzalkonium chloride (BAC). METHODS: A solution of 0.2% BAC was administered topically to mouse eyes for 14 days, twice daily, to induce dry eye. Various concentrations of EEDK were administrated daily by oral gavage for 14 days after BAC treatment. Preservative-free eye drops were instilled in the positive-control group. The tear secretion volume (Schirmer's test), tear break-up time (BUT), and fluorescein score were measured on the ocular surface. BAC-induced corneal damage was tested with hematoxylin-eosin staining. Moreover, apoptotic cell death in the corneal epithelial layer was investigated with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The protein expression level of interleukin-1alpha (IL-1a), IL-1b, IL-6, tumor necrosis factor- alpha (TNF-a), and monocyte chemotactic protein-1 (MCP-1) was determined with western blot analysis. Furthermore, squamous metaplasia in the corneal epithelial layer was detected with immunofluorescent staining for cytokeratine-10. The cellular proliferation in the cornea was examined with immunohistochemical staining for Ki-67. RESULTS: EEDK treatment resulted in prolonged BUT, decreased fluorescein score, increased tear volume, and smoother epithelial cells compared with BAC treatment alone in the cornea. Moreover, EEDK treatment inhibited the inflammatory response and corneal epithelial cell death in a BAC-induced murine dry eye model, and changes in squamous cells were inhibited. Proliferative activity in the corneal epithelium cells was improved with EEDK. CONCLUSIONS: EEDK could be a potential therapeutic agent in the clinical treatment of dry eye.
27110091	14	28	Diospyros kaki	Species	Species:35925
27110091	89	95	murine	Species	Species:10090
27110091	207	221	Diospyros kaki	Species	Species:35925
27110091	246	251	mouse	Species	Species:10090
27110091	368	373	mouse	Species	Species:10090
27110091	1008	1026	interleukin-1alpha	Gene	16175(Species:10090)
27110091	1028	1033	IL-1a	Gene	16175(Species:10090)
27110091	1036	1041	IL-1b	Gene	16176(Species:10090)
27110091	1043	1047	IL-6	Gene	16193(Species:10090)
27110091	1049	1077	tumor necrosis factor- alpha	Gene	21926(Species:10090)
27110091	1079	1084	TNF-a	Gene	21926(Species:10090)
27110091	1091	1121	monocyte chemotactic protein-1	Gene	20296(Species:10090)
27110091	1123	1128	MCP-1	Gene	20296(Species:10090)
27110091	1287	1302	cytokeratine-10	Gene	16661(Species:10090)
27110091	1396	1401	Ki-67	Gene	17345(Species:10090)
27110091	1697	1703	murine	Species	Species:10090

20161747|t|Negative feedback regulation of Wnt4 signaling by EAF1 and EAF2/U19.
20161747|a|Previous studies indicated that EAF (ELL-associated factor) family members, EAF1 and EAF2/U19, play a role in cancer and embryogenesis. For example, EAF2/U19 may serve as a tumor suppressor in prostate cancer. At the same time, EAF2/U19 is a downstream factor in the non-canonical Wnt 4 signaling pathway required for eye development in Xenopus laevis, and along with EAF1, contributes to convergence and extension movements in zebrafish embryos through Wnt maintenance. Here, we used zebrafish embryos and mammalian cells to show that both EAF1 and EAF2/U19 were up-regulated by Wnt4 (Wnt4a). Furthermore, we found that EAF1 and EAF2/U19 suppressed Wnt4 expression by directly binding to the Wnt4 promoter as seen in chromatin immunoprecipitation assays. These findings indicate that an auto-regulatory negative feedback loop occurs between Wnt4 and the EAF family, which is conserved between zebrafish and mammalian. The rescue experiments in zebrafish embryos showed that early embryonic development required the maintenance of the appropriate levels of Wnt4a through the feedback loop. Others have demonstrated that the tumor suppressors p63, p73 and WT1 positively regulate Wnt4 expression while p21 has the opposite effect, suggesting that maintenance of appropriate Wnt4 expression may also be critical for adult tissue homeostasis and prevention against tumor initiation. Thus, the auto-regulatory negative feedback loop that controls expression of Wnt4 and EAF proteins may play an important role in both embryonic development and tumor suppression. Our findings provide the first convincing line of evidence that EAF and Wnt4 form an auto-regulatory negative feedback loop in vivo.
20161747	32	36	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	50	54	EAF1	Gene	415205(Species:7955),85403(Species:9606)
20161747	59	63	EAF2	Gene	415252(Species:7955),55840(Species:9606)
20161747	64	67	U19	Gene	415252(Species:7955),55840(Species:9606)
20161747	101	104	EAF	Gene	55840(Species:9606),85403(Species:9606)
20161747	106	127	ELL-associated factor	Gene	55840(Species:9606),85403(Species:9606)
20161747	145	149	EAF1	Gene	85403(Species:9606)
20161747	154	158	EAF2	Gene	55840(Species:9606)
20161747	159	162	U19	Gene	55840(Species:9606)
20161747	218	222	EAF2	Gene	55840(Species:9606)
20161747	223	226	U19	Gene	55840(Species:9606)
20161747	297	301	EAF2	Gene	380216(Species:8355),398779(Species:8355),415252(Species:7955)
20161747	302	305	U19	Gene	380216(Species:8355),398779(Species:8355),415252(Species:7955)
20161747	350	355	Wnt 4	Gene	108697659(Species:8355),397706(Species:8355)
20161747	406	420	Xenopus laevis	Species	Species:8355
20161747	437	441	EAF1	Gene	415205(Species:7955)
20161747	497	506	zebrafish	Species	Species:7955
20161747	523	526	Wnt	Gene	30123(Species:7955)
20161747	554	563	zebrafish	Species	Species:7955
20161747	576	585	mammalian	Species	Species:9606
20161747	610	614	EAF1	Gene	415205(Species:7955),85403(Species:9606)
20161747	619	623	EAF2	Gene	415252(Species:7955),55840(Species:9606)
20161747	624	627	U19	Gene	415252(Species:7955),55840(Species:9606)
20161747	649	653	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	655	660	Wnt4a	Gene	30123(Species:7955)
20161747	690	694	EAF1	Gene	415205(Species:7955),85403(Species:9606)
20161747	699	703	EAF2	Gene	415252(Species:7955),55840(Species:9606)
20161747	704	707	U19	Gene	415252(Species:7955),55840(Species:9606)
20161747	719	723	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	762	766	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	911	915	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	924	927	EAF	Gene	415205(Species:7955),415252(Species:7955),55840(Species:9606),85403(Species:9606)
20161747	963	972	zebrafish	Species	Species:7955
20161747	977	986	mammalian	Species	Species:9606
20161747	1014	1023	zebrafish	Species	Species:7955
20161747	1126	1131	Wnt4a	Gene	30123(Species:7955)
20161747	1211	1214	p63	Gene	8626(Species:9606)
20161747	1216	1219	p73	Gene	7161(Species:9606)
20161747	1224	1227	WT1	Gene	7490(Species:9606)
20161747	1248	1252	Wnt4	Gene	54361(Species:9606)
20161747	1270	1273	p21	Gene	1026(Species:9606)
20161747	1342	1346	Wnt4	Gene	54361(Species:9606)
20161747	1526	1530	Wnt4	Gene	30123(Species:7955),54361(Species:9606)
20161747	1535	1538	EAF	Gene	415205(Species:7955),415252(Species:7955),55840(Species:9606),85403(Species:9606)
20161747	1692	1695	EAF	Gene	415205(Species:7955),415252(Species:7955),55840(Species:9606),85403(Species:9606)
20161747	1700	1704	Wnt4	Gene	30123(Species:7955),54361(Species:9606)

